

# Index

- A**
- Abdominoperineal resection (APR), 166
- Aberelix, for prostate cancer, 1085
- Abiraterone, for prostate cancer, 1085, 1085.e1
- Abscopal effect, 89
- Absolute dosimeters, 114
- Absorption edge, 104, 104f
- ABVD regimen, for Hodgkin's lymphoma  
advanced-stage, 1503, 1516-1517  
early-stage, 1502, 1511  
pediatric, 1475
- Accelerated fractionation, 37
- Accelerated partial-breast irradiation (APBI),  
282, 283f, 283t, 319-320, 1323-1324  
balloon brachytherapy device for, 1323,  
1323.e1f  
for in-breast tumor recurrence (IBTR), 285  
interstitial implantation for, 1323, 1323.e1f  
intraoperative electron applicator for,  
1323.e2f  
intraoperative intrabeam system for, 1323.e1f  
local recurrence with, 1323-1324, 1323.e3t  
using mixed photons and electrons, 1323.e2f  
whole breast *versus*, 1323, 1323.e3t
- Accessibility, 217  
concept of, 218  
definition of, 224  
dimensions of, 218b  
factors affecting, 224f, 225-226, 226f, 226t  
measurement of, 224-227, 225f  
measuring the need for, 226-227  
need for studies of, 218  
research on, 218-227  
spatial, 218, 218b  
waiting lists and, 218-223  
causes of, 220  
consequences of, 220-223, 221b  
direct effects of, 221-222, 221b, 222f  
indirect effects of, 221b, 222-223  
measurement of, 219-220, 219f  
societal effects of, 221b, 223
- Accommodation, 218, 218b
- Acentric fragments, 10
- Acid phosphatase, in prostate cancer, 1055
- Acinar cell carcinoma, of pancreas, 937  
treatment of, 947.e1t
- Acinic cell carcinomas, 699
- Acitretin, for mycosis fungoides, 1567
- ACOSOG. *see* American College of Surgeons  
Oncology Group (ACOSOG)
- Acoustic nerve, late effects of radiation on,  
256t-257t, 260-261
- Acoustic neuroma. *see* Vestibular  
schwannoma(s)
- Acquired immunodeficiency syndrome (AIDS).  
*see* Human immunodeficiency virus (HIV)
- Acromegaly, 512-514  
laboratory assessment of, 506  
medical therapy for, 513
- Acromegaly (*Continued*)  
radiation therapy for, 514, 514t  
stereotactic radiosurgery for, 514, 514t  
surgery for, 513  
treatment algorithm for, 512-513, 513f
- Active breathing control (ABC), 298
- Active scanning, with proton beam  
radiotherapy, 368, 369f
- Activity, 111t  
in radioactive decay, 138
- Acute lymphoblastic leukemia (ALL),  
1455-1460  
biology of, 1455  
classification of, 1455-1456  
CNS prophylaxis for, 1458  
consolidation and maintenance therapy for,  
1457  
cytogenetics of, 1456  
epidemiology of, 1455  
etiologic of, 1456  
evaluation of, 1456, 1457b  
immunophenotyping of, 1456  
induction treatment for, 1457-1458  
late sequelae of, 1455, 1460  
palliation for, 1455  
presentation of, 1456  
prognostic factors in, 1457, 1457b, 1458t  
radiation therapy for, indications of, 1455,  
1459  
relapse of, 1455  
staging of, 1455  
testicular, 1459  
treatment for, 1455, 1457-1459, 1458f
- Acute lymphoid leukemia, total body  
irradiation for, 352, 352.e2t
- Acute myelogenous leukemia (AML)  
after total body irradiation, 349, 349f  
pediatric, 1460-1461  
biology of, 1455  
classification of, 1455, 1460  
epidemiology of, 1455  
extramedullary, 1461  
late sequelae of, 1455  
morphology of, 1460t  
postremission therapy for, 1460  
presentation of, 1460  
radiation therapy for, indications of, 1455  
relapse and palliation for, 1455  
staging of, 1455  
stem-cell transplants for, 1461  
therapy for, 1455  
treatment of, 1460  
total body irradiation for, 352, 352.e2t
- Acute odynophagia, 860
- Adaptive design, 250-251
- Adenocarcinoma, 192  
colorectal, comparison of staging systems for,  
898t  
of esophagus, incidence of, 844t  
gastric, 194
- Adenocarcinoma (*Continued*)  
pancreatic, 934  
of the rectum, surgery for, 165-167, 167t  
of small bowel, 194-195
- Adenoid cystic carcinomas (ACCs), of salivary  
glands, 699  
intensity-modulated radiation therapy of,  
711f  
pathways of spread of, 703  
perineural invasion by, 703, 703f  
transoral robotic resection of, 705f
- Adenomatous polyps, benign, colorectal cancers  
from, 993
- Adenosquamous carcinoma  
of endometrium, 1205  
of pancreas, 937  
treatment of, 947.e1t
- Adjuvant colorectal cancer, 898-899  
impact of TN category on relapse and  
survival, 898-899
- Adjuvant gastric cancer, 900
- Adjuvant Lung Project Italy (ALPI), 824
- Adnexal carcinoma  
diagnostic and treatment algorithms for, 776  
eccrine, 768  
irradiation techniques for, 774-775  
setup, field arrangement, and dose  
fractionation schedule, 775, 775f  
target volume, 774  
microcystic, 768  
sebaceous, 767-768  
treatment of, 772
- Adrenal gland removal, for renal cell carcinoma,  
1145
- Adrenal metastases, of non-small cell lung  
cancer, 816
- Adrenal tumors, imaging of, 200
- Adrenocorticotrophic hormone (ACTH)  
deficiency, from central nervous system  
tumors, 1401
- Adult T-cell lymphoma/leukemia, 1562
- Afatinib, 81t-82t, 84, 177-178
- Affinity, in antibodies, 399
- Affordability, 218, 218b
- Aflatoxin B, and hepatocellular carcinoma, 961
- Aflibercept (Zaltrap), 81t-82t
- Age  
breast-conservation therapy and, 1314  
and prostate cancer  
as predictive factor, 1047  
as risk factors, 1039  
response, through cell cycle, 17-18, 18f
- Age-related macular degeneration (AMD)  
dry, 543  
etiology and epidemiology of, 543  
primary and adjuvant therapy for, 552-553  
wet, 543
- AGES system  
for follicular thyroid carcinoma, 720  
for papillary thyroid carcinoma, 719

Note: Page numbers followed by “f” refer to illustrations; page numbers followed by “t” refer to tables; page numbers followed by “b” refer to boxes.

- Aggressive fibromatosis, 1368-1369, 1378-1379  
 AGITG trial, 1005  
 Agreement states, 145-146  
 Air ionization chamber, 152, 152f-153f  
 Air kerma strength, 111t  
   of brachytherapy, 140-142  
 AIRE gene, and thymic tumors, 867  
 AJCC. *see* American Joint Commission on Cancer (AJCC)  
 ALARA, 145  
 Albumin-bound paclitaxel, 71  
 Alcohol use  
   and head and neck tumors, 561  
   and laryngeal cancer, 650  
   and oral cavity cancer, 570  
   and oropharyngeal cancer, 598-600  
 Alectinib, 81t-82t  
 Alemtuzumab (Campath), 81t-82t  
 Alkylating agents, 70-71, 171  
 All trans-retinoic acid (ATRA), 176  
 Allogeneic transplant, 343  
   total body irradiation for, 353, 353f  
 Alpha-beta equation, 12, 12f  
 Alpha decay, 137, 137f  
 Alpha-emitters, 400-401  
 Alpha-fetoprotein (AFP)  
   in hepatocellular carcinoma, 961-962  
   in pediatric extracranial germ cell tumors, 1489  
   in testicular cancer, 1126  
 Alpha interferon, with targeted radionuclide therapy, 404  
 ALPI. *see* Adjuvant Lung Project Italy (ALPI)  
 Altered fractionation, for salivary gland tumors, 708  
 Aluminum oxide dosimeter, 114  
 Alveolar rhabdomyosarcoma (ARMS), 1406  
 American Brachytherapy Society (ABS), 1067  
 American College of Surgeons Oncology Group (ACOSOG), 945  
 American Joint Commission on Cancer (AJCC), 995  
   TNM staging system, for colorectal cancer, 997t, 1000.e1  
 American Joint Committee on Cancer, TNM staging for pancreatic cancer, 940-941, 941b  
 AMES system  
   for follicular thyroid carcinoma, 720  
   for papillary thyroid carcinoma, 719, 719t  
 Amifostine, 25f, 25t, 26-27, 58-59, 60f, 60t, 414, 836  
 Amorphous silicon flat panel imager, 296-297  
 Amputation, for soft-tissue sarcoma, 1355  
 Anabolic signaling pathways, 46-47, 47f  
 Anal cancer  
   brachytherapy for, 288  
   chemoradiation for, 72, 73t, 72.e1t  
 Anal carcinoma, 1019-1034  
   adjuvant therapy, 1019  
   association with HIV infection, 1020  
   basaloid, 1022  
   biologic characteristics of, 1019, 1021-1022  
   chemotherapy, 1024-1027  
   clinical manifestations of, 1023-1024  
   cloacogenic, 1022-1023  
   disease control and survival rates after irradiation and chemotherapy for, 1025t  
   etiology and epidemiology of, 1019-1021  
   evaluation of, 1023  
   patient, 1023-1024  
   5-FU for, 1025-1027, 1026t-1027t  
   future directions of, 1032  
   human papillomavirus (HPV) and, 1019  
 Anal carcinoma (*Continued*)  
   incidence of, 1019  
   irradiation for, 1024-1027  
   techniques for, 1028-1032  
   traditional field design in, 1028-1029, 1029f  
   locally advanced, 1019, 1028  
   mucoepidermoid, 1022-1023  
   node involvement in, 1028  
   palliation for, 1019, 1028  
   pathology and pathways of spread, 1022-1023  
   pathways of tumor spread in, 1023  
   prevention and early detection of, 1021  
   primary therapy for, 1019, 1024-1028  
   prognostic factors for, 1019  
   radiation for, 1025-1027, 1026t-1027t  
   dose and fractionation, 1031  
   plus 5-FU and MMC *versus* 5-FU and cisplatin, 1027  
   radiotherapy for, 1024t, 1028  
   combined-modality therapy with, 1025  
   dose and fractionation, 1031  
   intensity-modulated, 1030, 1030f  
   target volumes and normal structures, 1029-1030  
   tumor regression, 1031-1032  
   risk factors for, 1020-1021  
   role of dose intensification, 1027  
   salvage therapy for, 1028  
   staging of, 1023-1024, 1024t  
   evaluation, 1019  
   surgery for, 1024  
   treatment algorithm for, 1032, 1033f  
   treatment tolerance with, 1027-1028, 1032  
 Anal cytologic smears, 1021  
 Anal melanoma, 1023  
   primary, 1023  
 Analgesics, for bone metastases, 435, 435f  
 Analytic beam model, 306t  
 Anaplastic gliomas, 450  
 Anaplastic large cell lymphoma (ALCL), 1526, 1527f, 1529, 1540  
   cutaneous, 1542, 1562  
   pediatric, 1462  
 Anaplastic thyroid cancer (ATC), 721  
   etiology and epidemiology of, 716, 716t  
   pathology of, 717  
   staging of, 718t  
   survival curves for, 721, 721f  
   treatment of, 726-727, 729  
 Anastrozole, for breast cancer, 1290, 1291t  
 Androgen deprivation therapy  
   and brachytherapy, 1069  
   effects on staging of prostatic cancer, 1046  
   metastatic, 1085  
   radiotherapy plus, 1077-1078, 1078t-1079t  
   salvage, 1082-1083  
   toxicity of, 1078-1079  
 Androgen receptor (AR), 1046  
 Aneurysmal bone cysts, 1381  
 Angiofibroma(s), 1376  
   juvenile nasopharyngeal. *see* Juvenile nasopharyngeal angiofibroma  
 Angiogenesis, tumor, 47-48, 85  
 Angiogenesis antagonists, chemotherapy and, 179-180  
 Angiogenesis inhibitors, 58, 85-87  
   as radiosensitizers  
   clinical studies of, 86-87  
   preclinical studies of, 86  
 Angiosarcoma, 1367  
   after radiotherapy for breast cancer, 1326  
 Annexin-V, 213  
 Annihilation radiation, 105  
 Antagonism, 68  
 Anterior compartment nodes, 740t, 741  
 Anthracyclines  
   cardiac toxicity, 1325-1326  
   for Hodgkin's lymphoma, pediatric, 1475  
   radiation injury and, 267  
 Antiandrogenic agents, for prostate cancer, 1085  
 Antiangiogenic agents, 86  
   for targeted radionuclide therapy, 404  
 Antiangiogenic therapy, 48  
 Antibody(ies), for targeted radionuclide therapy, 399  
   bispecific, 407-408  
   with immunomodulatory or biologic activity, 406-407  
   molecular engineering of, 403, 404f, 405.e1t  
 Antibody-based imaging agents, 213  
 Anti-CD20 Mabs, 410  
 Anti-CTLA-4 antibodies, 176-177  
 Anti-EGFR Mabs, in radioimmunotherapy, 407  
 Antiferritin antibody, 411  
 Antifolates, 70  
 Antihapten antibody, 407-408  
 Anti-Her2 antibody, 83  
 Anti-idiotypic, 409.e1t  
 Antimatter, 93  
 Antimetabolites, 70, 176  
 Antimitotic agents, 176  
 Antiparticle, 93  
 Anti-PD1 antibodies, 176-177  
 AntiPDL-1 antibodies, 176-177  
 Antitennascin, 408-409  
 Anti-vascular endothelial growth factor antibodies, for targeted radionuclide therapy, 404  
 AP endonuclease 1 (APE1), 1099-1100  
 Apocrine carcinoma, 768  
 Apoptosis, 46  
   and bladder cancer, 1098-1099  
   with chemoradiation, 67  
 Arc plan, 133f  
 Arm edema, after breast-conservation therapy, 1325  
 Arm function, after axillary irradiation, 1325  
 Aromatase inhibitors, for breast cancer, 1290, 1299-1300  
 Aromatic amines, and bladder cancer, 1097  
 Arrhenius relationship, 381-382, 382f  
 Arsenic trioxide, 176  
 Arteriovenous malformations (AVMs), 1374-1375, 1375t  
   stereotactic radiosurgery for, 422  
 Aryepiglottic folds, 652  
 Asbestos exposure, 883  
 Ascites, malignant, intraperitoneal  
   radioimmunotherapy for, 408.e4t  
 Astrocytic tumors, 453, 453t  
 Astrocytoma(s)  
   anaplastic, 475  
   childhood, 1396-1397, 1397f  
   diffuse, 453, 453t, 457f  
   imaging of, 190f, 191, 456f  
   pilocytic, 453, 453t, 460  
   observation for, 457f  
   pilocyxoid, 453t  
   prognostic and predictive molecular factors for, 454  
   proton beam radiotherapy for, 361-362  
   radiation toxicities with, 466f  
   recurrent, 462f  
   of spinal cord, 532-533, 532f  
   subependymal giant cell, 453t, 461  
 Asymmetrical exchanges, 10  
 ATM gene  
   breast-conservation therapy and, 1315  
   DNA double-stranded break response, 43-44  
 Atom, 93, 94f, 94t, 96t  
 Atomic number, 94-95

- Attainment factor, 217, 227-228
- Attenuation, 100-101, 100*f*  
 constant fractional, 100, 100*f*  
 exponential, 101  
 graphic representation of, 101*f*  
 for polyenergetic photons, 102*f*  
 for two different materials, 101*f*
- Attenuation coefficient(s), 102  
 linear, 100  
 mass, 102, 104-105, 104*f*  
 for photon beams, 116  
 total, 106, 106*f*
- Attenuation curves, 102, 102*t*
- Atypical teratoid rhabdoid tumor (ATRT), 1391, 1393-1394  
 treatment of, 1393-1394
- Auger electron, 103
- Autologous bone marrow transplantation, for Hodgkin's lymphoma, 1520
- Autologous stem cell support, 403
- Autologous transplant, 343  
 total body irradiation for, 353
- Autophagy, 11  
 with chemoradiation, 67  
 and hyperthermia, 386
- Autoradiography, 16
- Availability, 218, 218*b*
- Avastin. *see* Bevacizumab
- Avidin-biotin system, 407, 408.e3*t*
- Awareness, 218, 218*b*
- Axillary dissection, for breast cancer, 1314  
 early, 163-164, 164*f*
- Axillary irradiation, 1318, 1321-1322, 1321*f*-1322*f*  
 shoulder mobility after, 1325
- Axillary lymph nodes, breast cancer involving, 1285, 1286*f*-1287*f*
- Axillary nodal metastases, of melanoma, 784, 785*f*
- Axitinib, 81*t*-82*t*, 85-86, 179-180
- Aza-epothilone B, 71
- Azoospermia, from MOPP chemotherapy, 1475
- B**
- Bacillus Calmette-Guérin, for bladder cancer, 1102-1103
- Backscatter factor (BSF), 115
- Barrett's esophagus, 844
- Bartholin's complex carcinoma, 1232, 1253
- Baryons, 93
- Basal cell cancers, of eyelid  
 etiology and epidemiology of, 541  
 primary and adjuvant therapy for, 549
- Basal cell carcinoma (BCC)  
 biology and pattern of spread of, 764-765  
 diagnostic and treatment algorithms for, 775-776, 775*f*  
 etiology and epidemiology of, 763  
 of eyelid, pathology of, 544  
 in H zone, 764-765, 765*f*  
 infiltrative, 764  
 of lips, 572  
 morpheic (sclerosing), 764  
 nodular, 764, 764*f*  
 presentation and pathology of, 764  
 staging of, 769  
 superficial, 764  
 treatment of  
 for perineural invasion, 771  
 primary tumor, 769-771, 770*f*  
 for regional nodes, 771, 771*f*  
 sentinel lymph node biopsy in, 771
- Basaloid squamous cell carcinoma, of larynx and hypopharynx, 651
- Basaloid squamous variant, of oropharyngeal cancer, 601
- Base excision repair, 8-9
- Base-of-tongue implant, 288-289
- Base of tongue tumors. *see* Tongue base tumors
- BAX gene, in colorectal cancer, 993
- B-cell lymphoma(s)  
 diffuse large. *see* Diffuse large B-cell lymphoma (DLBCL)  
 pediatric, 1462  
 radioimmunotherapy for, 409.e1*t*
- BCL-2, follicular lymphoma and, 1527, 1527*t*
- BCNU, for mycosis fungoides, 1566
- BEACOPP regimen, for Hodgkin's lymphoma  
 advanced-stage, 1503, 1517, 1517.e1*t*  
 early-stage, 1502, 1511
- Beam definition, for conformal radiotherapy, 302-303
- Beam energy, 101, 102*f*, 835
- Beam hardening, 102
- Beam modifiers  
 of <sup>60</sup>Co unit, 97  
 of photon beam radiotherapy, 120, 120*f*
- Beam quality, 101-102
- BEAM regimen, for Hodgkin's lymphoma, 1520
- Beam shaping  
 iterative planning and, 310  
 for proton beam radiotherapy, 367, 368*f*
- Beam spoilers, for total body irradiation, 350, 350*f*
- Beam stopper  
 of <sup>60</sup>Co unit, 97  
 of linear accelerators, 98
- Beam weight, for conformal radiotherapy, 304
- Beam's-eye view, 296, 296*f*  
 of conformal fields, 304*f*  
 targeting of, 303, 304*f*
- Beckwith-Wiedemann syndrome, Wilms' tumor and, 1423
- Belinostat (Beleodaq), 81*t*-82*t*
- Benchmarking, 226-227, 227*f*
- Benign diseases, 1373-1384  
 of bony tissues, 1381-1383  
 of central nervous system, 1374-1376  
 of connective tissue and skin, 1378-1380  
 definition and classification of, 1373  
 of eye and orbit, 1376-1378  
 of head and neck, 1374-1376  
 of joints and tendons, 1378  
 radiobiologic aspects of, 1373-1374  
 radiotherapy for  
 indications for, 1373  
 mechanism of action of, 1374, 1374*t*  
 principles for, 1373, 1374*b*  
 radiobiologic reactions in, 1373  
 reactions in painful processes of, 1374  
 risk for tumor induction with, 1373, 1374*t*
- Benign prostatic hyperplasia, 1039
- Benzaldehyde, 61
- Beta decay, 137, 137*f*
- Beta-emitters, 400
- Bethesda system, for cervical cancer, 1174, 1174*t*
- Bevacizumab, 26, 58, 58*t*, 81*t*-82*t*, 86, 179, 184, 407  
 for cervical cancer, 1189  
 in chemotherapy, 951-952  
 for colon cancer, 983-984  
 for colorectal cancer, 1004  
 for nasopharyngeal carcinoma, 638
- Bexarotene, for mycosis fungoides, 1566
- Bexxar (tositumomab), in radioimmunotherapy, 410, 409.e1*t*
- Bias, 239-240  
 in survival analysis, 247
- Biased-coin design, 241
- Bicalutamide, for prostate cancer, 1078, 1085
- Bilateral nodal disease, 604
- Bile duct cancers, extrahepatic, 971*t*
- Bimodality Lung Oncology Team (BLOT), 826-827
- Biologic imaging, 135, 135*f*
- Biologic models, for conformal radiotherapy, 309
- Biologic target volumes, 135, 135*f*
- Biologic therapy, for oropharyngeal cancer, 613
- Biological cooperation, 65*t*, 66
- Biological materials, interaction of ionizing radiation with, 6-7
- Biological systems, 2
- Biologically effective dose (BED)  
 for bone metastases, 438, 438*f*  
 method, 38
- Biologics, radiation and, interactions with, 80-92  
 angiogenesis inhibitors as, 85-87  
 c-MET, 90  
 designing clinical trials in, 91-92, 91*f*  
 DNA repair inhibitors, 87-89  
 epidermal growth factor receptor family inhibitors, 80-85  
 FDA-approved, 81*t*-82*t*  
 future directions of, 90-92  
 immune targeted, 89-90  
 PI3K/Akt/mTOR pathway and, 83*f*, 87  
 targeting cancer stem cells in, 90-91  
 transforming growth factor- $\beta$  (TGF- $\beta$ ), 90, 90*f*
- Biomarkers, 250, 250*f*-251*f*
- Biopsy  
 for breast, 160-161, 160*f*  
 core-needle, 159-160  
 dosimetry, for radioimmunotherapy, 416.e1  
 excisional, 160-161, 160*f*  
 for histologic diagnosis, 159  
 incisional, 160  
 sentinel lymph node, 164, 164*f*. *see also* Sentinel lymph node biopsy (SLNB)
- Bio-reductive drugs, 24-27, 25*t*, 56-57, 57*f*  
 oxygenation status and, measurement of, 24
- Birt-Hogg-Dubé (BHD) syndrome, renal cell carcinoma with, 1142
- Bisphosphonates  
 for bone metastases, 434-435  
 for prostate cancer, 1086
- Bladder  
 biopsy, 1100-1101  
 late effects of radiation on, 256*t*-257*t*, 272-273  
 dose-volume data on, 272-273  
 organ function and clinical significance and, 272  
 QUANTEC Review on, 273  
 primary tumors of, 201-202, 202*f*  
 transitional cell carcinoma of, 202*f*
- Bladder cancer, 1036, 1096-1120  
 adjuvant therapy for, 1096  
 biologic characteristics of, 1096  
 biomarkers for, 1100  
 bladder preservation in. *see* Bladder preservation  
 brachytherapy for, 1118-1119  
 interstitial, 1106-1107  
 carcinoma in situ as, 1098  
 chemoradiation for  
 combined, and TURBT, 1113  
 complete response in, 1112  
 follow-up after, 1113  
 prognostic factors in, 1112-1113  
 recurrent disease in bladder and, 1113  
 survival in, 1113

Bladder cancer (*Continued*)

chemotherapy for  
 adjuvant, 1108-1109, 1109*t*  
 conservative surgery and, 1106  
 neoadjuvant therapy and, 1107-1108, 1108*t*  
 radical local therapy and, 1107-1109  
 clinical presentation of, 1100-1102  
 combined-modality therapy for, 1107-1113  
 cystectomy for. *see* Cystectomy  
 etiology and epidemiology of, 1097  
 external beam irradiation for, 1114-1118, 1115*f*  
 controversial issues in, 1117-1118  
 fields for, 1115, 1116*f*  
 nodal treatment and, 1117  
 partial bladder treatment and, 1117-1118  
 radiation dose and, 1118  
 radical, 1106, 1106*t*  
 simulation for, 1114-1117  
 target volumes for, 1115, 1116*f*  
 total dose of, 1116  
 treatment break to evaluate response in, 1116-1117  
 treatment margins and, 1118  
 grading of, 1098  
 hyperthermia for, 395, 395*t*  
 incidence of, 1096  
 irradiation techniques and tolerance for, 1114-1119  
 locally advanced disease and, 1096, 1114  
 lymph node involvement in, 1117  
 molecular biology of, 1098-1100  
 molecular markers of, 1036  
 molecularly targeted therapy for, 1100  
 muscle-invasive, 1104-1106  
 radiation therapy for, 1105  
 radical cystectomy for, 1104-1105.  
*see also* Cystectomy  
 noninvasive, 1102-1104  
 intravesical therapy for, 1102-1103  
 superficial, irradiation in, 1103-1104  
 transurethral resection for, 1102  
 palliation of, 1096, 1114  
 pathology of, 1098  
 pathways of spread of, 1098  
 patient evaluation for, 1100-1102  
 prevention and early detection of, 1097-1098  
 primary therapy for, 1096, 1102-1114, 1103*f*  
 quality-of-life studies in, 1113-1114  
 radiation therapy for  
 postoperative, 1105  
 preoperative, 1105  
 salvage, 1106  
 risk factors for, 1097  
 squamous cell carcinoma as, 1098  
 staging of, 1096, 1100-1102, 1101*t*, 1102*f*  
 superficial, 1098  
 transitional cell carcinoma as, 1098  
 transurethral resection of, 1102  
 treatment algorithm, challenges, and future possibilities in, 1117*f*, 1119  
 workup for, 1096, 1100-1101  
 bimanual examination in, 1101  
 biopsy in, 1100-1101  
 endoscopy in, 1100  
 imaging in, 1101  
 transurethral resection of bladder tumor, 1100-1101  
 urinary cytology in, 1101

Bladder preservation, 1106-1107  
 combined-modality therapy for, 1107-1113  
 conservative surgery and, 1106  
 interstitial brachytherapy for, 1106-1107, 1107*t*

Bladder preservation (*Continued*)

with limited resection, chemotherapy, and irradiation, 1109-1113, 1110*f*, 1110*t*  
 radical external beam irradiation for, 1106, 1106*t*  
 cooperative group experience, 1111, 1112*t*  
 single-institutional experiences, 1109-1111  
 radical local therapy and, 1107-1109

Bleomycin, 171  
 for Hodgkin's lymphoma, pediatric, 1475

Blobs, in energy deposition, 6-7, 7*f*

Blocks, for conformal radiotherapy, shaping with, 303-304, 303*f*-304*f*

Blood-brain barrier, and drug sanctuaries, 182

Blood transfusion, 163

BLOT. *see* Bimodality Lung Oncology Team (BLOT)

Body habitus, and prostate cancer, 1040

Bone lymphoma, 1540

Bone marrow suppression, due to radioimmunotherapy, 413

Bone marrow transplantation (BMT)  
 for multiple myeloma, 1552  
 for mycosis fungoides, 1568  
 radioimmunotherapy for, 409-410

Bone metastases, 432-441  
 diagnosis of, 433-434  
 distribution of, 432, 433*t*  
 of Ewing's sarcoma, 1419  
 incidence by primary site of, 432, 433*t*  
 of neuroblastoma, 1452  
 of non-small cell lung cancer, 837*t*  
 pathophysiology of, 432-433  
 prevalence by primary site of, 432, 433*t*  
 of renal cell carcinoma, 1151  
 treatment of, 434-441  
 hemibody irradiation for, 438-439, 439*t*  
 local field radiotherapy for, 437-438, 437*t*, 438*f*  
 pharmacologic, 434-435, 435*f*  
 stereotactic radiosurgery of spine for, 439-440  
 surgical, 435-437, 435*f*, 436*t*  
 systemic radionuclide therapy for, 440-441, 440*t*-441*t*  
 techniques for, 438

Bone scans, of prostate cancer, 1054-1055

Bone toxicity, of total body irradiation, 348

Bony tissues, benign disorders of, 1381-1383

Boost techniques, for intraoperative radiotherapy, 327

Boosting, in total body irradiation, 355

Borderline tumors, of ovary, 1267

Boron neutron capture therapy (BNCT), 376-379  
 early clinical studies of, 377, 377*f*  
 historical perspective of, 376-377  
 modern clinical trials of, 377-379  
 overview of, 376

Bortezomib, 179  
 as biologic modifier, 81*t*-82*t*  
 for multiple myeloma, 1551

Bosutinib (Bosulif), 81*t*-82*t*

Bowen's disease, 765, 765*f*-766*f*

Brachial plexopathy, after radiotherapy for breast cancer, 1325

Brachytherapy, 136-145, 276-293  
 advantages of, 137  
 afterloading in, 142  
 high-dose-rate (HDR) remote, 280  
 applicators in, 142, 144*f*, 277-279, 279*f*, 284  
 for base-of-tongue cancers, 610-611  
 for breast cancer, 282-285, 283*f*, 283*t*  
 balloon-based intracavitary technique, 284-285, 284*f*-285*f*

Brachytherapy (*Continued*)

californium 252, 379  
 for central nervous system, 290-291  
 for cervical cancer, 1193-1199  
 high-dose-rate, 1196-1199  
 fractionation schedules for, 1197  
 image-guided, 1199  
 linear quadratic (LQ) model for, 1196  
*versus* low-dose-rate, 1196, 1196*t*  
 sedation methods for, 1198  
 tandem and ring system for, 1198, 1198*f*  
 timing of, 1197-1198  
 interstitial, 1199  
 low-dose-rate intracavitary therapy, 1194-1196  
 dose specification for, 1195-1196, 1195*f*  
 Fletcher-Suit-Delclos applicator system for, 1194*f*, 1195  
 Henschke applicator for, 1194  
 high-dose-rate *versus*, 1196, 1196*t*  
 Manchester system for, 1195-1196  
 placement of system in, 1195  
 vaginal cylinders for, 1195  
 plus external beam irradiation, 1181  
 central dose escalation with, 1195, 1195*f*  
 defined, 96  
 dose rates for treatment delivery in, 277*t*  
 for gastrointestinal cancer, 286-288  
 anal, 288  
 esophageal, 286-287, 287*f*  
 rectal, 287-288, 288*f*  
 general principles of, 276-277  
 for genitourinary cancers, 280-282  
 penile cancer, 282  
 prostate, 277*f*, 280-282, 281*f*, 281*t*  
 urethral cancer, 282, 282*f*  
 for gynecologic cancers, 277-280  
 cervix cancer, 277-279, 278*f*  
 endometrial cancer, 279-280, 279*f*  
 for head and neck cancers, 288-289  
 interstitial, 280, 280*f*, 282*f*, 288  
 isotopes in, 139-140, 139*t*, 140*f*-141*f*, 277*t*, 281*t*, 140*e1f*-140*e2f*  
 lung-endobronchial, 285, 286*f*  
 for nasal vestibule tumors, 689, 689*f*, 689*e1f*  
 for nasopharyngeal carcinoma, 641, 642*f*  
 ophthalmic, 291-292, 291*f*  
 for oropharyngeal cancer, 623-624  
 other techniques for, 145  
 in pediatrics, 291  
 planning in, 276-277, 277*f*  
 post-planning, 276-277  
 pre-planning, 276  
 real-time/dynamic planning, 276  
 systems for, 277  
 for prostate cancer, 1067-1073  
 and androgen ablative therapy, 1069-1070  
 complications of, 1071-1073  
 lower gastrointestinal, 1072  
 sexual function, 1072-1073, 1073*f*  
 urinary, 1071-1072, 1072*f*  
 dosimetry during, 1090  
 EBRT and, 1068-1069, 1069*t*  
 high-dose rate, 1070-1071  
 outcomes of, 1073  
 isotope selection for, 1068  
 outcomes of, 1071  
 patient selection for, 1067-1068, 1068*f*  
 post-implant dosimetry for, 1070, 1070*t*  
 prostate biopsy after, 1073  
 ultrasound localization for, 1087*e1*  
 radioactive decay in, 137-138, 137*f*  
 mathematics in, 138-139  
 as salvage treatment, 282  
 for sarcoma, 289-290, 290*f*, 290*t*  
 skin/superficial, 289, 289*f*



Brachytherapy (*Continued*)

- source strength, 140-142
- summary and future possibilities of, 292
- thoracic wall, 286, 286f
- time, distance, and shielding in, 276
- treatment planning for, 142-145
  - dose specification in, 144-145
  - for gynecologic implants, 142, 142f-143f
  - with high-dose-rate remote afterloading, 143-144, 144f
  - for interstitial implants, 142-143, 143f
  - vaginal. *see* Vaginal brachytherapy
  - vascular, 292

## B-RAF inhibitors, 177

## Bragg peak, 108, 108f

- in charged particle radiotherapy, 358, 359f

## Brain, late effects of radiation on, 256-258, 256t-257t

- dose-volume data on, 258
- organ function and clinical significance and, 256-258

## QUANTEC Review, 258

## Brain cancer

- conformal radiotherapy for, 319-320
- treatment goals and rationale for, 320
- radioimmunotherapy for, 408, 408.e3t

## Brain metastases, 432, 443-445

- arterial hematogenous spread of, 443
- diagnosis of, 443
- incidence of, 443
- of non-small cell lung cancer, 809
- palliative management of, 837t
- presenting symptoms of, 443
- prognosis for, 443
- renal cell carcinoma in, 1151, 1151t
- stereotactic radiosurgery for, 424-425, 425t
- treatment of, 443-445
  - radiosurgery for, 444-445
  - surgical resection for, 444, 444t
  - whole brain radiotherapy for, 443-444, 444t

## Brain tumors

- benign, 483-501
- extraaxial, 187, 188f-189f
- gliomas as
  - high-grade, 469-482
  - low-grade, 452-468
- imaging of, 187-191, 188f-190f
- intraaxial, 187
- orbital, ocular, and optic nerve, 541-560

## Brainstem

- gliomas, 1397
- late effects of radiation on, 256t-257t, 259
- dose-volume data on, 259
- organ function and clinical significance and, 259
- QUANTEC Review on, 259

## BRCA1/2

- breast cancer and, 1288, 1289b, 1289t
- breast-conservation therapy and, 1314, 1314.e1t
- in DNA repair, 9-10, 45-46
- ovarian cancer and, 1266

## Breast

- anatomy of, 1285-1287, 1286f
- lymphatic drainage of, 1285, 1286f
- phyllodes tumor of, 1367
- Breast abscesses, after surgery, 1324
- Breast augmentation, breast-conservation therapy and, 1314
- Breast boost volume, 1320-1321, 1321.e1f-1321.e3f

## Breast cancer

- age and risk of, 1287
- axillary management of, 1296, 1296b
- bilateral, 1315

Breast cancer (*Continued*)

- biologic characteristics of, 1294-1295
- biologic markers of, 1316
- brachytherapy for, 282-285, 283f, 283t
  - balloon-based intracavitary technique, 284-285, 284f-285f
- breast-conserving therapy for. *see* Breast-conserving therapy
- chemotherapy for
  - adjuvant, 1298t, 1299
  - neoadjuvant, 1297-1299, 1298t
  - advantages of, 1333
  - breast conservation after, 1333
  - postmastectomy radiation therapy after, 1336-1337, 1336t
- conformal radiotherapy for, 319-320
- treatment goals and rationale for, 320-321
- cytotoxic therapies for, 1297-1299, 1298t
- detection of, means of, 1315
- diagnostic overview of, 1291-1292
- endocrine therapies for, 1299-1300, 1299t
- epidemiology of, 1287-1292
- etiology of, 1284, 1287-1292
- with extensive intraductal component, 1316
- genetic factors of, 1284, 1288, 1289b, 1289t
- hormonal therapy for, 1299-1300
- hyperthermia for, 392, 393t
- incidence and mortality rates of, 1284, 1287
- infiltrating lobular, 1316
- inflammatory, 1342
  - biology of, 1330
  - treatment algorithms for, 1342, 1343f
- locally advanced, 1329-1344
  - biologic characteristics of, 1329
  - clinical manifestations of, 1331-1332, 1331f
  - epidemiology of, 1330
  - evaluations of, 1331-1332, 1332f
  - irradiation techniques for, 1337-1339, 1337f-1341f
    - after breast-conserving surgery, 1337
    - after mastectomy, 1338
  - neoadjuvant chemotherapy for
    - advantages of, 1333
    - breast conservation after, 1333
    - postmastectomy radiation therapy after, 1336-1337, 1336t
  - new therapeutic approaches for, 1342, 1343f
  - outcome of, 1329, 1342
  - pathology of, 1330
  - pathways of spread of, 1330
  - postmastectomy radiation therapy for, 1334-1336, 1334t-1335t
    - and breast reconstruction, 1339-1342
    - techniques of, 1337-1339, 1337f-1341f
  - staging of, 1329, 1331-1332
  - therapy for, 1329
  - treatment algorithm for, 1343f
  - treatment overview for, 1332-1333
- locoregional treatments for, 1295-1297, 1296b
- lymph nodes in, 1316
  - internal mammary, 1285, 1285t, 1287f
  - level III axillary (infraclavicular), 1285, 1286f
  - Rotter's, 1285, 1286f
  - supraclavicular, 1285-1287
  - margin status of, 1315-1316, 1315t
- mastectomy for, 1295-1296
- molecular classification of, 1294
- multiple ipsilateral, 1315
- noninvasive, 1303-1312
  - biologic and pathologic characteristics of, 1303
  - ductal carcinoma in situ as, 1306-1311. *see also* Ductal carcinoma in situ (DCIS)
  - incidence of, 1303

Breast cancer (*Continued*)

- lobular carcinoma in situ as, 1303-1305, 1304t, 1305f
- Paget's disease as, 1305-1306, 1305t, 1306f
- staging and evaluation of, 1303
- treatment of, 1303
- PET scan of, 212
- predictive markers for, 1294-1295
- prevention strategies for, 1289-1291, 1291t
- prognostic and predictive factors of, 1284
- radiation for, 1296-1297
- radioimmunotherapy of
  - with chemotherapy, 406, 405.e2t-405.e4t
  - with chL6, 406-407
  - with external beam radiotherapy, 406
  - intraperitoneal delivery of, 408.e4t
  - monoclonal antibodies for, 402.e2t-402.e4t, 402.e6t
  - with pretargeting, 408.e3t
- radiotherapy for
  - after breast-conserving surgery, 1337
  - intraoperative, 332-333
    - INTRABEAM system for, 333, 338, 333.e1f
    - mobile units for, 338
    - NOVAC 7 for, 332
  - postmastectomy, 1334-1336, 1334t-1335t
    - and breast reconstruction, 1339-1342
    - techniques for, 1338, 1339f-1341f
  - proton beam, 366
  - techniques of, 1337-1339, 1337f-1341f
- risk factors for, 1284, 1287-1288, 1288t
- screening for, 1288-1289, 1290t
- sentinel lymph node surgery for, 1296
- size and location of, 1315
- stage I-II, 1313-1328
  - accelerated partial-breast irradiation for, 1323-1324. *see also* Accelerated partial-breast irradiation (APBI)
  - balloon brachytherapy device for, 1323, 1323.e1f
  - interstitial implantation for, 1323, 1323.e1f
  - intraoperative electron applicator for, 1323.e2f
  - intraoperative intrabeam system for, 1323.e1f
  - local recurrence with, 1323-1324, 1323.e3t
  - using mixed photons and electrons, 1323.e2f
  - whole breast *versus*, 1323, 1323.e3t
- axillary dissection for, 1314
- breast boost volume for, 1320-1321, 1321.e1f
- breast-conserving therapy for. *see* Breast-conserving therapy
- differential diagnosis of, 1327
- evaluation of, 1327
- follow-up for, 1313, 1326-1327
- local recurrence of, 1327
- local-regional failure in, treatment of, 1327-1328
- local-regional recurrence of, therapy for, 1313
- nodal irradiation for, 1318-1319
  - axillary, 1318, 1321-1322, 1321f-1322f
  - doses, 1323
  - internal mammary, 1318-1319, 1322, 1318.e1t, 1322.e1f
  - supraclavicular, 1318, 1321-1322, 1321f-1322f
- pathologic evaluation of, 1314
- pretreatment evaluation of, 1313-1314
- radiotherapy in

- Breast cancer (*Continued*)  
 carcinogenesis and, 1326  
 complications of, 1324-1326  
 cosmetic results of, 1326, 1326f, 1326.e1f  
 dose and schedule parameters for, 1322-1323  
 patient position and immobilization for, 1319, 1319.e1f  
 salvage therapy for, 1328  
 sentinel node biopsy for, 1314  
 surgical techniques for, 1314  
 treatment of, 1313  
   techniques for, 1319-1322  
 whole-breast irradiation for, 1319-1320.  
   *see also* Whole-breast irradiation  
   accelerated partial-breast irradiation  
     *versus*, 1323, 1323.e3t  
   deep-inspiration breath-holding and, 1319-1320, 1319.e3f  
   field borders and blocks in, 1319, 1320b, 1320f-1321f, 1319.e1f  
   intensity-modulated, 1319, 1319.e2f  
   multiple-gantry angle in, 1319-1320, 1320.e1f  
 staging of, 1292-1294, 1292t-1293t  
 surgical treatment of, 163-164  
   early, 163-164, 164f  
 systemic treatments for, 1297-1300, 1298f  
 therapies for  
   selection of, 1294-1295, 1297  
   sequencing of, 1300  
 treatment of, 1284, 1295-1300, 1295f
- Breast conservation surgery, 163  
 for early breast cancer, 163
- Breast-conserving therapy  
 accelerated partial-breast irradiation in.  
   *see* Accelerated partial-breast irradiation (APBI)  
 complications of, 1324-1326  
 for ductal carcinoma in situ, 1308  
 follow-up after, 1326-1327  
 for lobular carcinoma in situ, 1304t  
 local recurrence after, 1327  
 for locally advanced breast cancer  
   after neoadjuvant chemotherapy, 1333  
   techniques for, 1337  
*versus* mastectomy, 1311, 1313.e1t  
 nodal irradiation for, 1318-1319  
   axillary, 1318, 1321-1322, 1321f-1322f  
   doses, 1323  
   internal mammary, 1318-1319, 1322, 1318.e1t, 1322.e1f  
   supraclavicular, 1318, 1321-1322, 1321f-1322f  
 for Paget's disease, 1305, 1305t  
 patient position and immobilization for, 1319, 1319.e1f  
 patient selection for, 1313  
 pretreatment evaluation for, 1313-1314  
 with radiation therapy, 1314-1316  
   clinical factors in, 1315  
   pathologic factors in, 1315-1316  
   patient factors in, 1314-1315  
   prognostic indices in, 1316  
 radiotherapy dose and schedule parameters for, 1322-1323  
 surgical techniques for, 1314  
 without radiation therapy, 1316-1318  
   correlates of local recurrence in, 1316-1317  
   randomized trials of, 1316, 1317t, 1316.e1t  
   results of, 1316, 1317f
- Breast lymphoma, 1540
- Breast reconstruction, postmastectomy  
 radiation and, 1339-1342
- Breast sarcomas, 1367
- Breast specific gamma imaging (BSGI), 214
- Bremsstrahlung photon, 106
- Bremsstrahlung radiation, 107-108
- Bremsstrahlung spectrum, 99, 100f
- Brentuximab vedotin (Adcetris), 81t-82t
- British MAGIC trial, 914
- British Stomach Cancer Group (BSCG), 914
- 5-Bromodeoxyuridine, 25f, 25t, 26
- Bronchial carcinoid. *see* Pulmonary carcinoid
- Bronchiolitis obliterans organizing pneumonia,  
 after radiotherapy for breast cancer, 1325
- Bronchoalveolar carcinoma (BAC), 192
- Bronchopulmonary carcinoids. *see* Pulmonary carcinoid
- Brown fat, FDG-PET scanning with, 209
- BSCG. *see* British Stomach Cancer Group (BSCG)
- Buccal gingival sulcus carcinomas, etiology of, 570
- Buccal mucosa, 585
- Buccal mucosa cancer  
 early, 586, 587f  
 manifestations of, 586  
 moderate to locally advanced, 586, 588  
 pathology of, 586  
 staging of, 586  
 treatment of, 586  
   algorithm for, 586f  
   complications of, 588  
   results of, 586-587, 587t  
   techniques of irradiation for, 587-588
- Buccal nodes, 739f, 740t
- Buildup phenomenon, 114-115, 114f
- Burkitt's lymphoma, 1461, 1461t  
 and *c-MYC*, 1528-1529
- Buserelin, for prostate cancer, 1085
- Busulfan, 181t
- C**
- CA 19-9, 946
- CA 125, 1266, 1268-1269
- Cabazitaxel, for prostate cancer, 1085
- Cabozantinib (Cometriq), 81t-82t, 85-86
- Calcium, and prostate cancer, 1039.e1
- Calcium fluoride (CaF) dosimeter, 112-113
- Californium 252 (<sup>252</sup>Cf) brachytherapy, 379
- Calorimetry, 114
- Camptothecins, 72
- Cancer cell biology, 173
- Cancer Genome Atlas Project (CGA), 1206
- Cancer of the Prostate Risk Assessment (CAPRA) score, 1050.e1
- Cancer personalized profiling by deep sequencing (CAPP-Seq), 91-92
- Cancer stem cells, targeting of, 90-91
- Capacitive radiofrequency heating, 387t, 389
- Capecitabine, 70, 902  
 for rectal cancer, 1000, 1004.e1, 1003.e1t
- Capromab pendetide (ProstaScint), 1055
- Carbon ion radiotherapy, 369-370  
 for head and neck tumors, 566  
 for prostate cancer, 1066.e1
- Carbon monoxide, 61, 61f
- Carboplatin, 71, 181t, 901  
 for endometrial cancer, 1218.e1  
 for ovarian cancer, 1275
- Carcinoembryonic antigen (CEA), 404  
 with immunomodulatory or biologic activity, 407  
 minimal tumor burden setting with, 405  
 pretargeting of, 408.e3t  
 scans, 213
- Carcinoids, 879  
 atypical, 879f  
 pulmonary. *see* Pulmonary carcinoid  
 radioimmunotherapy of, 405.e2t-405.e4t
- Carcinoids (*Continued*)  
 of small bowel, 194-195  
 thymic, 867  
   pathology and pathways of spread, 867-868, 868f  
   prevention and early detection of, 866-867  
   treatment of, 875, 877f-878f
- Carcinoma in situ (CIS)  
 of bladder, 1098  
 ductal. *see* Ductal carcinoma in situ (DCIS)  
 glottic, 659-660, 659t  
 of larynx, 651  
 lobular. *see* Lobular carcinoma in situ (LCIS)  
 testicular, 1123-1124
- Carcinosarcoma, of uterus, 1220
- Cardiovascular toxicity, of total body irradiation, 347
- Carfilzomib, 179  
 as biologic modifier, 81t-82t  
 for multiple myeloma, 1551
- Caries, 571, 624
- Carmustine, 71  
 for mycosis fungoides, 1566
- Carmustine-eluting (Gliadel) wafers, for high-grade glioma, 473
- Carotenoids, for non-small cell lung cancer, 813
- Carotid artery stenosis, after neck irradiation, 760
- Cataracts  
 after total body irradiation, 347  
 radiation-induced, 31-32
- β-Catenin, 1423
- Catumaxomab (Removab), 81t-82t
- Caudal jugular nodes, 740t
- Cavernous hemangiomas, from central nervous system tumors, 1401
- CC chemokine receptor 4 (CCR4), in mycosis fungoides, 1557, 1558f
- <sup>11</sup>C-choline, for prostate cancer imaging, 213
- CCND1, in head and neck tumors, 561
- CCNU, 71
- CD10, 1456
- CD30+ large cell cutaneous T-cell lymphoma, 1562
- CD33 antigen, 411-412
- CD45 antigen, 412
- CDH-1 gene, 908
- CDK4 genes, 778
- CDKN1A protein, cell cycle arrest and, 43
- CDKN2A gene  
 in head and neck tumors, 561  
 in melanoma, 778  
 in non-small cell lung cancer, 811
- CEA. *see* Carcinoembryonic antigen (CEA)
- Celiac trunk, and borderline resectable pancreatic cancer, 947.e1t
- Cell cycle  
 blocks and delays of, radiation-induced, 18-19  
 cell kill dependency on, 174, 174f  
 ionizing radiation and, 16-19, 17f-18f  
 redistribution in tissues and, 19  
 volume doubling times and, 28, 28t, 29f
- Cell cycle arrest, 42-43, 42f
- Cell cycle checkpoints, 42-43, 42f
- Cell cycle checkpoint genes, 19
- Cell cycle effects, of chemoradiation, 66
- Cell cycle kinetics, and drug administration schedules, 182
- Cell cycle phase specificity, and drug administration schedules, 182
- Cell cycle receptors, and bladder cancer, 1098-1099
- Cell death  
 definition of, 11  
 pathway effects, of chemoradiation, 67

- Cell kill, 2  
   cell cycle dependency of, 174, 174f  
   fractional, 173-174, 174f
- Cell loss factor, 28-29, 28t
- Cell survival curves, 11-14  
   cell death in, 11  
   clonogenic assays  
     in vitro for, 12-13, 13f  
     in vivo, 13  
   exponential, 12  
   models of, 11-12, 12f  
   nonclonogenic assays in vivo for, 13-14
- Cellular biology, 41-50  
   anabolic signaling pathways in, 46-47, 47f  
   basic concepts and techniques of radiation sciences in, 49  
   of cancer, radiation and, 48  
   DNA double-stranded break response in.  
     see Double-stranded break response  
   essential steps in tumor progression in, 41  
   ionizing radiation-induced programmed cell death pathways in, 46  
   normal tissues in, 49, 49f  
   programmed cell death in, 41, 46  
   radiation and RNA world in, 47  
   radiation therapy and radiation biology in, 41-42  
   replicative senescence in, 46  
   targeting molecular pathways in, 48
- Cellular repair, 14-16, 14f-15f  
   in tissues, 16
- Cellular triage, after ionizing radiation exposure, 43, 43f
- Cellulitis, after surgery, for breast cancer, 1324
- Central endobronchial tumors, non-small cell lung cancer, 816
- Central nervous system (CNS)  
   benign disorders of, 1374-1376  
   metastases, and testicular cancer, 1135  
   prophylaxis, for acute lymphoblastic leukemia, 1458, 1458f  
   retinoblastoma of, 1439  
   sequelae, of acute lymphoblastic leukemia, 1460
- Central nervous system (CNS) tumors, 450  
   benign, 483-501  
   brachytherapy for, 290-291  
   in children, 1389-1402  
     astrocytoma as  
       high-grade, 1397, 1397f  
       low-grade, 1396-1397  
     atypical teratoid rhabdoid tumor as, 1393-1394  
     choroid plexus tumors as, 1400  
     craniopharyngioma as, 1398-1400, 1400f  
     diffuse pontine glioma as, 1397  
     embryonal, 1391  
     ependymoma as, 1394-1396  
     ETANTR as, 1394  
     etiology of, 1389  
     evaluation of, 1389  
     germ cell tumors as, 1397-1398  
     histologic subtypes of, 1389  
     incidence and overall survival of, 1389  
     normal tissue tolerance and side effects with, 1400  
   radiation delivery for, 1389-1391  
     IMRT, 1390, 1390f  
     proton radiation, 1390-1391, 1391f  
     SRS/SRT, 1390  
   radiation therapy for  
     acute and subacute toxicity from, 1400  
     leukoencephalopathy from, 1401-1402  
     necrosis from, 1401  
     neurocognitive toxicity from, 1400-1401  
     neuroendocrine toxicity from, 1401
- Central nervous system (CNS) tumors  
   (Continued)  
     ototoxicity from, 1401  
     pseudo-progression from, 1401  
     second malignancy from, 1402  
     vascular complications from, 1401  
     visual outcomes of, 1401  
   spinal cord tumors as, 1400  
   three-dimensional treatment planning for, 1390
- gliomas as, 450  
   high-grade, 469-482  
   low-grade, 452-468
- imaging of, 450-451
- irradiation for, 451
- lymphoma as, 450
- orbital, ocular, and optic nerve, 541-560
- pituitary, 502-520
- primary therapy for, 451
- spinal cord tumors as, 521-540
- stereotactic radiosurgery for. *see* Stereotactic radiosurgery
- surgery for, 451
- Cerebrospinal fluid examination, 526
- Cerebrovascular syndrome, 31
- Ceritinib (Zykadia), 81t-82t
- Cervical cancer, 1171, 1173-1202  
   adjuvant therapy for, 1173  
   advanced, 1188-1189  
     chemotherapy for, 1188-1189, 1188.e1t  
     irradiation for, 1189  
   Bethesda system for, 1174, 1174t  
   biology of, 1173  
   brachytherapy for, 277-279, 278f, 1193-1199  
     high-dose-rate, 1196-1199  
       fractionation schedules for, 1197  
       image-guided, 1199  
       linear quadratic (LQ) model for, 1196  
       *versus* low-dose-rate, 1196, 1196t  
       sedation methods for, 1198  
       tandem and ring system for, 1198, 1198f  
       timing of, 1197-1198  
   interstitial, 1199  
   low-dose-rate intracavitary therapy, 1194-1196  
     dose specification for, 1195-1196, 1195f  
     Fletcher-Suit-Delclos applicator system for, 1194f, 1195  
     Henschke applicator for, 1194  
     high-dose-rate *versus*, 1196, 1196t  
     Manchester system for, 1195-1196  
     placement of system in, 1195  
     vaginal cylinders for, 1195  
   plus external beam irradiation, 1181  
     central dose escalation with, 1195, 1195f  
   chemoradiation for, 76-77, 77t, 1180-1181, 1180.e1f  
     cisplatin-based, 1181  
       with hydroxyurea, 1180.e1f  
       risk reduction in, 1180, 1180f  
     definitive, systemic therapy after, 1181  
     radiation therapy *versus*, 1181.e1t  
   chemotherapy for  
     for advanced disease and palliation, 1188-1189  
     neoadjuvant, 1183-1184  
   clinical manifestations of, 1178-1179  
   diagnostic algorithm for, 1178, 1179f  
   distant metastases of, 1176  
   epidemiology and etiology of, 1173-1174  
   high-grade squamous cell intraepithelial lesion and, 1174  
   HPV and, 1174  
     molecular biology of, 1176-1177, 1177f  
   imaging of, 1178  
     staging and patient evaluation, 1178-1179
- Cervical cancer (Continued)  
   IMRT for, 1191-1193, 1193f  
   incidence of, 1173  
   irradiation techniques and tolerance for, 1189-1200  
     external beam, 1189-1191  
       dosimetry plan for, 1191, 1192f  
       “field-based planning” for, 1190, 1190f  
       image-guided CT or MRI planning for, 1190-1191, 1190f  
       ports for, 1191, 1191f  
       intensity modulated, 1191-1193, 1193f  
       normal tissue effects of, 1199-1200  
   locally advanced disease and, 1188-1189  
   lymphangiography of, 1178  
   magnetic resonance imaging of, 1178  
   microinvasive, 1184-1185  
   molecular biology of, 1176-1177  
   palliation of, 1173, 1188-1189  
     advanced disease and, 1188-1189  
     chemotherapy for, 1188-1189, 1188.e1t  
     irradiation for, 1189  
   pathology of, 1176  
   pathways of spread of, 1176  
   pelvic lymph node involvement in, 1176  
   PET scanning of, 1178  
   preinvasive, 1184  
   prevention and early detection for, 1174-1176  
   primary therapy for, 1173, 1179-1188  
     by disease extent, 1173, 1179, 1180t  
     by disease stage, 1184-1188  
     for FIGO stages IB and IIA disease, 1185-1188, 1185f  
     for microinvasive disease, 1184-1185  
     for preinvasive disease, 1184  
   prognostic factors for, 1176  
   radiation therapy for  
     adjuvant postoperative, 1186-1187  
     dose and duration of, 1181-1182  
     extended-field, 1182-1183, 1182t  
     impact of anemia and tumor hypoxia on outcome of, 1183  
     smoking and cigarette cessation during, 1183  
     variables in, 1181-1184  
   radiotherapy for, intraoperative, 326  
   recurrent, treatment of, 1188  
     isolated locoregional relapse, 1188  
   risk factors for, 1174  
   RTOG Protocol 90-01 for, 1180f, 1181  
   sentinel lymph node assessment, 1186  
   staging of, 1173, 1175, 1175t  
   surgical, 1178  
   surgery for  
     adjunctive, 1187-1188  
     fertility-preserving, 1186  
     minimally invasive, 1186  
   treatment algorithm and future possibilities in, 1200, 1200f
- Cervical esophagus, 846
- Cervical lymph node metastases  
   hyperthermia for, 394  
   of melanoma, 784, 784f
- Cervical tumors  
   hyperthermia for, 393t, 394  
   primary, 202
- Cervix, lymphatics of, 1176
- Cesium-131 (<sup>131</sup>Cs), in brachytherapy, 277t, 281
- Cesium-137 (<sup>137</sup>Cs)  
   in brachytherapy, 277t  
   for teletherapy, 96
- Cetuximab, 26, 81t-82t, 83, 178, 407  
   for colon cancer, 984  
   for esophageal cancer, 855  
   for head and neck squamous cell carcinomas, 567

- Cetuximab (*Continued*)  
 for oropharyngeal cancer, 616  
 for rectal cancer, 1004
- Characteristic x rays, 103
- Charged-particle equilibrium, 109, 109f
- Charged particle interactions, 106-109  
 of heavy charged particles, 108, 108f  
 of heavy uncharged particles (neutrons), 108  
 of light charged particles, 107-108, 107f
- Charged particle radiotherapy, 358-372  
 carbon ions, 369-370  
 helium, 370  
 linear energy transfer in, 358  
 $\pi$ -meson, 370, 370f  
 neon ion, 370  
 for ocular melanoma, 550  
 for prostate cancer, 1065-1067, 1066.e1  
 carbon ion therapy as, 1066.e1  
 proton therapy as, 1065-1067  
 clinical outcomes of, 1066  
 future applications of, 1066-1067  
 historical perspective of, 1065.e1  
*versus* IMRT, 1065-1066, 1067f  
 radiobiology and second malignancies with, 1066  
 technical issues with, 1065-1066, 1066f-1067f  
 proton beam. *see* Proton beam radiotherapy  
 spread-out Bragg peak dose distribution for, 358, 359f
- CHART. *see* Continuous hyperfractionated accelerated radiation therapy (CHART)
- Checkpoints, 42-43, 42f
- Chelators, 400.e1  
 toxicities and, 413
- Chemical dosimeter, 114
- Chemical shift imaging (CSI) MRI, 200
- Chemoablation, for liver metastases, 446
- Chemodectoma, 1375-1376
- Chemoprevention  
 of bladder cancer, 1097-1098  
 of head and neck tumors  
 adjuvant, 568  
 of malignant transformation, 568  
 of nasopharyngeal carcinoma, 630  
 of non-small cell lung cancer, 813  
 of prostate cancer, 1040
- Chemoradiation  
 for anal cancer, 72, 73t, 72.e1t  
 for bladder cancer. *see* Bladder cancer  
 for cervical cancer, 1180-1181, 1180.e1f  
 cisplatin-based, 1181  
 with hydroxyurea, 1180.e1f  
 risk reduction in, 1180, 1180f  
 definitive, systemic therapy after, 1181  
 radiation therapy *versus*, 1181.e1t  
 concurrent. *see* Concurrent chemoradiation  
 for oropharyngeal cancer, 613-614  
 for salivary gland tumors, 709-710  
 for vulvar cancer  
 GOG Protocol, 1242, 1242t, 1243f  
 preoperative, 1240-1242, 1241f, 1242.e1f-1242.e2f  
 primary, 1242-1244  
 treatment of inguinal nodes, 1243-1244, 1244t  
 treatment of primary lesions, 1242-1243
- Chemoradiotherapy, for sinonasal cancer, 695
- Chemosensitization, 63
- Chemotherapy, 171-185  
 adjuvant, 175  
 angiogenesis antagonists and, 179-180  
 basis of, 173  
 combination, 184
- Chemotherapy (*Continued*)  
 cytotoxic drugs and, 176  
 drug administration, clinical schedules of, 181-183  
 drug sanctuaries and, 182-183  
 drug resistance in, 183-184, 183t  
 drugs that induce differentiation, 176  
 epigenetic modifiers and, 180  
 HER-2 directed, 178  
 high-dose, 175  
 history of, 171-173  
 hyperthermia and, 385-386  
 clinical, 391  
 factors to consider for, 386  
 sequencing as, 386  
 temperature dependence as, 386  
 in vitro results in prediction of in vitro activity as, 386  
 phase III clinical trials of, 395, 395t  
 with radiotherapy, 385  
 clinical, 391  
 rationale for, 385  
 immunotherapy and, 176-177  
 induction, 175  
 models for, 173-175, 174f  
 neoadjuvant, 175  
 pharmacokinetics and pharmacodynamics of, 180, 181t  
 PI3 kinase as target for, 178-179, 179f  
 predicting tumor response to, 183  
 proteasome inhibition and, 179  
 receptor tyrosine kinases as targets of, 177-178  
 solid tumor, 175-176  
 targeted therapies and, 177  
 for thyroid cancer, 725
- Chemotherapy and radiation interaction, 63-79  
 analysis of, 67-69, 67f  
 median dose effect principle in, 68-69, 69f  
 clinical examples of, 72-77  
 cervical cancer, 76-77, 77t  
 gastrointestinal cancers, 72-74  
 anal cancer, 72, 73t, 72.e1t  
 esophagus/esophago-gastric junction, 73  
 gastric, 73  
 rectal, 73-74, 74t  
 genitourinary cancer, 77  
 glioblastoma as, 77  
 head and neck cancers, 74-75, 75t  
 non-small cell lung carcinoma, 75-76, 76t  
 combinations of cytotoxic agents, 69-72  
 chemotherapeutic classes in, 70-72, 70f  
 general concepts of, 69-70  
 from bench to the clinic, 69  
 therapeutic benefits as, 69-70  
 historical perspective of, 63  
 for molecular prediction, 77-78  
 potential biological mechanisms of, 66-67  
 cell cycle effects as, 66  
 cell death pathway effects as, 67  
 hypoxia/tumor microenvironment and, 66-67  
 increasing radiation damage as, 66  
 inhibition of DNA repair as, 66  
 repopulation as, 66  
 rationale for, 63-66  
 biological cooperation and, 65t, 66  
 enhanced tumor response (cytotoxic enhancement), 65t, 66  
 limitations in current therapeutic approach, 63-64  
 increased toxicity in, 64  
 to inherent and acquired resistance, 63-64, 64f  
 in tumor detection, 63
- Chemotherapy and radiation interaction (*Continued*)  
 normal tissue protection and, 65, 65t  
 spatial cooperation and, 65-66, 65t  
 temporal modulation and, 65t, 66  
 therapeutic index as, 64-66, 64f  
 strategies to improve, 65
- Chemotherapy drugs, 902  
 analogs of natural metabolites as, 172f  
 classes of, 70-72, 70f  
 alkylating agents as, 70-71  
 anthracyclines as, 72  
 antifolates as, 70  
 antimetabolites as, 70  
 dactinomycin as, 72  
 microtubule targeting as, 71  
 mitoxantrone as, 72  
 platinum as, 71  
 podophyllotoxins as, 72  
 topoisomerase inhibitors as, 71-72  
 clearance mechanisms of, 180, 181t  
 drug sanctuaries and, 182-183  
 examples of pharmacokinetic drug interactions involving, 181t  
 pharmacodynamic relationships of, 181t  
 as radiosensitizers, 26  
 resistance to, 174, 183-184, 183t
- Chest, imaging of, 191-194  
 lymphoma in, 193, 193f  
 metastatic disease to the chest in, 193-194  
 primary tumors of the lungs in, 191-193, 192f
- Chest wall, soft-tissue sarcoma of, 1367
- Childhood cancers, 1385-1387, 1386t  
 of CNS. *see* Central nervous system (CNS)  
 tumors, in children  
 desmoplastic small round cell tumor as. *see* Desmoplastic small round cell tumor (DSRCT), pediatric  
 epidemiology of, 1385  
 extracranial germ cell tumors as. *see* Germ cell tumors, pediatric  
 Hodgkin's lymphoma as. *see* Hodgkin's lymphoma, pediatric  
 juvenile nasopharyngeal angiofibroma as. *see* Juvenile nasopharyngeal angiofibroma  
 Langerhans cell histiocytosis as. *see* Langerhans cell histiocytosis, pediatric  
 leukemias and lymphomas as, 1455  
 low-grade gliomas in, 455, 455t  
 molecularly targeted agents for, 1387  
 morbidities of, 1385-1386  
 nasopharyngeal cancer as. *see* Pediatric nasopharyngeal cancer  
 neuroblastoma as, 1447  
 pleuropulmonary blastoma as. *see* Pleuropulmonary blastoma, pediatric  
 radiation therapy for, 1385-1386  
 neurocognitive effects of, 1387  
 photon beam, 1386-1387  
 and secondary carcinogenesis, 1387  
 retinoblastoma as, 1433  
 sarcomas as  
 of bone. *see* Sarcoma(s), of bone, pediatric  
 of soft tissue. *see* Soft-tissue sarcoma (STS)  
 as syndromes, 1385  
 threshold radiation levels for, 1387  
 total body irradiation for, 350-351  
 Wilms' tumor as, 1422
- Chimeric C2B8, 409.e1t
- chl6, 406-407
- Chlamydia psittaci*, and lymphoma, 1525
- Chlorambucil, 70
- Chlorination, and bladder cancer, 1097
- Chloroma, spinal canal, 536



- Cholangiocarcinoma  
   diagnosis of, 965  
   distal, 970  
   epidemiology and etiology of, 961  
   etiology of, 961  
   extrahepatic, 968-970, 975, 975f  
     adjuvant therapy for, 970  
     brachytherapy for, 975, 975f  
     gallbladder cancer and, 973  
     neoadjuvant chemoradiation plus  
       transplant for, 970  
   intrahepatic, 973  
     irradiation technique for, 974-975,  
       974f  
     primary therapy for, 968  
   molecular biology of, 962  
   pathology of, 963  
   prevention and early detection, 962  
   radiographic studies of, 964  
   radiotherapy for, conformal, 972  
 Cholangitis, symptoms and signs of, 963  
 Chondrosarcoma, of spine, 527t, 536  
 CHOP chemotherapy, with  
   radioimmunotherapy for lymphoma,  
   411  
 Chordoma, 527t, 535-536  
 Choriocarcinomas, 1124.e1  
   pediatric, 1489, 1489t  
 Choroid plexus tumors, 1400  
 Choroidal hemangioma, 1377  
 Choroidal metastasis  
   etiology and epidemiology of, 542  
   pathology of, 544  
   presentation of, 548  
   primary and adjuvant therapy for, 550  
 Chromatin, in DNA double-stranded break  
   response, 44  
 Chromic phosphate, for ovarian cancer  
   advanced-stage, 1277, 1277t  
   early-stage, 1270-1271  
 Chromosomal instability (CIN), in colorectal  
   cancer, 993  
 Chromosomal rearrangements, salivary gland  
   tumors and, 699-700  
 Chromosome 1q, gain of, 1424  
 Chromosome aberrations, ionizing radiation  
   and, 10, 10f  
 Chronic immunosuppression, 1021  
 Chronic myelogenous leukemia (CML), 352,  
   352.e2t  
 Chronic obstructive pulmonary disorder  
   (COPD), and non-small cell lung cancer,  
   810  
 Cigarette smoking. *see also* Tobacco use  
   and anal carcinoma, 1021  
   and bladder cancer, 1097  
   and cervical cancer, 1183  
   and laryngeal cancer, 650  
   and non-small cell lung cancer, 810  
   and oropharyngeal cancer, 598-599  
   and pancreatic cancer, 935  
   and renal cell carcinoma, 1140  
   and sinonasal cancer, 674  
   and small cell lung cancer, 798-799  
   and upper urinary tract cancer, 1140  
   and vulvar carcinoma, 1231  
 CIMP. *see* CpG island methylator phenotype  
   (CIMP)  
 CIN. *see* Chromosomal instability (CIN)  
 Circulating tumor DNA (ctDNA), 91-92  
 Circumferential resection margin (CRM),  
   166, 998, 998.e1f  
 Circumscribed scleroderma, of breast,  
   1324  
 Cirrhosis, 961  
 CIS. *see* Carcinoma in situ (CIS)
- Cisplatin, 71, 886  
   for anal carcinoma, 1027  
   for cervical cancer, 1181  
     advanced, 1188, 1188.e1t  
   for endometrial cancer, 1218, 1220.e1  
   for nasopharyngeal carcinoma, 636, 637t  
   for oropharyngeal cancer, 612  
   for ovarian cancer, 1275  
   pharmacodynamic of, 181t  
   radioimmunotherapy with, 406  
 c-KIT/CD117, 700-701  
 Clear cell adenocarcinoma (CCAC), of vagina,  
   1255, 1262-1263  
 Clear cell carcinoma(s)  
   cervical, 1174  
   of endometrium, 1205  
   of ovary, 1268  
 Clear cell sarcoma, 1351  
   of kidney, 1424, 1424t, 1425f  
     chemotherapy for, 1430  
 Clearing agent, 417.e1  
 Clinical research, 217  
 Clinical setup, 123  
 Clinical target volume (CTV), 125, 126f, 300,  
   300f, 1029-1030  
   determination, 890f  
   for head and neck cancer, 318  
 Clinical trials, 239-252  
   defined, 239  
   goals of, 239  
   phase I, 240-241  
     newer designs, 241  
     traditional cohorts-of-3 design, 240-241  
   phase II, 241-243  
     randomized design, 242-243  
     traditional single-arm  
       one-stage design, 241-242, 242t  
       two-stage design, 242, 242t  
   phase III, 243-246  
     current topics in, 249-251  
       adaptive design in, 250-251  
       biomarkers, 250, 250f-251f  
       surrogate end points, 249-250  
     intent to treat in, 244-246, 244f-245f  
     monitoring ongoing trials in, 246  
     rationale for randomization in, 243  
     stratification of treatment assignments in,  
       243-244  
 Cloacogenic carcinoma, 1022-1023  
 Clonogen doubling time, 28t, 29-30  
 Clonogenic assays  
   in vitro, 12-13, 13f  
   in vivo, 13  
 Clonogenic cell survival assay, 41-42, 67-68  
 Clonogenic death, 11  
 "Cluster" hypothesis, 7  
 c-MET, 90  
 c-MYC, Burkitt lymphoma and, 1528-1529  
 CO-1686, 81t-82t  
 Cobalt-60 (<sup>60</sup>Co)  
   as radionuclide, 95-96  
   for teletherapy, 96, 97f  
   radiation sources for, 99  
 Cochlea  
   dose-dependent damage of, with  
     nasopharyngeal carcinoma, 645  
   late effects of radiation on, 256t-257t, 260-261  
 Cognitive impairment, from central nervous  
   system tumors, 1400-1401  
 Coherent scattering, 103, 103f, 109  
 Cohorts-of-3 phase I design, 240-241  
 Collimators  
   for <sup>60</sup>Co unit, 96f, 97  
   of linear accelerators, 97-98  
   multileaf, for conformal radiotherapy,  
   132-133
- Colon cancer, 977-991  
   adjuvant therapy for, 977  
     with or without chemotherapy, 984-987,  
       984f, 984t  
     rationale, 977-978  
   analyses, SEER, 899, 900t  
   biologic characteristics of, 978-979  
   chemotherapy for  
     adjuvant, 981-984  
       locally advanced disease, 987  
   clinical manifestations of, 979, 979f  
   etiology and epidemiology of, 978  
   hereditary nonpolyposis, ovarian cancer and,  
   1266  
   irradiation for  
     adjuvant, 984-986, 985f-986f  
     intraoperative, 989-990  
     palliative, 987  
     techniques of, 987-988, 988f-989f  
   locally advanced, 977, 987  
   metastatic, 987  
   molecular biology of, 978-979  
   palliation of, 977, 987  
   pathology of, 977, 979  
   pathways of spread of, 979  
   prevention and early detection of, 978  
   primary therapy for, 977, 979-987  
   prognostic factors for, 979  
   radiotherapy for  
     intraoperative electron, 977  
     phase III intergroup trial of, 986  
   screening of, 978  
   staging of, 979, 979f  
     evaluation, 977, 979, 979f  
     TNM, 982t  
   surgery for, 979-981, 981f  
   survival outcomes for, 982t  
   treatment algorithm, conclusions and future  
     possibilities in, 989-990, 990b  
 Colonoscopy, virtual, 993  
 Colorectal adenocarcinoma, comparison of  
   staging systems for, 898t  
 Colorectal cancer, 992. *see also* Colon cancer;  
   Rectal cancer  
   adjuvant, 898-899  
   etiology and epidemiology of, 978  
   hereditary nonpolyposis, 977  
   and endometrial cancer, 1204  
   hyperthermia for, 393t, 394  
   imaging of, 195  
     PET scan of, 211, 212f  
   intraoperative radiotherapy for, 326, 336-338,  
     337t  
   pathology and pathways of spread of, 979  
   prevention and early detection of, 978  
   prognostic factors for, 979, 980b  
   radioimmunotherapy of  
     with external beam radiotherapy, 406  
     with liver metastases, 405, 408.e4t  
     monoclonal antibodies for, 402.e2t-402.e4t,  
       402.e6t  
     with pretargeting, 408.e3t  
   stages II and III, AJCC, 900t  
   staging of, 898, 980t, 997t  
 Combination index, 69  
 Combination therapy. *see* Chemoradiation  
 Combined-modality therapy, for  
   nasopharyngeal carcinoma, 636-639  
 Combined radiotherapy and systemic therapy,  
   principles for, 565  
 Combretastatin, 404  
 Combretastatin A-4 phosphate, 58, 59f  
 Common hepatic artery (CHA), and borderline  
   resectable pancreatic cancer, 947.e1t  
 Compensators, 120  
 Complete response, 5

- Complex hyperplasia, 1205  
 Compton effect, 103*f*, 104-105, 109  
 Compton electrons, 104-105  
 Compton photon, 104  
 Compton scattering, 105  
 Computed tomographic guidance, for biopsy, 159  
 Computed tomographic simulation, 124-125  
   for mesothelioma, 889  
 Computed tomography (CT)  
   advantages of, 186  
   cone beam, 314  
   for conformal radiotherapy, 298-299, 298*b*-299*b*  
   4D, 298, 316  
   simulation, 298-299, 298*b*-299*b*  
   for esophageal tumors, 194, 194*f*  
   for head and neck, 190*f*, 191  
   for oropharyngeal cancer, 605-606  
   planning for, endometrial cancer, 1221, 1221*f*  
   for prostate cancer, 1053  
   for stages III/IV thymoma, 870*f*  
   for thymic tumors, 870*f*  
   for tumor hypoxia, 52  
 Computed tomography-based screening studies, non-small cell lung cancer, 812-813  
 Concomitant boost, for non-small cell lung cancer, 830  
 Concurrent chemoradiation  
   for nasopharyngeal carcinoma, 640, 640*t*  
   for oropharyngeal cancer, 612-613, 612*t*-613*t*  
   for sinonasal cancer, 688  
 Concurrent cisplatin-based chemoradiotherapy (C-CRT), 235  
 Concurrent oxaliplatin regimens, 1003-1004  
 Conditioning, for hematopoietic stem cell transplant, 343  
 Conduction bands, 112-113  
 Cone beam CT (CBCT), 314  
 Cone radiotherapy, intraoral, 579  
 Conformal radiotherapy  
   beam's-eye view in, 296, 296*f*  
   clinical considerations for, 316-323  
   determining the targets as, 317-318  
   immobilization and setup uncertainties as, 317  
   patient and organ motion as, 317  
   definitions for, 294, 295*f*  
   delivery of, 314-316  
   IGRT process and, 315  
   manual and computer-controlled, 315-316  
   electronic medical records, patient treatment chart, and treatment management systems and, 316  
   setup error and patient motion management, consideration of, 316  
   tools for image guidance and, 314-315  
   CBCT as, 314  
   KV imaging as, 314  
   MR devices as, 314-315  
   MV imaging as, 314  
   RF beacons as, 314  
   video surface imaging as, 315  
   transitioning to image-guided radiation therapy, 314  
   dose considerations in, 317  
   for gynecologic cancers, 319, 321  
   issues for clinical use of, 297  
   for pediatric tumors, 321  
   planning for, 297-309, 297*f*  
   anatomy for, 299  
   beam arrangements for, 310  
   beam definition and, 302-303  
   beam technique in, 303  
 Conformal radiotherapy (*Continued*)  
   CT, CT simulation, MRI, and other cross-sectional imaging in, 298-299, 298*b*-299*b*  
   dataset registration and fusion in, 301, 302*f*  
   dose calculations for, 305  
   algorithms for, 305-306, 306*t*  
   other issues in, 306  
   three-dimensional, 305  
   dose display in, 306-308, 307*f*  
   dose-volume histograms in, 308, 308*f*  
   evaluation tools in, 306  
   forward, 309-310  
   plan evaluation for, 310  
   setting planning goals for, 310  
   functional imaging modalities in, 302  
   isocentric, 305  
   motion, setup, and four-dimensional anatomy in, 301-302  
   multileaf collimator and blocks, shaping with, 303-304, 303*f*-304*f*  
   normal tissues in, 300-301  
   other quantitative metrics in, 308-309  
   positioning and immobilization in, 297-298  
   structure delineation and contouring in, 299  
   target volume definition and margins in, 299-300, 300*f*, 300*t*  
   three-dimensional anatomic model in, 299  
   short history of, 294-297  
   three-dimensional, 130-133, 134*f*  
 Conjunctiva, radiation and, 556  
 Conjunctival melanoma, etiology and epidemiology of, 541-542, 541*e1f*  
 Connective tissue  
   benign diseases of, 1378-1380  
   radiobiologic reactions in, 1373  
 Contact radiotherapy, for rectal cancer, 287  
 Continual reassessment method (CRM), 241  
 Continuous hyperfractionated accelerated radiation therapy (CHART)  
   for head and neck tumors, 563  
   for non-small cell lung cancer, 830-831  
   for oropharyngeal cancer, 617  
 Continuous thymidine labeling, 28  
 Contrast agents, 186  
 Contrast media-induced nephropathy, 186  
 Conus medullaris lesions, 526  
 Conversion electron, 138  
 Convolution models, for photon dose calculation, 127-128  
 Cooper's suspensory ligaments, 1285  
 Copper-67 (<sup>67</sup>Cu), in radioimmunotherapy, 400*t*, 400*e1*  
 Core-needle biopsy, 159-160  
   in soft-tissue sarcoma diagnosis, 1352-1353  
 Cornea, radiation and, 556  
 Corticosteroids  
   for acute lymphoblastic leukemia, 171  
   topical, for mycosis fungoides, 1566  
 Cost-benefit analysis, 236  
 Cost-effectiveness studies, 236  
 Cost studies, 236  
 Costomediastinal sulcus, 889*f*  
 Cough, non-small cell lung cancer and, 835*t*  
 Coulomb (C), 109  
 COX-2. *see* Cyclooxygenase-2 (COX-2)  
 Cox proportional hazard model, for survival analysis, 249  
 CpG island methylator phenotype (CIMP), 896-897  
   in colorectal cancer, 993  
 Cranial irradiation, prophylactic  
   for non-small cell lung cancer, 824, 824*t*  
   for small cell lung cancer, 803-804  
 Cranial jugular nodes, 740*t*  
 Craniofacial resection, for sinonasal cancer, 694-695, 694*e1f*  
 Craniopharyngioma(s), 502, 519  
   anatomy of, 519*e1*  
   biologic characteristics of, 519*e1*  
   in children, 1398-1400, 1400*f*  
   clinical manifestations of, 519*e1*  
   imaging of, 519*e1*  
   pathology of, 519*e1*  
   pathways of spread of, 519*e1*  
   patient evaluation in, 519*e1*  
   radiotherapy for, 519  
   techniques and tolerance to, 519*e2*  
   staging of, 519*e1*  
   treatment of, 519  
 Cribriform plate, 677*f*  
 Criterion-based benchmarking, 226-227, 227*f*  
 Crizotinib, 81*t*-82*t*, 178  
 CRM. *see* Circumferential resection margin (CRM)  
 Cryosurgical freezing, for renal lesions, 1145  
 Cryotherapy, for retinoblastoma, 1436-1437  
 CSSANZ trial, 1005  
 cT1N0M0, rectal cancer, 1016*e2f*  
 cT2N0M0, rectal cancer, 1016*e2f*  
 CTLA-4 inhibitors, 89  
 CTNNB1 gene, 1423  
 Cumulative dose-volume histogram (cDVH), 308, 308*f*  
   for external beam treatment evaluation, 128, 128*f*  
 Cumulative equivalent minutes (CEM), for hyperthermia, 381  
 "Curative resection," relapse patterns after, in gastric cancer, 912-913, 912*t*, 913*f*, 912*e1t*  
 Cushing's disease, 514-516  
   imaging of, 507  
   laboratory assessment of, 506  
   medical therapy for, 516  
   radiation therapy for, 516  
   stereotactic radiosurgery for, 516, 516*t*  
   surgery for, 515-516  
   treatment algorithm for, 515, 515*f*  
 Cutaneous anaplastic large cell lymphoma, 1562  
 Cutaneous carcinoma, 763-776  
   adjuvant treatment of, 763  
   adnexal. *see* Adnexal carcinoma  
   basal cell. *see* Basal cell carcinoma (BCC)  
   biologic characteristics of, 763  
   diagnostic and treatment algorithms for, 775-776  
   etiology and epidemiology of, 763  
   evaluation of, 768-769  
   imaging studies of, 768, 768*f*  
   irradiation techniques for, 773-775  
   setup, field arrangement, and dose fractionation schedule, 773-774, 774*f*  
   target volume, 773  
   locally advanced, 763, 772, 773*f*  
   manifestations of, 764-768  
   Merkel cell. *see* Merkel cell carcinoma (MCC)  
   palliation for, 763, 772, 773*f*  
   pathobiology of, 764-768  
   patient care during and after radiotherapy for, 775  
   prevention and screening of, 764  
   primary treatment for, 763, 769-772  
   squamous cell. *see* Squamous cell carcinoma (SCC)  
   staging of, 763, 768-769  
 Cutaneous lymphocyte antigen (CLA), in mycosis fungoides, 1557, 1558*f*  
 Cutaneous lymphomas, 1541-1542, 1542*f*  
 Cutaneous T-cell lymphoma (CTCL), 1556  
   CD30+ large cell, 1562

- Cutaneous T-cell lymphoproliferative disorders, 1562-1563
- Cyclic RGD peptide, 404
- Cyclin D1  
in esophageal cancer, 846  
in head and neck tumors, 567
- Cyclin-dependent kinases, 42-43, 42f
- Cyclins, 42-43
- Cyclooxygenase-2 (COX-2)  
and esophageal cancer, 845, 850  
inhibitors, 630  
and rectal cancer, 993
- Cyclophosphamide, 70-71, 181t
- Cyclophosphamide, doxorubicin and cisplatin (CAP), for salivary gland tumors, 710
- Cyclotron, 100
- CYP2E1, 1497
- Cyproterone, for prostate cancer, 1085
- Cystectomy  
partial, 1106  
radiation as adjunct to, 1105  
radical, 1104-1105  
cancer outcome after, 1104-1105  
with continent urinary tract reconstruction, 1104  
with cutaneous urinary reservoir, 1104.e1  
with incontinent urinary tract reconstruction, 1104  
morbidity of, 1104  
with orthotopic diversion, 1104.e1  
surgical methods for, 1104
- Cysteine, 58-59, 59f
- Cystic neoplasms, of pancreatic cancer, 937
- Cytokines, 33  
radiation pneumonitis and, 263
- Cytoreductive surgery, for ovarian cancer, advanced-stage, 1272-1273
- Cytosine arabinoside, deoxycytidine and, 172f
- Cytotoxic chemotherapy, for oropharyngeal cancer, 615-616
- Cytotoxic drugs, 176
- Cytotoxic enhancement, in chemoradiation, 65t, 66
- Cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), 89
- Cytotoxicity, 2
- D**
- Dabrafenib, 81t-82t, 177
- Dacarbazine, 71
- Dactinomycin, 72
- "Daisy chaining", 154
- Danish Head and Neck Cancer Study Group (DAHANCA), 617
- Daratumumab, 81t-82t
- Dark energy, 93
- Dark matter, 93
- Dasatinib (Sprycel), 81t-82t
- Data Safety Monitoring Board (DSMB), 246
- Dataset registration and fusion, 301, 302f
- Daunorubicin, 72
- Debulking, for ovarian cancer, advanced-stage, 1272-1273
- Decadron (dexamethasone), for spinal cord compression, 442
- Decay constant, 138
- Decision supportive tools, for rectal cancer, 1016-1017
- Deep Inspiration Breath Hold (DIBH) methods, 316
- Degarelix, for prostate cancer, 1085
- Denileukin diftitox, for mycosis fungoides, 1567
- Denosumab, 81t-82t, 1086
- Densely ionizing radiation, 19-20  
linear energy transfer, 19, 19f  
relative biological effectiveness, 19-20, 20f  
factors that influence, 20, 20f-21f
- Density scaling, 122
- Dental caries. *see* Caries
- Dental health, 571
- Denys-Drash syndrome, 1423
- Deoxycytidine, cytosine arabinoside and, 172f
- Dermatofibrosarcoma protuberans, 1347, 1368
- Dermatomes, 524, 525f
- DES. *see* Diethylstilbestrol (DES)
- Desmoid, 1378-1379  
extraabdominal, 1368
- Desmoplastic small round cell tumor (DSRCT), pediatric, 1494-1495  
adjuvant therapy for, 1495, 1495f  
biology of, 1494  
challenges on, 1495  
clinical manifestations of, 1494-1495  
etiology and epidemiology of, 1494  
evaluation for, 1494-1495, 1495f  
irradiation techniques for, 1495  
pathology of, 1494  
pathways of spread of, 1494  
primary therapy for, 1495, 1495f  
staging of, 1494-1495  
treatment algorithms, controversies and future possibilities in, 1495
- Dexamethasone, 442  
for multiple myeloma, 1551
- Diabetes, FDG-PET scanning and, 208
- Diet  
and colorectal cancer, 993  
and oropharyngeal cancer, 600.e1  
and prostate cancer, 1039  
and renal cell carcinoma, 1140
- Diethylstilbestrol (DES)  
and cervical cancer, 1174  
for prostate cancer, 1077, 1085  
and vaginal carcinoma, 1255
- Differential dose-volume histogram (dDVH), 308  
for external beam treatment evaluation, 128, 128f
- Differentiating intermitotic (DIM) cells, 27
- Differentiation inducers, 176
- Diffuse large B-cell lymphoma (DLBCL), 1527-1528  
advanced, 1538  
cutaneous, 1542  
localized, 1537-1538, 1538f  
pediatric, 1462  
relapsed and refractory, 1538-1540  
RT management of, 1545  
testicular, 1540  
of thyroid, 726  
treatment of, 1503-1504
- Diffuse pontine glioma, 1397
- Diffusion-limited hypoxia, 23
- Diffusion-weighted imaging (DWI), 187, 207-208
- Digital rectal examination (DRE), in prostate cancer  
in physical examination, 1053.e1  
for screening, 1041
- 3,4-Dihydroxy-6-<sup>18</sup>F-fluoro-phenylalanine (<sup>18</sup>F-FDOPA), 214
- 2,3-Diphosphoglycerate (2,3-DPG), 56
- Direct dose volume histogram (dDVH), 308, 308f
- Division delay, 18
- DNA damage  
biochemical repair of, 8-9  
from ionizing radiation, 7, 8f
- DNA damage (*Continued*)  
response to, 8  
as clinical target, 9-10
- DNA dependent protein kinase (DNA-PK), 44, 45f, 46-48
- DNA repair, 8  
base excision, 8-9  
double-stranded break, 9, 44-46, 45f  
inhibition of, chemoradiation and, 66  
mechanisms of, 44  
mismatch repair, 9  
nucleotide excision in, 9, 44  
PARP and, 87-88, 88f, 88t  
single-stranded break, 9
- DNA repair inhibitors, 87-89  
CHK1 and WEE1, 88-89
- DNA strand breaks, 44  
double. *see* Double-stranded break(s) (DSBs)
- DNA synthesis  
cytotoxic drugs and, 176  
inhibitors, 16-17
- Docetaxel, 71, 1085
- Dorsal cervical nodes, 740t
- Dose, 109-111, 110f, 111t  
primary and scatter, 116
- Dose colorwash, for nasopharyngeal carcinoma, 644f, 647f
- Dose equivalent, 111t, 145
- Dose fractionation effects, 34-35, 35f, 35t
- Dose-limiting toxicity (DLT), 240
- Dose profile, 116, 117f, 117t
- Dose reduction factors (DRFs), 27
- Dose-response modifiers, 51-62  
dose-response relationship, 51, 52f  
radiation protectors as, 58-61  
modifiers of oxygen supply as, 61, 61f  
others, 61  
sulfhydryl-containing compounds as, 58-61, 59f-60f, 60t  
tumor hypoxia and, 51-52  
evidence for, 52, 53f  
importance of oxygen in, 51-52  
overcoming, 53-57  
with bioreductive drugs, 56-57, 57f  
by changing oxygen consumption, 56  
by dealing with the problem of fluctuating (acute) hypoxia, 56, 57f  
with dose modification based on hemoglobin, 55-56  
with high-oxygen-content gas breathing, 53, 53t  
with hypoxic cell radiosensitizers, 53-55, 54t, 55f  
vascular targeting agents as, 58, 58t, 59f
- Dose-volume histograms (DVHs)  
for conformal radiotherapy, 301, 308, 308f  
utility and limitations of, 253-254, 254f
- Dosimeters  
absolute, 114  
chemical (Fricke), 114  
MOSFET, 113, 113f, 129-130  
personnel, 114  
thermoluminescent, 112-113, 113f, 129
- Dosimetry  
defined, 415  
for external beam treatment, 125-129  
beam nomenclature, 127, 127f  
dose computation algorithms in, 127-128  
dose specifications, 125-127, 126f  
dose recording and reporting, 126  
dose reporting for different techniques, 126-127  
evaluation and optimization of, 128  
monitor unit calculations in, 128-129  
purpose and procedures for, 125, 125f

- Dosimetry (*Continued*)  
 three-dimensional treatment planning in, 127, 127f  
 two-dimensional treatment planning in, 127  
 for radioimmunotherapy, 415-416  
 of stereotactic radiosurgery beams, 149-154  
 considerations in, 152-153  
 detector selection for, 152, 152f  
 percent depth dose (PDD) in, 153, 153f  
 relative output factors in, 152, 153t  
 verification of, 129-130  
 in vivo, 129-130
- Double-scattered proton technique, 1390-1391
- Double-stranded break(s) (DSBs), 3  
 repair, 9
- Double-stranded break response, 42-46  
 ATM gene in, 43-44  
 cell cycle arrest in, mechanisms of, 42-43, 42f  
 damage and repair in, 44-46, 45f  
 DNA strand breaks in, 44  
 histones and chromatin structure in, 44  
 TP53 in, 43, 43f
- Doubling time(s)  
 effective, 28t, 29-30  
 potential, 28t, 29-30  
 volume, 28, 28t, 29f
- Doxorubicin, 72, 176, 181t  
 for endometrial cancer, 1218  
 pharmacodynamic of, 181t  
 for soft-tissue sarcoma, 1362, 1370
- Drug administration, clinical schedules of, 181-183
- Drug interactions  
 and drug administration schedules, 181-183  
 with irradiation, 175
- Drug resistance, 174, 183-184, 183t
- Drug sanctuaries, 182-183
- Dry eye syndrome, 556
- Ductal carcinoma in situ (DCIS), 1306-1311  
 accelerated partial breast irradiation for, 1310  
 biologic characteristics of, 1307  
 breast-conserving therapy for, 1308  
 classification of, 1307  
 epidemiology of, 1306  
 excision for, 1309, 1309t  
 and invasive cancer, 1307  
 management decision tree for, 1311f  
 mastectomy for, 1308  
 molecular markers of, 1307  
 pathologic characteristics of, 1307  
 pathways of spread of, 1307  
 prevention and early detection of, 1306-1307  
 primary therapy for, 1308-1311, 1308t-1309t  
 radiotherapy for, after excision, 1309  
 risk factors for, 1306  
 assessment of, 1310  
 tamoxifen for, 1309t, 1310  
 whole-breast irradiation for, 1308  
 wide excision alone for, 1310
- Dupuytren's contracture, 1379-1380
- Dural tail, 489
- Dutasteride, for prostate cancer, 1040
- Dutch Colorectal Group, 1004
- Dutch RAPIDO Phase III trial, 1004
- Dynamic contrast enhancement (DCE)-MRI, of prostate cancer, 1054
- Dynamic multileaf collimator, 296, 313
- Dynamic wedge, 120
- Dysembryoplastic neuroepithelial tumors, 461
- Dysgerminoma(s), 1489  
 ovarian, 1280
- Dysgeusia, 712
- Dysphagia, 625-626, 860
- Dyspnea, non-small cell lung cancer and, 816, 835t
- Dysproteinemias, 1547
- E**
- Early effects, in normal tissues, 30-34  
 following radiotherapy, 33-34  
 versus late, 30  
 teratogenesis as, 31  
 whole body radiation syndromes as, 30-31
- Early Mortality Risk Score (EMRS), 941
- Early-stage oropharyngeal carcinomas, treatment of, 607
- Early stopping rules, 242
- Eastern Cooperative Oncology Group (ECOG) Phase II multicenter trial, 600
- EBRT. *see* External beam radiation therapy (EBRT)
- EBV. *see* Epstein-Barr virus (EBV)
- EBVP II regimen, for Hodgkin's lymphoma, early-stage, 1511
- E-cadherin* gene, 1303
- Eccrine carcinoma, 768
- Edema, breast cancer and, 1331
- Effective doubling time, 28t, 29-30
- Effectiveness, 227-228  
 outcomes research and, 234-236
- Efficacy, defined, 227-228
- Efficiency, defined, 217
- EGFR. *see* Epidermal growth factor receptor (EGFR)
- Elastic interaction, 106-107
- Elective nodal irradiation (ENI), 793, 953  
 for prostate cancer, 1087
- Electromagnetic force, 93-94
- Electromagnetic (EM) heating, 387t, 388-389  
 capacitive radiofrequency as, 387t, 389  
 deep, 387t, 388  
 devices for, 388, 388f  
 magnetic induction as, 387t, 388-389  
 microwave array as, 387t  
 microwave waveguide as, 387t, 388f  
 radiofrequency phased array as, 387t, 389, 389f  
 superficial, 387t, 388
- Electromagnetic radiation, 2, 95
- Electromagnetic spectrum, 95
- Electrometer, 112
- Electron(s)  
 in atomic structure, 94f  
 Auger, 103  
 charged particle interactions of, 107-108, 107f  
 Compton, 105  
 conversion, 138  
 defined, 96t  
 physical characteristics of, 94t  
 secondary, distribution of, 105-106
- Electron beams, 120-123  
 dose characteristics of, 120-121, 121f, 121t  
 effect of energy on, 121-122, 121f-122f, 121t  
 effect of field size on, 122  
 penumbra of, 122, 122f
- Electron capture, 137f, 138
- Electron cutouts, 123
- Electron-positron pair, 105, 105f
- Electron volt, 96t
- Electronic balloon brachytherapy, 284
- Electronic equilibrium, 109, 109f, 152
- Electronic medical records, 316
- Electronic portal imaging devices (EPIDs), 129, 130f
- Electroporation, irreversible, 951.e2
- Elementary particles, 93
- Embryonal carcinomas, 1489, 1489t
- Embryonal rhabdomyosarcoma (ERMS), 1406
- Embryonal tumor with abundant neuropil and true rosettes (ETANTR), 1391, 1394
- Embryonal tumors, CNS, 1391
- EMLA-ALK, 812
- Empirical survival curve, 248
- EMRS. *see* Early Mortality Risk Score (EMRS)
- En bloc resection, of retroperitoneal sarcoma, 168, 169f
- End-to-end target localization, 154-155, 156f
- Endocrine dysfunction, and oropharyngeal carcinoma, 645
- Endocrine orbitopathy, 1376
- Endocrine therapy, without radiation therapy, for breast cancer, 1316-1317
- Endodermal sinus tumor(s), 1280, 1489, 1489t, 1124.e1
- Endometrial cancer, 1172, 1203-1229  
 adenosquamous, 1205  
 adjuvant therapy for, 1203  
 high risk, early stage, 1213-1214  
 histologic types, 1214-1215  
 hormonal, 1215-1216  
 stages I, 1211-1217, 1211t  
 stage II, 1211-1217, 1211t, 1215t  
 biologic characteristics of, 1203, 1206-1207  
 brachytherapy for, 279-280, 279f  
 techniques for, 1224-1225  
 vaginal, 1225  
 chemotherapy for, adjuvant, 1216-1217, 1216t-1217t, 1217.e1t  
 clear cell, 1205  
 clinical manifestations of, 1207-1208  
 diagnostic algorithm for, 1208, 1208f  
 endometrioid, 1205  
 etiology and epidemiology of, 1204  
 follow-up algorithm for, 1225-1226, 1227f  
 genetic abnormalities in, 1207, 1207t  
 imaging of, 202  
 incidence of, 1203  
 locally advanced disease and, 1203, 1217-1220  
 stage IIIA disease, 1218  
 stage IIIB disease, 1218  
 stage IIIC disease, 1218  
 stage IV disease, 1218-1219  
 lymph node involvement in, 1210, 1210t  
 lymphadenectomy for, 1209  
 lymphovascular space invasion in, 1205-1207  
 nonendometrioid, 1205  
 palliation of, 1203-1204, 1217-1220  
 pathology of, 1205-1206  
 pathways of spread of, 1205-1206  
 patient evaluation of, 1208  
 prevention and early detection of, 1204-1205  
 primary therapy and results for, 1203  
 prognostic factors for, 1207  
 radiation therapy for  
 complications of, 1222-1224  
 CT planning for, 1221, 1221f  
 extended-field irradiation, 1222  
 external beam pelvic, 1220-1222  
 intensity-modulated, 1222, 1222f-1224f  
 palliation, 1219  
 PORTEC and GOG-99 trials and risk reduction with, 1212, 1212t  
 primary, 1210  
 for recurrent disease, 1219  
 techniques of, 1220-1225  
 serous, 1205  
 staging of, 1203, 1208-1209  
 surgical, 1208, 1209t  
 surgery for, 1209-1210  
 early-stage disease, 1210-1211



- Endometrial cancer (*Continued*)  
 systemic therapy for, recurrent/metastatic disease, 1219-1220  
 chemotherapy for, 1219-1220  
 hormonal therapy for, 1219  
 treatment algorithm, conclusions, and challenges for, 1225-1228, 1226f  
 type I and type II, 1206, 1206t
- Endometrial hyperplasia, with atypia, 1205
- Endometrial stromal sarcoma, 1220
- Endometrioid carcinomas, 1268
- Endorectal ultrasound (ERUS), 995.e1f
- Endoscopic laser surgery, for gastric cancer, 912
- Endoscopic sinus surgery, for sinonasal cancer, 695
- Endoscopy, for bladder cancer, 1100
- Energy  
 deposition, 6-7, 7f  
 effect on electron beams, 121-122, 121f-122f, 121t  
 effect on photon beams, 118, 118f-119f, 118t
- ENI. *see* Elective nodal irradiation (ENI)
- Entinostat, 81t-82t
- Enucleation, for retinoblastoma, 1436
- Envelope of additivity, 68
- Enzalutamide, for prostate cancer, 1085
- Eosinophilic granuloma, 1496
- Ep-CAM, 408.e3t
- Ependymoma(s), 1394-1396, 1395f  
 histopathology of, 1394  
 imaging of, 191  
 infratentorial, 1395, 1395f  
 intracranial, 366, 1394  
 presentation of, 1394  
 radiation therapy for, 1395-1396  
 regional radioimmunotherapy for, 408.e6t  
 relapses of, 1396, 1396f  
 of spinal cord, 527t, 533-535, 534f  
 with drop metastases, 534f  
 myxopapillary, 533, 534f  
 pathology of, 533  
 prognostic factors of, 533-534  
 sacral, 534f  
 treatment and outcomes of, 534-535  
 treatment of, 1394-1395
- Epidermal growth factor (EGF)-like family, 80-83
- Epidermal growth factor receptor (EGFR)  
 biology of, 80-83  
 in bladder cancer, 1099  
 combination chemotherapy and radiation and, 84-85  
 in endometrial cancer, 1206.e1  
 in esophageal cancer, 845, 850  
 in gastric cancer, 909  
 in head and neck tumors, 562, 567  
 inhibitors, 80-85, 177-178  
 preclinical studies of, as radiosensitizers, 84  
 in laryngeal cancer, 654  
 lung cancer and, 789  
 in non-small cell lung cancer, 812  
 in oropharyngeal cancer, 600-601  
 radiation response and, 84-85  
 in salivary gland tumors, 700  
 tumor pathogenesis and, 83
- Epidermoid tumor, 536-537
- Epigenetics, 180
- Epiglottic tumors, 652
- Epirubicin, 72
- Epithelial ovarian neoplasms, 203
- Epithelial tumors, malignant, World Health Organization (WHO) classification of, 1022
- Epithelioid sarcoma, 1351
- Epothilone(s), 71
- Epothilone B, 71
- Epratuzumab, for B-cell lymphoma, 409.e1t
- Epstein-Barr virus (EBV)  
 and lymphoma  
 Hodgkin's, 1466, 1507  
 non-Hodgkin's, 1525  
 and nasopharyngeal carcinoma, 562, 567, 630, 633  
 pediatric, 1497  
 and thymic tumors, 866
- Equivalent uniform dose, for conformal radiotherapy, 309
- ERBB, 567
- ERBB1, 562
- ERBB2, 812, 909, 1206
- Erbix. *see* Cetuximab
- ERG overexpression, 1046
- Erlotinib, 81t-82t, 84, 177-178, 1206.e1
- ERUS. *see* Endorectal ultrasound (ERUS)
- Erythema, 345
- Erythroderma, mycosis fungoides with, 1558, 1561
- Erythroplakia, 600
- Erythropoietin, 56
- Esophageal cancer, 843-864  
 biologic characteristics of, 843, 845-846  
 biology of, 789  
 brachytherapy for, 286-287, 287f, 859-860  
 chemoradiation for, 851  
 definitive, 853t, 857  
   *versus* radiation alone, 854t  
 neoadjuvant, 858-859, 858t  
 residual disease following, 859  
 postoperative, 858  
 preoperative, 855-856  
   *versus* surgery alone, 856-857  
 chemoradiotherapy for, 852-857  
 comparing definitive irradiation alone with, 853t  
 definitive, 853t  
 concurrent, 853t  
 preoperative, 858t  
 chemotherapy for, 849  
 combination-agent activity, 850t  
 combined-modality, 851-859  
 concurrent, 853-855, 853t  
 induction, 855  
 neoadjuvant or adjuvant, 851-852  
 radiation therapy with and without, 859t  
 sequential, 854-855  
 single-agent activity in, 849t  
 twice-a-day radiation, 851  
 clinical manifestations of, 846-848  
 definitive therapy for, 843  
 epidemiology of, 788, 843-844, 844t  
 etiology of, 843-844, 844t  
 evaluation of, 846-848  
 staging, 843  
 and heat shock protein 90 (Hsp90), 851  
 hyperthermia for, 393t, 394  
 incidence of, 843  
 intensity-modulated radiation therapy for, 861  
 irradiation for  
   definitive concurrent chemotherapy and, 853-854  
   definitive induction and concurrent chemotherapy, 855  
   definitive sequential chemotherapy, 854-855  
   techniques of, 860-862, 862f  
   molecular biology of, 845-846  
   palliation for, 843, 859-860, 859t  
   pathologic findings and pathways of spread of, 846  
   prevention and early detection of, 844-845  
   primary therapy for, 848-859
- Esophageal cancer (*Continued*)  
 ablative, 849  
 single-modality, 848-851  
 radiation therapy for, 851, 851t  
 radiotherapy for  
   benign strictures, 860  
   followed by surgery, 852, 852t  
   tracheoesophageal fistula, 860  
 staging of, 846-848, 847b  
 and workup, 790  
 surgery for, 848-849  
 chemoradiotherapy and  
   chemoradiotherapy with targeted agents, 856t  
   with neoadjuvant or adjuvant chemotherapy, 851-852  
 preoperative chemoradiation *versus*, 856-857, 857t  
 radiotherapy followed by, 852, 852t  
 targeted biologic therapies for, 849-851, 856t  
 treatment algorithm for, 863f  
 controversies, and future possibilities in, 862  
 treatment considerations for, 794-795
- Esophageal/esophago-gastric junction cancer, chemoradiation for, 73
- Esophageal toxicity, 791
- Esophageal tumors, 859-861  
 primary, 194, 194f
- Esophagectomy, 848-849
- Esophagitis, 860  
 acute, radiation and, 268  
 non-small cell lung cancer and, 835t
- Esophagogastric anastomosis, 848
- Esophagus, late effects of radiation on, 256t-257t, 268  
 dose-volume data on, 268  
 organ function and clinical significance and, 268  
 QUANTEC Review on, 268
- Esthesioneuroblastoma, 678  
 manifestation, patient evaluation, and staging of, 681-683, 681.e1f  
 pathology of, 678  
 primary therapy for, 686, 686.e1f
- Esthesioneurocytoma. *see* Esthesioneuroblastoma
- Estramustine, 71, 1085
- Estrogen  
 in breast cancer progression, 1290  
 for prostate cancer, 1085
- Estrogen receptor (ER)  
 in breast cancer, 1290, 1294  
   breast-conserving therapy and, 1316  
 in gastric cancer, 909
- Estrogen replacement therapy, breast cancer from, 1287
- Estrogenic therapy, for prostate cancer, 1085
- Etanidazole, 25
- ETANTR. *see* Embryonal tumor with abundant neuropil and true rosettes (ETANTR)
- Ethmoid air cells, 675-678, 677f-680f, 675.e1f
- Ethmoid sinus tumors  
 EBRT for, 689  
 IMRT for, 690, 690t  
 irradiation techniques and tolerance for, 689-692  
   dose fractionation schedule in, 692  
   setup and field arrangement for, 692, 692f, 692.e1f  
   target volume in, 689-690, 690f-691f, 690t, 690.e1f  
 manifestation, patient evaluation, and staging of, 681, 682t  
 pathology of, 675  
 primary therapy for, 686

- Ethmoid sinus tumors (*Continued*)  
 radiotherapy for, adjuvant, 690, 690f, 690t  
 treatment algorithms for, 696, 696t
- Ethmoid sinuses, 675, 675.e1f
- Etoposide, 72, 1476
- Etoposide phosphate, 72, 181t
- Etretnate, for nasopharyngeal carcinoma, 630
- ETS family of genes, 1046
- European Organization for Research and Treatment of Cancer (EORTC) trial, 1000
- Everolimus, 81t-82t, 87, 178-179
- Evidence-based requirements analysis (EBRA), 226
- Ewing's sarcoma, 1368, 1368f, 1412  
 adjuvant therapy for, 1412  
 advanced, 1412, 1415  
 biologic characteristics of, 1412  
 clinical manifestations of, 1413-1414  
 etiology and epidemiology of, 1412  
 evaluation of, 1413-1414  
 incidence of, 1412  
 local therapy for, 1415-1417  
 palliation for, 1412, 1415  
 pathology of, 1413  
 pathway of spread of, 1413, 1413f  
 prevention and early detection of, 1412  
 primary therapy for, 1412, 1414-1415, 1415f, 1416t  
 radiotherapy for  
   for bone metastases, 1419  
   definitive, 1417  
   dose and fractionation of, 1417  
   for lung metastases, 1418-1419  
   postoperative, 1417  
   preoperative, 1417  
   target volume of, 1417-1418, 1418f-1419f  
   techniques of, 1417-1419  
   staging of, 1412-1414, 1414t  
   treatment of, 1414-1419
- Excision repair cross-complementing 1 (ERCC1), 1099
- Excision repair cross-complementing (ERCC) groups, in DNA strand break repair, 44
- Excisional biopsy, 160-161, 160f  
 in soft-tissue sarcoma diagnosis, 1353
- Exemestane, for breast cancer, 1290, 1291t
- Exponential survival curves, 12
- Exposure, 109, 111t
- Exposure limits, 145, 145t
- Exposure rate constant, 111t
- Extended-field irradiation, in endometrial cancer, 1222
- Extended-field radiotherapy (EFRT)  
 for cervical cancer, 1182-1183, 1182t  
 for Hodgkin's lymphoma, early-stage, 1511
- Extended radical neck dissection (RND), 749t, 757
- "Extensive intraductal component" (EIC), 1316
- Extensive stage small cell lung cancer (E-SCLC)  
 clinical trials for, 807  
 controversies in, 807  
 initial management of, 807  
 prophylactic cranial irradiation for, 803-804, 807  
 role of non-CNS radiotherapy, 804-805
- External beam irradiation, 95-96, 906-907  
 general techniques for, 130  
   arc plan as, 133f  
   four-field plan as, 133f  
   parallel-opposed plan as, 131f-132f  
   three-field plan as, 132f  
   wedged-field plan, 131f  
 with intraoperative radiotherapy, 918  
 meta-analyses, 918  
 for nasal vestibule tumors, 689, 688.e1f  
 for non-small cell lung cancer, 809
- External beam irradiation (*Continued*)  
 for pancreatic adenocarcinoma, 165  
 postoperative, 914  
 preoperative, 914-915, 915f  
   chemotherapy, 916-917  
 for retroperitoneal sarcoma, 168  
 simulation of, 123-125  
 treatment planning and dosimetry for, 125-129  
   beam nomenclature, 127, 127f  
   dose computation algorithms in, 127-128  
   dose specifications, 125-127, 126f  
   dose recording and reporting, 126  
   dose reporting for different techniques, 126-127  
   evaluation and optimization of, 128  
   monitor unit calculations in, 128-129  
   purpose and procedures for, 125, 125f  
   three-dimensional treatment planning in, 127, 127f  
   two-dimensional treatment planning in, 127  
   verification for, 129-130, 129f  
   vs. intraoperative radiotherapy, 918
- External beam radiation therapy (EBRT), 901, 998  
 of anal carcinoma, 1031  
 for oropharyngeal cancer, 610-611  
 with targeted radionuclide therapy, 406  
 for thyroid cancer, 724-725, 724t
- External beams, dose relationships for, 115-116
- Extraabdominal desmoid tumors, 1368
- Extracorporeal photochemotherapy, 1567-1568
- Extragenital germ cell tumors (EGCTs), 1134
- Extrahepatic cholangiocarcinoma. *see* Cholangiocarcinoma, extrahepatic
- Extranodal marginal zone lymphoma, MALT type, 1528
- Extrapelvic colon cancers, irradiation tolerance of, 903
- Extrapleural pneumonectomy (EPP), 796, 884-885, 887f
- Extraprostatic extension (EPE)  
 and clinical target volumes, 1087, 1088f  
 as predictive factor, 1046-1047  
 in staging, 1044-1045
- Extrathoracic metastases, evaluation for, non-small cell lung cancer, 817
- Eye, benign disorders of, 1376-1378
- Eyelid skin, radiation and, 556
- Eyelid skin cancers  
 etiology and epidemiology of, 541-543  
 pathology of, 544  
 patient evaluation of, 545
- F**
- F-18 fluorodeoxyglucose (FDG)-enhanced fused positron emission tomography/computed tomography (PET/CT), 186
- f factor, 110, 111f
- <sup>18</sup>F-FDOPA. *see* 3,4-Dihydroxy-6-<sup>18</sup>F-fluorophenylalanine (<sup>18</sup>F-FDOPA)
- Familial adenomatous polyposis (FAP), 992
- Familial medullary thyroid carcinoma (FMTC), 562
- Familial polyposis syndrome (FAP), 896
- Family history, in oropharyngeal cancer, 600.e1
- FAMTX regimens, in gastric cancer, 922.e1
- FAP. *see* Familial adenomatous polyposis (FAP)
- Farber, Sidney, 171
- Farmer chamber, 112, 112f
- Fast neutron radiotherapy, 373-376  
 for glioblastoma multiforme, 376  
 historical perspective of, 373  
 location of centers for, 373, 374t
- Fast neutron radiotherapy (*Continued*)  
 overview of, 373  
 for prostate cancer, 375, 375f  
 for salivary gland tumors, 373-375, 374f  
 for sarcomas, 376  
 for squamous cell carcinoma, 376  
 summary of, 376
- Fatigue, after surgery, for breast cancer, 1324
- FDG-PET, 206, 208  
 applications of, in other malignancies, 212  
 with brown fat, 209  
 with diabetes, 208  
 general aspects of tumor visualization on, 208, 209f  
 indications for, 209-214  
 patient preparation for, 208-209  
 potential pitfalls in, 208b
- Fecal immunochemical testing (FIT), 993
- Fecal occult blood testing (FOBT), 993
- Fédération Francophone de la Cancérologie Digestive trial, 1000-1001
- Female genital tract, cancers of, 1020
- Fentanyl, in endometrial cancer, 1203-1229
- Fibroblast overreaction, 1373
- Fibroma, juvenile nasopharyngeal, 1376
- Fibromatosis, aggressive, 1368-1369, 1378-1379
- Fibrosis  
 breast, after surgery, 1324  
 late effects of radiation on lung and dose-volume data on, 263-265  
   QUANTEC Review on, 265-266
- Fiducials, of radiosurgery, 149, 150f-151f
- Field cancerization, 568, 813-814
- Field modifications and boost techniques, for nasopharyngeal carcinoma, 641
- Field size  
 for <sup>60</sup>Co unit, 97  
 effect on electron beam, 122  
 effect on photon beams of, 118-119, 119f  
 of linear accelerators, 97-98  
 "50% take dose" (TD<sub>50</sub>), 13
- Film, 113, 113f, 153
- Finasteride, for prostate cancer, 1040
- Fine-needle aspiration biopsy (FNAB), 721, 1353
- Fine-needle aspiration cytology, 159  
 percutaneous radiograph-directed, 159
- FIT. *see* Fecal immunochemical testing (FIT)
- Fixed postmitotic (FPM) cells, 27
- Fletcher-Suit-Delclos applicator system, 1194f, 1195
- Flexible (Type F) tissues, 27
- Flexner-Wintersteiner rosettes, 1434
- Floor of mouth, 575
- Floor-of-mouth neoplasms  
 brachytherapy for, 579  
 concomitant postoperative chemoradiation for, 578  
 early, 577, 579  
 evaluation for, 576-577  
 intraoral stent for, 579, 580f  
 irradiation for, 578-581, 580f  
 locally advanced, 578-581  
 manifestations of, 576-577  
 moderately advanced, 577-578  
 pathology and patterns of spread of, 575-576, 576f, 576t  
 radiotherapy for, 578, 578t-579t  
 sentinel lymph node biopsy for, 577  
 staging of, 576-577  
 treatment of, 577-578, 577f, 581t  
   complications of, 581
- Flow cytometer, 17, 17f
- Fludarabine phosphate, 181t
- Fluorescence-activated cell sorter, 17

- <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG-PET), 789
- Fluorodeoxyglucose single-photon-emission computed tomography (FDG-SPECT), for unknown head and neck primary site, 731-732, 732t
- Fluorodeoxyuridine, 70
- Fluorodeoxyuridine triphosphate (FdUTP), 901f
- Fluoropyrimidines, 70, 982-983
- <sup>18</sup>F-fluorothymidine, 213
- 5-Fluorouracil (5-FU), 63, 70, 171, 181t, 901-902, 901f
- for anal carcinoma, 1019, 1025-1027, 1026t-1027t
- for cervical cancer, 1181
- for colon cancer, 977, 985t
- for colorectal cancer, 999
- with mitomycin C, 72.e1
- for nasopharyngeal carcinoma, 636, 637t
- for pancreatic adenocarcinoma, 165
- radioimmunotherapy with, 405-406
- Fluorouracil triphosphate (FUTP), 901f
- Flutamide, for prostate cancer, 1078, 1085
- FOBT. *see* Fecal occult blood testing (FOBT)
- FOLFIRINOX regimens, 950
- Folic acid, 171
- Follicular cell- derived cancers (FCDC), of thyroid, 715-716
- Follicular lymphoma
- advanced, 1535-1536
- and *BCL-2*, 1527, 1527t
- localized, 1534-1535, 1535f, 1535t
- RT management of, 1545
- treatment of, 1504
- Follicular thyroid carcinoma (FTC), 719-720
- cause-specific survival with, 720, 720f
- etiology and epidemiology of, 716, 716t
- nodal metastases of, 720
- oxyphilic variant, 719-720
- pathology of, 717
- presentation of, 719-720
- prognostic factors for, 720
- staging of, 718, 718t
- treatment algorithm for, 728-729
- Formication, 768
- Forward planning, for conformal radiotherapy, 309-310
- plan evaluation for, 310
- setting planning goals for, 310
- Four-dimensional anatomy, 301-302
- Four-field plan, 133f
- Fovea ethmoidalis, 675
- Fractional cell kill, 173-174, 174f
- Fractionated stereotactic radiotherapy (FSRT), for vestibular schwannoma, 495-499, 497t, 499f
- Fractionation, 354-355, 403
- for nasopharyngeal carcinoma, 638
- for oropharyngeal cancer, 616-618
- Free-flap reconstructions, for oropharyngeal cancer, 614
- Free radicals, 7
- Fricke dosimeter, 114
- Functional imaging modalities, 302
- Functional magnetic resonance imaging, for conformal radiotherapy, 298
- Functional subunits, 33-34
- Fundamental particles, 93, 94t
- Fusion genes, in soft-tissue sarcoma, 1347
- G**
- G<sub>1</sub> cell cycle checkpoint response, 8
- G2 delay, 18-19
- Gadolinium chelate, 186-187
- Gallbladder cancer
- adjuvant therapy for, 968
- epidemiology of, 961
- etiology of, 961
- and extrahepatic cholangiocarcinoma, 973
- pathology of, 963
- primary therapy for, 968
- staging of, 965
- symptoms and signs of, 963
- Gamma emission, isomeric transition by fast, 138
- Gamma-emitters, 400
- Gamma interferon, with targeted radionuclide therapy, 404
- Gamma Knife radiosurgery, 148, 150f
- Gamma rays, 96, 96t, 138
- photon interaction with, 102-105
- Gangliogliomas, 461
- Ganglioneuroblastomas, 1448, 1448t. *see also* Neuroblastoma
- Ganglioneuromas, 1448, 1448t. *see also* Neuroblastoma
- Gardner's syndrome, 1346
- Gas-filled detectors, 111-112, 112f, 112t
- Gastrectomy, 912
- node dissection *versus* type local regional relapse, 912.e1t
- Gastric adenocarcinoma, 194
- Gastric cancer, 906-933
- adjuvant, 900
- adjuvant therapy for, 906
- chemoradiation for, 918
- IORT alone, 918, 918.e1t
- IORT plus EBRT, 918
- IORT *versus* EBRT, 918
- meta-analysis of, 918
- nutritional support with, 929-930
- preoperative, 918
- chemotherapy for
- adjuvant therapy for, 906, 913-914, 918
- EBRT alone or, 917-918, 917t
- irradiation plus, 915-918, 917f
- primary, 930-932
- biologic characteristics of, 906
- borderline resectable disease, 932
- challenges in, 930-932
- neoadjuvant, 921, 921.e1t
- unresectable, 921
- perioperative, 914
- supportive care *versus*, 922-923
- clinical manifestations of, 909-910
- epidemiology of, 907, 907.e1f-907.e2f
- etiology of, 907
- external beam irradiation for, 906-907
- with intraoperative radiotherapy, 918
- meta-analyses, 918
- postoperative, 914
- preoperative, 914-915, 915f
- chemotherapy, 916-917
- vs.* intraoperative radiotherapy, 918
- follow-up for, 910
- incidence of, 906
- intraoperative electron radiation for, 919f
- irradiation technique for, 918, 923-930
- adjuvant, 914-915
- dose-limiting organs and structures, 923, 923.e3f
- field design, 923-929, 924f-927f, 923.e1f-923.e2f, 923.e4f
- multiple-field techniques, 923-928
- locally advanced, 906, 918-921
- challenges, 930-932
- diagnostic algorithm of, 910t
- irradiation for, 919-920
- irradiation plus chemotherapy for, 920-921
- Gastric cancer (*Continued*)
- irradiation with or without chemotherapy for, 916t, 919-921, 915.e1t
- surgery for, 919
- treatment algorithms for, 930-932, 931f
- locally unresectable, 932
- lymph node dissection for, 911-912
- meta-analysis of, 914
- metastatic, 907, 932
- chemotherapy for, 922-923
- diagnostic algorithm of, 910t
- laser or irradiation for, 922
- palliation for, 921-923
- surgery for, 922
- molecular biology of, 908-909
- palliation for, 906
- metastatic, 921-923
- locally advanced, 921.e1
- potentially resectable, 921.e1
- pathology of, 909
- pathways of spread of, 909, 909.e1f
- direct extension, 909
- hematogenous, 909
- lymphatics, 909
- peritoneal involvement, 909
- patient evaluation in, 910, 910t
- prevention and early detection of, 908
- primary therapy for, 906, 911-918
- prognostic factors for, 908
- relapse patterns after "curative resection", 912-913, 912t, 913f, 912.e1t
- staging of, 910
- evaluation of, 906, 910
- TNM, 911t
- surgery for, 911-912, 912t
- quality of life (QOL) after, 912
- survival results, 912, 912.e1t
- treatment algorithms for, 930-932, 930t, 931f
- unresectable or residual, 920t
- Gastric lymphoma, 1544-1545
- Gastroesophageal junction cancer, 906-933
- dose-limiting organs and structures and, 923, 923.e3f
- idealized treatment field guidelines for, 928-929, 928t-929t, 928.e1t
- irradiation technique for, 923-930, 924f, 926f-927f, 923.e4f
- phase III trial for, 922
- preoperative chemoradiation *vs.* chemotherapy for, 918
- Gastroesophageal reflux disease (GERD), 650, 844
- Gastrointestinal cancers
- biology of, 896-897
- conformal radiotherapy for, 319, 321
- pelvic, 903-904
- stereotactic body radiation therapy for, 430
- Gastrointestinal stromal tumors (GISTs), 909, 1350-1351, 1366
- Gastrointestinal syndrome, 31
- Gastrointestinal tract
- metastatic disease to, 195
- primary tumors of, 194-203, 194f
- Gastrointestinal tumors
- anal carcinoma as, 1019-1034
- anatomy and pathways of tumor spread, 897
- chemoradiation, 901-902, 901f
- epidemiology and prevention of, 895-896
- intraoperative radioimmunotherapy for, 408.e4t
- irradiation technique for, 902-904
- normal tissue tolerance, 903-904
- prognostic factors and patterns of relapse, 898-900
- proton beam radiotherapy for, 364
- rectal cancer as, 992-1018

- Gastrointestinal tumors (*Continued*)  
 staging of, 897-898  
 treatment of, single- *versus* combined modality, 900-902
- Gating, 298
- Gefitinib, 81*t*-82*t*, 84  
 in chemotherapy, 177-178  
 for non-small cell lung cancer, 812
- Gemcitabine, 70, 405-406, 901-902  
 for metastatic leiomyosarcoma, 1220.e1  
 plus cisplatin, for hepatobiliary cancer, 960  
 plus nab-paclitaxel (Abraxane), 902
- Gemcitabine-based chemoradiation, for pancreatic cancer, 945
- Gene therapy, 417
- Genetic factors, breast-conservation therapy and, 1314-1315, 1314.e1*t*
- Genital tract, female, cancers of, 1020
- Genitourinary cancer, chemoradiation for, 77
- Genitourinary tumors, 1035  
 bladder cancer as, 1036  
 kidney and ureteral cancer as, 1036-1037  
 penile cancer as, 1037  
 prostate cancer as, 1035-1036  
 testicular cancer as, 1036
- Genomic instability, 9
- Genomics, chemotherapy-radiation interactions in, 78
- Geometric conformation, 303, 304*f*
- GERD. *see* Gastroesophageal reflux disease (GERD)
- Germ cell function, MOPP chemotherapy and, 1475
- Germ cell tumors  
 of CNS, 1397-1398  
 chemotherapy for, 1398  
 craniospinal irradiation for, 1398, 1399*f*  
 diagnosis of, 1397  
 ovarian, 1279-1280, 1279.e1*t*  
 pediatric, 1489-1490  
 adjuvant therapy for, 1486, 1489-1490, 1490*t*  
 biology of, 1486, 1489  
 clinical manifestations of, 1489  
 etiology and epidemiology of, 1489  
 evaluations for, 1489  
 incidence of, 1486  
 irradiation techniques for, 1490  
 locally advanced, 1486, 1490  
 ovarian, 1490  
 palliation for, 1487, 1490  
 pathology of, 1489  
 pathways of spread of, 1489  
 prevention and early detection of, 1489  
 primary therapy for, 1486, 1489-1490  
 staging of, 1486, 1489, 1490*t*  
 testicular, 1490  
 treatment algorithms, controversies, challenges, and future possibilities for, 1490  
 tumor marker profiles for, 1489, 1489*t*  
 testicular. *see* Testicular germ cell cancer (TGCC)
- Germanium (GeLi) detector, 114
- Germinomas, 1398, 1399*f*, 1489, 1489*t*
- Gingiva, 588-590
- Gingival cancer  
 early, 589, 590*f*  
 manifestations of, 588  
 moderate to locally advanced, 589-590, 590*f*  
 pathology of, 588, 588*f*  
 staging of, 588  
 techniques of irradiation for, 589-590  
 treatment of, 589
- Gingival cancer (*Continued*)  
 algorithm for, 589*f*  
 complications of, 590  
 results of, 589
- GISTs. *see* Gastrointestinal stromal tumors (GISTs)
- Gleevec. *see* Imatinib
- Gliadel (carmustine-eluting) wafers, for high-grade glioma, 473
- Glioblastoma, 450  
 chemoradiation for, 77  
 radioimmunotherapy for, 408-409
- Glioblastoma multiforme (GBM), 63-64, 188*f*-189*f*. *see also* Glioma(s), high-grade  
 biology of, 470  
 boron neutron capture therapy for, 377  
 "butterfly", 470, 470*f*  
 chemotherapy for, 473-474  
 clinical manifestations of, 470-471  
 in elderly, 475-476, 481  
 etiology and epidemiology of, 469  
 external beam irradiation for, 472-473  
 techniques of, 481  
 toxicities of, 481  
 treatment planning for, 479, 479*f*, 480*t*  
 fast neutron radiotherapy for, 376  
 hyperthermia for, 393*t*, 394  
 imaging of, 470-471, 470*f*-471*f*  
 incidence of, 469  
 locally advanced, 469  
 pathology and pathways of spread of, 470, 470*f*-471*f*  
 patient evaluation in, 470-471  
 primary therapy of, 469, 471-477  
 prognostic and predictive factors for, 471  
 recurrent, 469, 477-478  
 staging of, 469-471, 471*f*  
 stereotactic irradiation for, 473
- Glioma(s)  
 anaplastic, 450  
 boron neutron capture therapy for, 377  
 high-grade, 469-482  
 algorithm for diagnosis and treatment of, 471, 471*f*, 481  
 anaplastic, 470, 475, 475*f*  
 astrocytic, 470*f*  
 biology of, 470  
 brachytherapy for, 473  
 chemotherapy for, 472*t*, 473-474  
 clinical manifestations of, 470-471  
 in elderly, 475-476, 481  
 etiology and epidemiology of, 469  
 external beam irradiation for, 472-473, 472*t*  
 altered fractionation of, 473  
 chemotherapy for, 472*t*, 473-474  
 phase II trials of, 472*t*  
 reirradiation with, 478  
 techniques of, 478-481, 478*f*  
 tolerance to, 479, 480*f*, 480*t*  
 total irradiation dose in, 473  
 toxicities of, 475, 481  
 treatment planning for, 479, 479*f*, 480*t*  
 grading of, 470  
 imaging of, 470-471, 470*f*-471*f*  
 IMRT for, 479, 481  
 incidence of, 469  
 locally advanced, 469  
 margins for, 478, 479*t*  
 pathology and pathways of spread of, 470, 470*f*-471*f*  
 patient evaluation in, 470-471  
 prevention and early detection of, 469  
 primary therapy of, 469, 471-477  
 prognostic and predictive factors for, 471  
 pseudo-progression of, 476-477, 481
- Glioma(s) (*Continued*)  
 recurrent, 469, 477-478  
 staging of, 470-471  
 stereotactic irradiation for, 473  
 surgery for, 472  
 low-grade, 450, 452-468  
 biology of, 453-454  
 chemoradiation for, 460  
 chemotherapy for, 459-460, 459*f*-460*f*  
 clinical presentation of, 454-455, 454*t*-455*t*  
 epidemiology and etiology of, 453  
 external beam irradiation for, 458-459, 464*f*-466*f*, 466*t*  
 favorable variants of, 460-461  
 central neurocytomas as, 460-461  
 dysmorphic neuroepithelial tumors as, 461  
 gangliogliomas as, 461  
 pilocytic astrocytomas as, 460  
 pleomorphic xanthoastrocytomas as, 460  
 subependymal giant cell astrocytomas as, 461  
 subependymomas as, 461  
 grading systems for, 453  
 imaging of, 455-456, 455*t*, 456*f*-457*f*  
 IMRT for, 463-464  
 irradiation techniques for, 463-467  
 observation for, 456-458, 457*f*-458*f*  
 other radiation modalities for, 459  
 palliation for, 461-463  
 pathologic classification of, 453, 453*t*  
 patient evaluation in, 454-456  
 primary therapy for, 452, 456-460  
 recurrent, 452, 461-463, 462*f*-463*f*  
 surgery for, 458  
 toxicities of radiotherapy for, 464-467  
 treatment algorithm for, 467, 467*f*  
 optic nerve. *see* Optic nerve glioma  
 pediatric, 1396  
 diffuse pontine, 1397  
 radioimmunotherapy for monoclonal antibodies for, 402*t*  
 with pretargeting, 408.e3*t*  
 regional delivery of, 408, 408.e6*t*  
 of spinal cord, 527*t*
- Glomus tumor, 1375-1376
- Glottic tumors  
 IMRT for, 666, 666*f*  
 manifestations of, 654  
 pathways of spread, 652  
 primary radiation therapy for, 664-666, 665*f*-666*f*, 666*t*  
 in situ, 659-660, 659*t*  
 staging of, 655, 657*t*  
 therapy for, 657-659, 658*t*-659*t*, 662, 662*t*
- Glottis, 651-652
- Glucose transporters, 208
- Gluon, 93-94
- Glutathione, oxygen effect and, 22
- Glycosylases, 8-9
- GM-CSF, 413
- GOG-122, chemotherapy used in, 1216
- GOG-258 trial, in endometrial cancer, 1227
- Gonadal injury, from MOPP chemotherapy, 1475
- Gonadotropin-releasing hormone, 1085.e1
- Gonadotropin-secreting adenomas, 517
- Goserelin, for prostate cancer, 1078, 1085  
 in prevention, 1040, 1077
- Graft-*versus*-host disease (GVHD), 343
- Granulocytic sarcoma, 536
- Granulomatous slack skin, 1562
- Granulosa cell tumors, ovarian, 1280-1281
- Graves' disease, 551-552, 1376
- Graves' ophthalmopathy, 543, 549, 552*f*



- Gravitational force, 93-94  
 Graviton, 93-94  
 Grawitz's tumor, 1140  
 Groin lymph node metastases, of melanoma, 785, 785f  
 Gross target volume (GTV), for conformal radiotherapy, 299-300, 300f, 300t  
 Gross tumor volume (GTV), 125, 126f, 1087  
 Growth delay assay, 13-14  
 Growth dysfunction, after total body irradiation, 348  
 Growth factor(s), in non-small cell lung cancer, 811-812  
 Growth factor receptors, and bladder cancer, 1099  
 Growth fraction, 27-28, 28t  
 Growth hormone deficiency, from central nervous system tumors, 1401  
 Growth kinetics, 27-30  
   descriptive classification systems for, 27  
   parameters and methodologies of, 27-30, 28t  
 Gynecologic tumors, 1171  
   cervical cancer as, 1171  
   endometrial cancer as, 1172  
   ovarian cancer as, 1172  
   primary, 202-203  
   vaginal carcinoma as, 1172  
   vulvar carcinoma as, 1172  
 Gynecomastia, 1380
- H**
- H zone, in basal cell carcinoma, 764-765, 765f  
 H2AX, in genomic stress response, 44, 45f  
 H19 gene, 1423  
 HAART. *see* Highly active antiretroviral therapy (HAART)  
 Hadrons, 93  
 Half-value layer, 101, 118  
 Halogenated pyrimidines, 25f, 25t, 26, 51  
 HAMA response, 399  
 Hamoudi tumors, 937  
 Hand-Schüller-Christian disease, 1496  
 Hanging block apparatus, 554-555, 556f  
 Hard palate, 592-594  
 Hard palate cancer  
   evaluation for, 593  
   manifestations of, 593  
   pathology of, 593  
   staging of, 593  
   treatment of, 593  
     algorithm for, 593f  
     complications of, 594  
     results of, 593-594, 594t  
     for T1 and T2 lesions, 594, 595f  
     for T3 and T4 lesions, 594  
     techniques of irradiation for, 594  
 Harrison-Anderson-Mick (HAM) applicator, 339, 339f  
 HBsAg, 961  
 Head and neck  
   benign disorders of, 1374-1376  
   imaging of, 190f, 191  
   lymph vessels and nodes of, 676f  
 Head and neck cancers  
   brachytherapy for, 288-289  
   chemoradiation for, 74-75, 75t  
   conformal radiotherapy for, 318, 320  
   hyperthermia for, 393t, 394  
   PET scan of, 210-211  
   soft-tissue sarcoma as, 1366-1367  
 Head and neck squamous cell carcinoma (HNSCC), 567  
   postoperative irradiation or chemoradiation for, 758, 758t-759t
- Head and neck tumors  
   biomarkers and molecular targeting of, 567-568  
   concurrent radiation and chemotherapy for, sequential *versus*, 564-565  
   cutaneous carcinoma as, 763-776  
   larynx and hypopharynx cancer as, 649-672  
   locally advanced, 563-565  
     combination of radiation with chemotherapy for, 564-565  
     fractionation for, 563-564  
       accelerated, 563-564  
       efficacy of, 564  
       hyper, 563  
     high-precision radiotherapy for, 565-567  
   malignant melanoma as, 777-787  
   management of neck with, 738-762  
   molecular biology and ecogenetics of, 561  
   nasopharyngeal carcinoma as, 629-648  
   of oral cavity, 570-596  
   oropharyngeal cancer as, 597-628  
   prevention of, 568  
   receptor tyrosine kinases and, 562  
   salivary gland malignancies as, 698-714  
   sinonasal cancer as, 673-697  
   of unknown primary site, 731-737  
   viral causes of, 562-563  
 Health economics, 236  
 Health services research, 217-238  
   on accessibility of radiotherapy, 218-227  
   on efficiency of radiotherapy, 236-237  
   improved outcomes and, 217  
   need for, 217  
   on quality of radiotherapy, 227-236  
   scope of, 217-218, 218f  
 Hearing, late effects of radiation on, 256t-257t, 260-261  
   dose-volume data on, 260-261  
   organ function and clinical significance and, 260  
   QUANTEC Review on, 261  
 Hearing loss  
   from central nervous system tumors, 1401  
   with nasopharyngeal carcinoma, 645  
 Heart, late effects of radiation on, 256t-257t, 266-268  
   anthracyclines and, 267  
   dose-volume data on, 266-267  
   organ function and clinical significance and, 266  
   QUANTEC Review on, 267-268  
 Heat sensitivity, 382  
 Heat shock protein 90 (Hsp90), 851  
 Heat shock proteins, 386  
 Heavy charged particle interactions, 108, 108f  
 Heavy charged particle therapy, for salivary gland tumors, 708  
 Heavy uncharged particle interactions, 108  
 HeLa cell, survival curve of, 12-13, 13f  
 Helical tomotherapy, 296  
*Helicobacter pylori*  
   gastric cancer and, 907  
   and lymphoma, Non-Hodgkin's, 1525  
 Helium radiotherapy, 370  
 Hemangioblastoma(s)  
   imaging of, 191  
   spinal intramedullary, 537, 537f  
 Hemangioma(s)  
   choroidal, 1377  
   pediatric, 1493-1494  
     adjuvant therapy for, 1486, 1494  
     biologic characteristics of, 1486  
     clinical manifestations of, 1493  
     etiology and epidemiology of, 1493  
     evaluation for, 1493  
     incidence of, 1486
- Hemangioma(s) (*Continued*)  
   irradiation techniques for, 1494  
   locally advanced, 1486, 1494  
   palliation for, 1487, 1494  
   pathology of, 1493  
   pathways of spread of, 1493  
   primary therapy for, 1486, 1494  
   staging of, 1486, 1493  
   treatment algorithms, controversies, challenges, and future possibilities in, 1494  
   vertebral, 538, 1381  
 Hematopoietic stem cell transplant (HSCT), 342-343  
   allogeneic, 343, 353, 353f  
   autologous, 343, 353  
   conditioning for, 343  
   graft-*versus*-host disease and, 343  
   for Hodgkin's lymphoma, pediatric, 1483  
   indications for, 343  
   for multiple myeloma, 1551  
   radioimmunotherapy for, 410  
   syngeneic, 343  
   total body irradiation for, 351-356  
     allogeneic, 353, 353f  
     autologous, 353  
     for leukemia  
       acute lymphoid, 352, 352.e2t  
       acute myelogenous, 352, 352.e2t  
       chronic myelogenous, 352, 352.e2t  
     for mixed diseases, 352-353  
     for multiple myeloma, 352, 352.e2t  
     necessity for, 351-352  
     trends in use of, 342, 342f  
 Hematopoietic syndrome, 31  
 Hematopoietic toxicity, 345, 345f  
 Hematuria, workup of, 1100-1101  
 Hemibody irradiation, 438-439, 439t  
 Hemoglobin, dose modification based on, 55-56  
 Hemoptysis, 838t  
 Henschke applicator, 1194  
 Hepatic arterial delivery, 409  
 Hepatic cancer. *see* Hepatobiliary cancer  
 Hepatic metastases. *see* Liver metastases  
 Hepatic toxicity, 347  
 Hepatic tumors, pediatric  
   adjuvant therapy for, 1486  
   biologic characteristics of, 1486  
   incidence of, 1486  
   locally advanced, 1486  
   palliation for, 1487  
   primary therapy for, 1486  
   staging of, 1486  
 Hepatitis B surface antigen (HBsAg), 961  
 Hepatitis C virus, 962  
 Hepatobiliary cancer, 960-976  
   adjuvant therapy for, 960  
   BCLC classification for, 967f  
   biologic characteristics of, 960, 962  
   in children. *see* Primary malignant liver tumors (PMLTs), in children  
   cholangiocarcinoma as. *see* Cholangiocarcinoma  
   clinical manifestations of, 963-965  
   diagnosis of, 965  
   diagnostic algorithm of, 963t  
   epidemiology of, 961  
   etiology of, 961  
   external beam irradiation, chemotherapy or brachytherapy for, 973  
   follow-up for, 965  
   gallbladder cancer as. *see* Gallbladder cancer  
   hepatocellular carcinoma as. *see* Hepatocellular carcinoma (HCC)  
   incidence of, 960  
   irradiation techniques for, 974-975

- Hepatobiliary cancer (*Continued*)  
 dose-limiting organs in, 973-974  
 tolerance and, 973-975  
 laboratory studies of, 963-964, 963*t*  
 locally advanced, 960, 970-973  
 molecular biology of, 962  
 palliation of, 960-961, 970-973  
 pathology and pathways of spread of, 962-963  
 patient evaluation in, 963-965  
 prevention and early detection of, 961-962  
 primary therapy for, 960, 965-970  
 radiation therapy for, 969*t*  
   as definitive therapy, 968  
 radiographic studies of, 963*t*, 964-965, 964*f*-965*f*  
 staging of, 963-965  
   evaluation, 960  
 symptoms and signs of, 963  
 TNM classification of, 966*t*  
 treatment algorithm and future directions for, 967*f*, 975-976, 976*f*, 975.e1*f*
- Hepatoblastoma, in children  
 adjuvant therapy for, 1488  
 biology of, 1487  
 clinical manifestations of, 1487-1488  
 etiology and epidemiology of, 1487  
 evaluation for, 1487-1488  
 irradiation techniques for, 1488  
 locally advanced, 1488  
 palliation for, 1488  
 pathology of, 1487  
 pathways of spread of, 1487  
 primary therapy for, 1488  
 staging of, 1487-1488, 1487*t*, 1488*f*  
 treatment algorithms, controversies, challenges and future possibilities in, 1488-1489
- Hepatocellular cancer, stereotactic body  
 radiation therapy for, 430
- Hepatocellular carcinoma (HCC), 195, 196*f*, 896  
 adjuvant therapy for, 966  
 in children  
   adjuvant therapy for, 1488  
   biology of, 1487  
   clinical manifestations of, 1487-1488  
   etiology and epidemiology of, 1487  
   evaluation for, 1487-1488  
   irradiation techniques for, 1488  
   locally advanced, 1488  
   palliation for, 1488  
   pathology of, 1487  
   pathways of spread of, 1487  
   primary therapy for, 1488  
   staging of, 1487-1488, 1487*t*, 1488*f*  
   treatment algorithms, controversies, challenges and future possibilities in, 1488-1489  
 diagnosis of, 965  
 epidemiology and etiology of, 961  
 fibrolamellar, 962-963  
 irradiation technique for, 974-975, 974*f*  
 liver transplantation of, 967  
 locally advanced, 970-972  
   advanced stage of, 972  
   intermediate stage of, 970-972  
   radiation therapy for, 972  
   regional treatment of, 971-972  
   systemic treatment of, 972  
 molecular biology of, 962  
 pathology of, 962-963  
 percutaneous ablation for, 967  
 prevention and early detection of, 961-962  
 primary therapy for, 965-968  
 proton beam radiotherapy for, 364
- Hepatocellular carcinoma (HCC) (*Continued*)  
 radiation therapy for, predominantly  
   advanced stage, 972*t*  
 radiographic studies of, 964  
 radioimmunotherapy for, 409  
 staging of, 965  
 surgical resection for, 965-966  
 symptoms and signs of, 963
- Hepatocyte growth factor/mesenchymal epithelial transition factor (Hgf/Met), 850-851
- HER1, 562
- HER2, 1316  
 directed therapy, 178
- HER2 inhibitors, 84
- HER2/neu  
 in breast cancer, 1294, 1300  
   inflammatory, 1330  
   locally advanced, 1330  
 in esophageal cancer, 849-850  
 in salivary gland tumors, 700
- Herceptin. *see* Trastuzumab
- Hereditary factors, and prostate cancer, 1039
- Hereditary nonpolyposis colorectal cancer (HNPCC), 908-909, 979  
 and endometrial cancer, 1204  
 and ovarian cancer, 1266
- Heregulin families, 80-83
- Heterotopic ossification, 1381-1383, 1382*f*
- Heterozygosity, loss of, 1423-1424
- Heublein therapy, 341
- Hexokinase, 208
- HHV-8 virus, and lymphoma, Non-Hodgkin's, 1525
- Hidden target test, 155, 156*f*
- Hierarchical (type H) tissues, 27
- Higgs boson, 93-94
- High affinity antibodies, 399.e1
- High-dose chemotherapy, 175
- High-dose-rate (HDR) brachytherapy  
 low-dose-rate brachytherapy and, 279-280  
 remote afterloading, 143-144, 144*f*, 280
- High-dose-rate intraoperative radiotherapy (HDR-IORT), 338  
 afterloading devices for, 338, 339*f*  
 dose distribution characteristics of, 339, 339*f*  
 electron *vs.*, 339, 339.e1*t*
- High-grade squamous cell intraepithelial lesion (HGSCIL), 1174
- High-oxygen-content gas breathing, for tumor hypoxia, 53, 53*t*
- High-precision radiotherapy, for head and neck tumors, 565-567
- Highly active antiretroviral therapy (HAART), 1032
- Histamine-succinyl-glycine (HSG), antibodies against, 407-408
- Histiocytoma, malignant fibrous, 537-538, 1347
- Histiocytosis, Langerhans cell. *see* Langerhans cell histiocytosis, pediatric
- Histologic diagnosis, 159
- Histone(s), 44
- Histone deacetylase inhibitors, 180, 1567
- Histrelin, for prostate cancer, 1085
- HIV. *see* Human immunodeficiency virus (HIV)
- HN2, for mycosis fungoides, 1566
- HNPCC. *see* Hereditary nonpolyposis colorectal cancer (HNPCC)
- HN5CC. *see* Head and neck squamous cell carcinoma (HN5CC)
- Hodgkin disease, PET scan of, 211
- Hodgkin/Reed-Sternberg (HRS) cells, 1467, 1507
- Hodgkin's lymphoma, 1506-1523  
 advanced-stage  
   dose-escalated BEACOPP regimen for, 1517, 1517.e1*t*  
   primary therapy in, 1506, 1516-1519  
   radiation therapy for, 1518-1519, 1518*t*  
   Stanford V regimen for, 1517-1518, 1517.e1*t*  
   treatment of, 1502-1503, 1519  
     algorithm for, 1522*t*  
 autologous bone marrow transplantation for, 1520  
 biologic characteristics of, 1506  
 chemotherapy for  
   advanced-stage, 1516-1517  
   early-stage, 1511, 1515*t*  
   refractory and recurrent, 1520  
   relapse after, 1521  
 classical, 1508, 1508*t*  
 classification of  
   Ann Arbor staging, 1509, 1509*t*  
   Coltswolds staging, 1509, 1509*t*  
   prognostic, 1510*t*  
   WHO histological, 1508, 1508*t*  
 clinical manifestations of, 1508-1509  
 early-stage  
   chemotherapy for, 1511, 1515*t*  
   primary therapy in, 1506, 1510-1516  
   radiation therapy for, 1511, 1513*f*-1514*f*  
   treatment of, 1502, 1516  
     algorithm, 1522*t*  
 etiology and epidemiology of, 1506-1507  
 evaluation for, 1508-1510, 1510*t*  
 incidence of, 1506  
 lymphocyte depletion in, 1508  
 lymphocyte-rich, 1508  
 mixed cellularity, 1506-1507  
 nodular lymphocyte predominant, 1508, 1508*t*, 1519-1520  
   treatment of, 1503  
 nodular sclerosis, 1506-1507  
 pathology of, 1506, 1508  
 pediatric, 1464-1485  
   advanced-stage, 1473*t*-1474*t*, 1484*t*  
   biologic characteristics of, 1464  
   chemotherapy for, 1475-1478  
     ABVD, 1475  
     with etoposide, 1476  
     gender-based, 1476  
     MOPP, 1475  
     with radiation therapy, 1478-1479  
   clinical manifestations of, 1466-1467, 1467*t*  
   early-stage, 1471*t*-1472*t*, 1484*t*  
   etiology and epidemiology of, 1465-1466  
   evaluation for, 1467-1468  
   extended field radiotherapy for, 1468  
   gender-based therapy for, 1476  
   hematopoietic cell transplantation for, 1483  
   with HIV, 1466  
   IMRT for, 1479, 1480*f*-1481*f*  
   intermediate-stage, 1473*t*-1474*t*, 1484*t*  
   lymphocyte-rich classical, 1466  
   mixed cellularity, 1466  
   nodular lymphocyte-predominant, 1466, 1482-1483  
   nodular sclerosing, 1466  
   pathology of, 1466  
   pathways of spread of, 1466  
   PET scanning for, 1467-1468  
   primary therapy for, 1464, 1469-1483  
   prognostic factors of, 1468-1469, 1468*t*  
   radiation therapy for, 1475-1478  
     with chemotherapy, 1478-1479  
   considerations in, 1476-1477

- Hodgkin's lymphoma (*Continued*)  
 dose of, 1478  
 volume of, 1477-1478, 1477*t*  
 refractory, 1483  
 relapsed, 1483  
 response-based therapy for, 1470-1475  
 risk-adapted treatment approach for, 1469-1470  
 favorable risk disease in, 1479-1481  
 intermediate-risk disease in, 1481-1482  
 unfavorable risk disease in, 1482-1483  
 staging of, 1464, 1466  
 treatment for  
 algorithms for, 1483, 1484*t*  
 approaches for, 1478-1479  
 prognostic factors for, 1510, 1510*t*  
 radiation therapy for  
 advanced-stage, 1518*t*  
 dose of, 1512-1516  
 early-stage, 1511, 1513*f*-1514*f*  
 elimination of, based on PET-response, 1516  
 IMRT, 1521  
 modern conformal, 1521  
 before or after high-dose therapy, 1520-1521  
 PET-guided planning for, 1521-1522  
 proton, 1521  
 respiratory motion adaptation techniques for, 1522  
 techniques of, 1521-1522  
 radioimmunotherapy for, 411  
 refractory and recurrent, 1520-1521  
 salvage therapy for, 1506  
 staging of, 1506, 1509, 1510*t*  
 Ann Arbor staging classification for, 1509, 1509*t*  
 Coltswolds, 1509, 1509*t*  
 treatment algorithm, challenges, and future directions for, 1522, 1522*t*  
 Homer-Wright pseudorosettes, 1448  
 Homologous recombination (HR), 9, 44  
 Hong Kong Nasopharyngeal Study Group, 638  
 Hoosier Oncology Group (HOG), 829  
 Hormonal factors, and prostate cancer, 1039  
 Hormonal therapy, 1085, 1299-1300, 1085.e1*b*  
 Hormone-replacement therapy  
 endometrial cancer and, 1220.e1  
 ovarian cancer and, 1265-1266  
 Horseshoe kidney, germ cell tumors with, 1134  
 HSCT. *see* Hematopoietic stem cell transplant (HSCT)  
 HTLV-1, 1525  
 HuJ591, 407  
 $\beta$ -Human chorionic gonadotropin ( $\beta$ -HCG), 1126, 1489  
 Human chorionic gonadotropin (HCG), in testicular cancer, 1126  
 Human immunodeficiency virus (HIV) and lymphoma, 1525  
 Hodgkin's, 1466  
 and non-small cell lung cancer, 811  
 Human papillomavirus (HPV) and anal carcinoma, 1019  
 and cervical cancer, 1174  
 molecular biology of, 1176  
 and head and neck carcinoma, 562, 567-568  
 and laryngeal cancers, 650  
 and oropharyngeal cancer, 563, 597, 599-600, 599*t*  
 and penile cancer, 1161  
 vaccines for, 1177  
 and vulvar carcinoma, 1231  
 Hürthle cell carcinoma (HCC), 719-720, 728-729  
 Hutchinson's melanotic freckle, 778  
 Hybrid accelerated fractionation, for head and neck tumors, 563  
 Hydroxyethylene diphosphonate (HDP), 212-213  
 Hydroxyl radical, 7  
 Hyperbaric oxygen (HBO), multicenter randomized trials with, 53, 53*t*  
 Hyperfractionation, 37  
 for head and neck tumors, 563  
 for non-small cell lung cancer, 830  
 for oropharyngeal cancer, 616, 617*t*-618*t*  
 Hypermethylation of CpG island promoter, 908-909  
 Hypernephroma, 1140  
 Hyperostosis, 489  
 Hyperplasia  
 complex, 1205  
 endometrial, 1205  
 simple, 1205  
 Hypertension, and renal cell carcinoma, 1140  
 Hyperthermia (HT), 381-398  
 acquired resistance to, 381, 382*f*  
 Arrhenius relationship and thermal isoeffect dose in, 381-382, 382*f*  
 for augmented drug delivery, 396, 397*f*  
 biology of, 381-386  
 cellular and tissue responses to, 382  
 chemotherapy and, 385-386  
 clinical, 391, 395  
 factors to consider for, 386  
 phase III clinical trials of, 395, 395*t*  
 with radiotherapy, 385  
 rationale for, 385  
 clinical, 391-395  
 alone, 391  
 with chemotherapy, 391  
 normal tissue damage from, 391  
 with radiotherapy, 391-394, 393*t*  
 thermal ablation, 391  
 trimodality therapies, 391  
 cytotoxicity mechanisms of, 382-384  
 defined, 381  
 electromagnetic heating for, 387*t*, 388-389, 388*f*  
 immunologic effects of, 386, 386*f*  
 improvement in macromolecular and liposomal drug delivery and, 382-384, 383*f*  
 and metastases, 384  
 normal tissue damage from, 384, 391  
 physics/engineering of, 386-391, 387*t*  
 physiologic response to, 382-384, 382*f*  
 protein as target of, 382  
 radioimmunotherapy with, 406.e1  
 radiotherapy and  
 with chemotherapy, 391  
 clinical, 391  
 factors to consider for, 385  
 phase III clinical trials of, 392-394, 393*t*  
 rationale for, 384-385  
 "thermal enhancement ratio" for, 385  
 rationale for, 381  
 sensitization to, 382  
 with targeted agents, 385  
 technical challenges to, 395-396  
 temperature measurement during, 389-391  
 thermal dose for  
 outcome in, 391-392  
 prescription for, 396, 396*f*  
 in tri-modality therapies, 396  
 for tumor hypoxia, 51  
 and tumor metabolism and oxygenation, 384  
 ultrasound heating for, 387*t*, 389  
 vascular response to, 382, 382*f*  
 Hyperthermic cytotoxicity, mechanisms of, 382-384  
 Hypertrophic scars, 1380  
 Hypofractionated partial breast irradiation, 321  
 Hypofractionation, 37  
 Hypoglossal nerve (cranial nerve XII), 575, 581  
 Hypopharyngeal cancer, 649-672  
 adjuvant therapy for, 649  
 biologic characteristics of, 649  
 controversies, challenges, and future possibilities of, 671-672  
 distant metastases of, 653  
 early detection of, 651  
 epidemiology and etiology of, 650  
 evaluation for, 654-655, 654*t*, 656*f*  
 IMRT for, 667, 669*f*-670*f*  
 locally advanced, 649, 662*t*, 664, 664*t*  
 manifestations of, 654  
 molecular biology of, 653-654  
 neuroendocrine, 661  
 palliation for, 649  
 pathology of, 651  
 pathways of spread of, 652-653, 652*f*  
 postoperative radiation therapy for, 668-669, 670*f*  
 prevention of, 650-651  
 primary radiation therapy for, 666-668, 667*f*-670*f*  
 primary therapy for, 649, 661, 661*t*  
 sarcomatoid, 651, 661  
 staging of, 649, 656, 657*t*  
 treatment algorithm for, 669-671, 671*f*  
 verrucous, 651, 661  
 Hypopharyngeal tumors, target volumes in neck for, 747-748, 748*t*  
 Hypopharyngeal wall(s), 652-653  
 tumors, 653  
 Hyposalivation, 624  
 Hypothalamic-hypophyseal portal system, 505  
 Hypothalamic-pituitary function, after total body irradiation, 348  
 Hypothyroidism, 348, 760  
 from central nervous system tumors, 1401  
 Hypoxanthine, 6-mercaptopurine and, 172*f*  
 Hypoxia, 701, 1100, 1346  
 Hypoxic cell radiosensitizers, 24-25, 53-55, 54*t*, 55*f*  
 Hypoxic mammalian tumor cells, 1026  
 HypoxyProbe-1, 24  
 Hysterectomy, for endometrial cancer, 1209-1210  
**I**  
 IALT. *see* International Adjuvant Lung Cancer Trial (IALT)  
 Ibritumomab (Zevalin), 81*t*-82*t*  
 Ibritumomab tiuxetan, in radioimmunotherapy, 409.e1*t*  
 Ibrutinib, 81*t*-82*t*, 177  
 Idarubicin, 72  
 Idealized treatment field guidelines, 928-929, 928*t*-929*t*, 928.e1*t*  
 IDH1 mutations, 453-454  
 Idiopathic orbital inflammation, 1377-1378  
 IFG2 gene, 1423  
 IFN. *see* Interferon (IFN)  
 Ifosfamide, 70-71  
 in endometrial cancer, 1220.e1  
 for soft-tissue sarcoma, 1370  
 IgH rearrangements, in multiple myeloma, 1548  
 IGRT. *see* Image-guided radiation therapy (IGRT)  
<sup>131</sup>I-Lipiodol, 215  
 Image-guided brachytherapy (IGBT), for gynecologic tumors, 1171

- Image-guided radiation therapy (IGRT), 99, 134-135, 254, 294-324, 953, 1014-1015  
 definitions for, 294, 295f  
 process of, 315  
 short history of, 294-297  
 tools for, 314-315  
   CBCT as, 314  
   KV imaging as, 314  
   MR devices as, 314-315  
   MV imaging as, 314  
   RF beacons as, 314  
   video surface imaging as, 315  
 transitioning to, 314
- Image registration, 301, 302f  
 deformable, handling of, 301
- Imaging, 186-205  
 of adrenal tumors, primary and secondary, 200  
 of brain, 187-191, 188f-190f  
 of the chest, 191-194  
   lymphoma in, 193, 193f  
   metastatic disease to the chest in, 193-194  
   primary tumors of the lungs in, 191-193, 192f  
 of colon and rectum, primary tumors of, 195  
 of gastrointestinal tract  
   metastatic disease to, 195  
   primary tumors of, 194-195, 194f  
 of head and neck, 190f, 191  
 of liver  
   metastatic disease to, 195, 197f-198f  
   primary tumors of, 195, 196f  
 of pelvic organs  
   metastatic disease to, 203, 204f  
   primary tumors of, 200-203, 201f-203f  
 of primary stomach tumors, 194  
 in radiotherapy, 133-135  
   biologic, 135, 135f  
   image-guided, 134-135  
 of retroperitoneal organs, primary tumors of, 195-200, 198f-199f  
 of small bowel tumors, primary, 194-195  
 of the spine, 191
- IMAT. *see* Intensity-modulated arc therapy (IMAT)
- Imatinib, 48, 177  
 for aggressive fibromatosis, 1368-1369  
 as biologic modifier, 81t-82t  
 for gastrointestinal stromal tumors, 1366
- Immune targeted biologics, 89-90  
 cancer, immune system and, 89  
 CTLA-4 inhibitors, 89  
 ipilimumab, radiation, and abscopal effect, 89  
 PD-1 and PDL-1 inhibitors, 89-90
- Immunococonstructs, 403-404, 404f, 405.e1t
- Immunomodulatory derivatives, 180
- Immunotherapy, 176-177
- Implicit rationing, 220
- IMRT. *see* Intensity-modulated radiation therapy (IMRT)
- <sup>111</sup>In-octreotide, 213
- In vivo dosimetry, 129-130
- Incisional biopsy, 160  
 in soft-tissue sarcoma diagnosis, 1353
- Independent toxicity, 65
- Indirect radiation action, 7
- Indium-111 (<sup>111</sup>In)-DOTA-cT84.66 minibody, 403-404
- 111-Indium capromab prostate-specific membrane antigen monoclonal antibody imaging (ProstaScint), 1082.e1
- Induction chemotherapy, 175  
 for oropharyngeal cancer, 611-612
- Inelastic interaction, 106-107
- Infiltrating ductal carcinoma, 1316
- Inflammation, idiopathic orbital, 1377-1378
- Infraclavicular lymph nodes. *see* Axillary lymph nodes
- Infratentorial ependymomas, 1395, 1395f
- Inguinal lymph nodes, vulvar cancer in, 1233  
 assessment of, 1233-1234, 1234t  
 contralateral, 1234  
 incidence of metastasis to, 1234, 1234t  
 locally advanced disease and, 1247, 1247.e1f  
 management of, 1237  
 noninvasive imaging with, 1237, 1237.e1f  
 pathologic ultrastaging of, 1237  
 and primary tumor size, 1234t  
 sentinel node dissection for, 1236-1239  
 sentinel node study for, 1238, 1238.e1f  
 surgical exploration of, 1236  
 treatment of, 1243-1244, 1244t
- Intensity-modulated arc therapy (IMAT), 132-133, 1014
- Intensity-modulated radiation therapy (IMRT), 64-65, 254, 294-324, 902-903  
 alternate radiation and, 950-951  
 in anal carcinoma, 1030, 1030f  
 beam arrangements for, 312  
 beam definition for, 302-303  
 dose calculations in, 305  
   algorithms for, 305-306, 306t  
   issues in, 306  
   three-dimensional, 305  
 dose constraints of, 623, 623t, 643-644, 645b  
 for endometrial cancer, 1222, 1222f-1224f  
 future efforts in, 323  
 for gastric cancer, 927f  
 for gynecologic tumors, 1171  
 image guidance for, 134  
 indications for, 322  
 inverse planning for, 310-314  
   optimization method in, 312  
   plan evaluation for, 312-313  
   plan preparations in, 313  
   quality assurance (QA) checks for, 313  
 for mesothelioma, 890-892, 891f-893f, 891t  
 for nasopharyngeal carcinoma, 636, 638-639, 639t, 641-645  
 noncoplanar, plan for, 300f  
 normal tissue tolerance and complications of, 644-645, 645t  
 for oropharyngeal cancer, 620-623  
 for pancreatic cancer, 954  
 patient selection in, 620-621  
 physics of, 132-133  
 planning of, 621-623, 622f, 622t  
 potentially negative aspects of, 322-323  
 reproducibility in, 623  
 rotational, 351  
 segmental, 304  
 simulation and treatment planning of, 642-643, 643t  
 treatment goals and rationale for, 320  
 treatment planning and delivery of, 643, 644f-647f  
 treatment plans and, 954f  
 volumetric modulated arc, 313-314
- Intent to treat (ITT) analysis, 244-246, 244f-245f
- Interarm exchanges, 10
- Interchanges, 10
- Intercostal brachial nerve syndrome, 1325
- Interferon (IFN), for mycosis fungoides, 1567
- Interferon alpha-2b, for melanoma, 783
- Interferon-based chemoradiation, for pancreatic cancer, 944-945
- Interim analysis, 246  
 for fertility, 246
- Interleukin-1 (IL-1)  
 after radiotherapy, 33  
 with radioimmunotherapy, 413
- Interleukin-2 (IL-2), 406-407
- Intermediate-stage carcinomas, treatment of, 607
- Intermixed tissues, 27
- Internal conversion, 138
- Internal mammary chain (IMC), breast cancer and, 1285, 1285t
- Internal mammary nodal irradiation, 1318-1319, 1322, 1318.e1t, 1322.e1f
- Internal target volume (ITV), 126, 302
- International Adjuvant Lung Cancer Trial (IALT), 824
- International Federation of Gynecology and Obstetrics (FIGO) grading system, 1207
- International Neuroblastoma Pathology Committee (INPC), 1448-1449, 1448t
- International Staging System, 818t
- Interstitial irradiation, for lip cancer, 573, 573t
- Interstitial permanent seeds, 284-285, 285f-286f
- Interstitial treatment, 137
- Intraabdominal soft-tissue sarcomas, 1363-1366
- Intraarm exchanges, 10
- Intraarterial chemotherapy, for retinoblastoma, 1437
- Intraarterial radioimmunotherapy, 408
- INTRABEAM system, 333, 338, 333.e1f
- Intracavitary radioimmunotherapy, 408
- Intracavitary treatment, 137
- Intracranial ependymoma, 366
- Intraductal papillary mucinous neoplasms (IPMNs), 937  
 with invasive component, treatment of, 947.e1t
- Intradural spinal cord tumors, 523f, 528
- Intrahepatic cholangiocarcinoma. *see* Cholangiocarcinoma, intrahepatic
- Intralesional radioimmunotherapy, 408
- Intraluminal treatment, 137
- Intramedullary spinal cord tumors, 523f, 528
- Intraocular lymphoma  
 biology of, 543-544  
 etiology and epidemiology of, 542  
 evaluation of, 548  
 primary and adjuvant therapy for, 550
- Intraoperative electron irradiation therapy (IOERT), 919f, 918.e1  
 dose distribution characteristics of, 339, 339f  
 effects on peripheral nerves, 330, 330t, 330.e1t  
 effects on ureters, 329-330  
 mobile units for, 338  
   INTRABEAM, 333, 338, 333.e1f  
   Mobetron, 338, 339f  
   NOVAC 7, 332  
   vs. high-dose-rate, 339, 339.e1t
- Intraoperative radiation therapy (IORT), 325-340  
 biology of, 325, 326t  
 for breast cancer, 285  
 dedicated suites for, 338  
 defined, 325  
 dose-limiting structures for, 329-330  
   peripheral nerve as, 330, 330t, 330.e1t  
   ureter as, 329-330  
 dose of, 328-329  
   *versus* complications, 326-327, 327f  
   with EBRT, 328  
   influence of, 326, 327f, 326.e1t  
 electron. *see* Intraoperative electron irradiation therapy (IOERT)  
 with external beam irradiation  
   for breast cancer, 333  
   dose for, 328  
   for gastric cancer, 918, 918.e1t  
   *versus* EBRT, 918  
   plus EBRT, 918



- Intraoperative radiation therapy (IORT)  
(*Continued*)  
for gynecologic cancers, 334-336, 335*t*  
high-dose-rate, 338  
afterloading devices for, 338, 339*f*  
dose distribution characteristics of, 339, 339*f*  
vs. electron, 339, 339.e1*t*  
history of, 325  
limitations and drawbacks of, 338  
for local control, 325-326  
of cervical cancer, 326  
of colon and rectal cancer, 326  
and development of distant metastases, 327  
dose in  
versus complications, 326-327, 327*f*  
influence of, 326, 327*f*, 326.e1*t*  
of oligorecurrences, 326  
of pancreatic cancer, 326  
of retroperitoneal sarcoma, 326  
shrinking-field (boost) techniques for, 327  
for mesothelioma, 886  
mobile units for, 338  
INTRABEAM, 333, 338, 333.e1*f*  
Mobetron, 338, 339*f*  
NOVAC 7, 332  
patient selection and evaluation for, 327-328  
rationale for, 325  
results of, 330-338  
for breast cancer, 332-333, 333.e1*f*  
for cervical cancer, 335  
for colorectal cancer, 336-338, 337*t*  
for endometrial cancer, recurrent, 336  
for gynecologic cancers, 334-336, 335*t*  
for ovarian cancer, 336  
for pancreas cancer, 330-332, 331*t*-332*t*  
for retroperitoneal and pelvic soft-tissue sarcomas, 333-334, 334*t*, 334.e1*t*  
for uterine sarcoma, 336  
sequencing with surgery, 328  
technical aspects of, 329  
tolerance to, 329-330, 329*t*  
toxicity and dose constraints to normal tissues, 955, 957*t*
- Intraoral cone radiotherapy, 579
- Intraperitoneal radioactive chromic phosphate suspension ( $^{32}\text{P}$ ), for ovarian cancer  
advanced-stage, 1277, 1277*t*  
early-stage, 1270-1271
- Intraperitoneal radioimmunotherapy, 408, 408.e4*t*
- Intrapleural photodynamic therapy, for mesothelioma, 886
- Intravesical therapy, 1102-1103  
with bacillus Calmette-Guérin, 1102-1103  
with other agents, 1103.e1
- Intravitreal chemotherapy, for retinoblastoma, 1437
- Invasive thymoma, 867
- Inverse dose rate effect, 19
- Inverse planning, 294, 310-314  
beam arrangements for, 312  
goals for, 311-312  
MLC leaf sequencing for, 313, 314*f*  
optimization method for, 312  
plan evaluation for, 312-313  
plan preparation in, 313  
quality assurance (QA) checks for, 313
- Involved-field radiation therapy (IFRT), for Hodgkin's lymphoma, 1476, 1483  
advanced-stage, 1520  
early-stage, 1511-1512
- Involved-node radiation therapy (INRT), for Hodgkin's lymphoma  
early-stage, 1512  
pediatric, 1476
- Involved-site radiation therapy (ISRT), for Hodgkin's lymphoma, early-stage, 1512
- Iodine-123 ( $^{123}\text{I}$ )-cT84.66 minibody, 403-404
- Iodine-125 ( $^{125}\text{I}$ ), in brachytherapy, 276, 277*f*, 281*t*, 292
- Iodine-125 ( $^{125}\text{I}$ )-17-1A anti-Ep-Cam antibody, 406
- Iodine-125 ( $^{125}\text{I}$ )-Mab 425, 409
- Iodine-131 ( $^{131}\text{I}$ )-81C6, 408, 408.e6*t*
- Iodine-131 ( $^{131}\text{I}$ )-anti-CD45, 412
- Iodine-131 ( $^{131}\text{I}$ )-anti-CEA F(ab')<sub>2</sub>, 406
- Iodine-131 ( $^{131}\text{I}$ )-CC49, 402.e2*t*-402.e4*t*, 405.e1*t*, 402.e6*t*  
with external beam radiotherapy, 406
- Iodine-131 ( $^{131}\text{I}$ )-F6 F(ab')<sub>2</sub>, with minimal tumor burden setting, 405
- Iodine-131 ( $^{131}\text{I}$ )-Hepama-1, 409
- Iodine-131 ( $^{131}\text{I}$ )-hMN14, 405
- Iodine-131 ( $^{131}\text{I}$ )-MIBG therapy, for neuroblastoma, 1452
- Iodine-131 ( $^{131}\text{I}$ )-tositumomab, 410
- Iododeoxyuridine (IdUdR), 26
- IOERT. *see* Intraoperative electron irradiation therapy (IOERT)
- Ion, 96*t*
- Ionization, 96*t*
- Ionization chambers, 112, 112*f*  
for external beam treatment verification, 130
- Ionizing radiation, 41, 96*t*  
activation of anabolic signaling pathways by, 46-47, 47*f*  
cell cycle and, 16-19, 17*f*-18*f*  
cellular triage after, 43, 43*f*  
cytogenetic effects of, 10-11, 10*f*  
definition of, 2  
densely, 19-20  
factors that influence RBE, 20, 20*f*-21*f*  
linear energy transfer, 19, 19*f*  
relative biological effectiveness, 19-20, 20*f*  
detection and measurement of, 111-114  
gas-filled detectors for, 111-112, 112*f*, 112*t*  
ionization chambers for, 112, 112*f*  
solid-state detectors for, 112-114, 113*f*  
interaction with biological materials, 6-7  
interactions with matter, 100-109  
charged particle interactions as, 106-109  
photon interactions as, 100-106, 100*f*  
mechanisms of DNA repair after, 44  
programmed cell death induce by, 46  
quantities and measurement of, 109-114, 111*t*  
tumor microenvironment response to, 47-48
- Ionizing radiation exposure  
and salivary gland tumors, 699  
and thyroid cancer, 716
- IORT. *see* Intraoperative radiation therapy (IORT)
- Ipilimumab (Yervoy), 81*t*-82*t*, 89  
radiation, abscopal effect and, 89
- IPMNs. *see* Intraductal papillary mucinous neoplasms (IPMNs)
- Ipsilateral radiation, dominant criticism of, 610
- Ipsilateral tonsillectomy, for oropharyngeal cancers, 605
- Iressa. *see* Gefitinib
- Iridium-192 ( $^{192}\text{Ir}$ )  
in brachytherapy, 281  
in intraoperative radiotherapy, 338, 339*f*
- Irinotecan, 72, 803, 983
- Irradiated volume (IV), 126, 126*f*
- Irradiation boost techniques, 904
- Irradiation field, defined, 902-903
- Irradiation plus chemotherapy, for nasopharyngeal carcinoma, 636-638, 637*t*
- Irreversible electroporation, 951.e2
- Isobars, 94-95, 94*t*
- Isobologram, 68, 68*f*, 68.e1*f*  
Steel and Peckham's method for, 68.e1
- Isocenter, for treatment machines, 95-96, 96*f*
- Isocentric accuracy, 154, 156*f*
- Isodose curves, 832*f*-833*f*
- Isodose lines, 117-118, 117*f*, 119*f*, 306-307, 307*f*  
of electron beams, 122*f*  
physical wedges and, 120, 120*f*
- Isodose surface, 307-308, 307*f*
- Isoeffect curve, 6, 6*f*, 36, 36*f*-37*f*
- Isomeric transition, 138
- Isomers, 94-95, 94*t*
- Isotones, 94-95, 94*t*
- Isotopes, 94-95, 94*t*  
properties and applications of, 139-140, 139*t*, 140*f*-141*f*, 140.e1*f*-140.e2*f*
- Isotretinoin, 630  
for dysplasia, 600  
for mycosis fungoides, 1567
- Iterative planning, 310
- Ixabepilone, 71
- J**
- JAK/STAT pathway, in Hodgkin's lymphoma, 1507-1508
- Joints, benign diseases of, 1378
- Jugular lymph nodes, 738-740
- Juvenile nasopharyngeal angiofibroma, 1490-1492  
adjuvant therapy for, 1486, 1491-1492  
biology of, 1486, 1491  
clinical manifestations of, 1491  
etiology and epidemiology of, 1490-1491  
evaluation for, 1491  
incidence of, 1486  
irradiation techniques for, 1492, 1492*f*  
locally advanced, 1486, 1492  
palliation for, 1487, 1492  
pathology of, 1491  
pathways of spread of, 1491  
primary therapy for, 1486, 1491-1492  
staging of, 1486, 1491, 1491*t*  
treatment algorithms, controversies, challenges, and future possibilities for, 1492
- Juvenile nasopharyngeal fibroma (JNF), 1376
- K**
- K-RAS  
gene, in multiple myeloma, 1548  
protein, inhibitors of, 177
- Kaplan-Meier method, for survival analysis, 247-248, 247*f*
- Keloids, 1380
- Kerma, 111, 111*t*
- Kidney  
clear cell sarcoma of, 1424, 1424*t*, 1425*f*, 1430  
horseshoe, germ cell tumors with, 1134  
late effects of radiation on, 256*t*-257*t*, 272  
dose-volume data on, 272  
organ function and clinical significance and, 272  
QUANTEC Review on, 272  
primary tumors of, 196-200, 199*f*  
rhabdoid tumor of, 1424-1426, 1424*t*, 1425*f*, 1430  
toxicity, 974
- Kidney cancer, 1036-1037. *see also* Renal cell carcinoma (RCC); Renal pelvis cancer
- Kidney carcinoma. *see* Renal cell carcinoma (RCC)
- Kiloelectron volts, 96*t*
- Kilovoltage (kV) imaging as, 314
- Kinomics, chemotherapy-radiation interactions in, 78

- KITLG* gene, 1122  
 “Kompressionsanämie”, 51  
*KRAS* genes  
   in colorectal cancer, 993  
   in non-small cell lung cancer, 811
- L**
- Labial frenula, 571  
 Lacrimal gland, radiation and, 556  
 Lacrimal gland tumors, 542, 545, 549, 551  
 Lactate dehydrogenase (LDH), in testicular cancer, 1126  
 Lambert-Eaton syndrome, 800  
 Lamina papyracea, 675  
 Langerhans cell histiocytosis, pediatric, 1495-1497  
   adjuvant therapy for, 1486, 1496  
   biology of, 1486, 1496  
   clinical manifestations of, 1496  
   etiology and epidemiology of, 1495-1496  
   evaluation for, 1496  
   incidence of, 1486  
   irradiation techniques for, 1496  
   locally advanced, 1486, 1496  
   palliation for, 1487, 1496  
   pathology of, 1496  
   pathways of spread of, 1496  
   primary therapy for, 1486, 1496  
   staging of, 1486, 1496  
   treatment algorithms, controversies, challenges, and future possibilities for, 1496-1497
- Laparoscopy  
   for pancreatic malignancy, 161-162, 161f-162f  
   role of, in surgery, 161-162
- Laparotomy, for esophageal cancer, 848
- Lapatinib (Tykerb), 81t-82t, 84
- Large cell carcinomas, lung, 192
- Large cell lymphoma(s)  
   anaplastic, 1526, 1527f, 1529, 1540, 1562  
   pediatric, 1461t, 1462
- Large noncoding RNA, 47
- Laryngeal cancer, 649-672  
   adjuvant therapy for, 649  
   biologic characteristics of, 649  
   carcinoma in situ as, 651  
   controversies, challenges, and future possibilities of, 671-672  
   distant metastases of, 653  
   early detection of, 651  
   epidemiology and etiology of, 650  
   evaluation for, 654, 654t, 655f  
   HPV and, 650  
   IMRT for, for T1-2N0 glottic carcinomas, 666, 666f  
   locally advanced, 649, 662t, 663-664  
     bulky supraglottic cancer as, 663  
     T3 glottic cancer as, 662, 662t  
   manifestations of, 654  
   molecular biology of, 653-654  
   neuroendocrine, 661  
   palliation for, 649  
   pathology of, 651  
   pathways of spread of, 651-652, 651f  
   prevention of, 650-651  
   primary therapy for, 649  
     for glottic tumors, 657-659, 658t-659t  
     for supraglottic tumors, 660-661, 660t  
   radiation therapy for  
     postoperative, 668-669, 670f  
     primary, 664-668  
     for T1-2N0 glottic carcinomas, 664-666, 665f-666f, 666t
- Laryngeal cancer (*Continued*)  
   for T1-3 supraglottic carcinomas, 666-668, 667f-668f  
   for T3N0 glottic carcinomas, 666-668  
   techniques of, 664-669  
   sarcomatoid, 651, 661  
   staging of, 649, 655-656, 657t  
   treatment algorithm for, 669-671, 671f  
   verrucous, 651, 661
- Laryngeal edema, 262
- Laryngeal squamous cell carcinomas, metastatic neck nodes from, 745t
- Laryngeal tumors, target volumes in neck for, 747-748, 748t
- Larynx, 651-652, 651f  
   late effects of radiation on, 256t-257t, 262-263  
     dose-volume data, 262  
     on swallowing, 262  
   organ function and clinical significance and, 262  
   QUANTEC Review on, 262  
   on swallowing, 262-263
- Larynx shield, 733f
- Late effects, in normal tissues, 30-34, 253-274  
   of bladder, 256t-257t, 272-273  
   of brain, 256-258, 256t-257t  
   of brainstem, 256t-257t, 259  
   carcinogenesis as, 32-33  
   cataracts as, 31, 32  
   dose-volume histograms and, 253-254, 254f  
   *versus* early, 30  
   of esophagus, 256t-257t, 268  
   following radiotherapy, 33-34  
   of hearing, 256t-257t, 260-261  
   of heart, 256t-257t, 266-268  
   anthracyclines and, 267  
   of kidney, 256t-257t, 272  
   of larynx and pharynx, 256t-257t, 262-263  
   of liver, 256t-257t, 271-272  
   of lung, 256t-257t, 263-266, 264t-265t  
     organ function and clinical significance of, 263  
     and pneumonitis and fibrosis, 263-265  
     and pulmonary function, 266  
   of optic nerves and chiasm, 256t-257t, 260  
   organ structure, definition of, 254-255, 255f  
   of penile bulb, 256t-257t, 273  
   QUANTEC initiative, 255-256, 256t-257t  
   radiation technologies, opportunities and challenges of, 254  
   of rectum, 256t-257t, 269-271, 270t  
   of salivary glands, 256t-257t, 261-262  
   of spinal cord, 256t-257t, 259-260  
   statement of the problem, 253  
   of stomach and small bowel, 256t-257t, 268-269  
     dose-volume data on, 269  
     organ function and clinical significance of, 268  
   QUANTEC Review on, 269  
   target cells/tissues for, 253
- Latency membrane proteins (LMPs), 562
- Lead-212 (<sup>212</sup>Pb), 400.e1
- Lead cutout, 774, 774f
- Leiomyosarcoma, 1220, 1350, 405.e2t-405.e4t  
   adjuvant chemotherapy for, 1220.e1
- Lenalidomide, 180  
   for multiple myeloma, 1551
- Lens, radiation and, 556
- Lentigo maligna, 778
- Lentigo maligna melanoma, 778
- Leptomeningeal disease, 187-191, 190f
- Leptomeningeal spread, of glioblastoma, 470
- Leptons, 93, 94t
- Letterer-Siwe disease, 1496
- Leucovorin, for colon cancer, 977
- Leukemia(s)  
   acute lymphoblastic. *see* Acute lymphoblastic leukemia (ALL)  
   acute lymphoid, 352, 352.e2t  
   acute myelogenous. *see* Acute myelogenous leukemia (AML)  
   chronic myelogenous, 352, 352.e2t  
   pediatric, 1455-1463  
   radiation-induced, 1326  
   radioimmunotherapy for, 409-413, 409.e2t  
   testicular, 1459
- Leukoencephalopathy, from central nervous system tumors, 1401-1402
- Leukoplakia, 600
- Leuprolide, for prostate cancer, 1040, 1085
- Leydig cell tumors, 1133
- LHRH. *see* Luteinizing hormone-releasing hormone (LHRH)
- Li-Fraumeni syndrome, 1315, 1346
- Limited stage small cell lung cancer (L-SCLC)  
   clinical trials in, 807  
   controversies in, 807  
   with good performance status and TRT, 807  
   prophylactic cranial irradiation for, 803-804, 807  
   in special populations: elderly and with lower performance status, 807  
   thoracic radiotherapy for, 801-803  
   treatment fields, 806f
- Linear accelerator(s), 97-99  
   major electronic and beamline components of, 98t  
   multileaf collimator of, 98-99, 99f  
   photon spectra for, 99, 100f  
   schematic of, 98f  
   treatment machine geometry for, 95-96, 96f
- Linear accelerator-based radiosurgery, 148, 150f
- Linear accelerator technology, for radiosurgery, 148, 150f
- Linear attenuation coefficient, 100
- Linear energy transfer (LET), 6-7, 10-11, 19, 19f  
   for charged particle radiotherapy, 358  
   of fast neutron therapy, 373
- Linear quadratic equation, 12, 12f
- Linear-quadratic isoeffect model, 35-36, 37f, 38t  
   clinical applications of, 36-39  
   parameters of, 39t  
   reciprocal dose plot in, 35-36, 36f
- Lingual nerve, 575, 581
- Lingual tonsils, 604
- Lip(s), 571
- Lip cancer  
   early, 572  
   etiology of, 570-571  
   locally advanced, 572  
   manifestations of, 572  
   moderately advanced, 572  
   Mohs' surgery for, 574  
   neck management in, 572  
   pathology of, 572  
   radiotherapy for  
     external beam, 573-574, 574t  
     interstitial, 573, 573t  
     parallel-opposed fields in, 574-575, 575f  
     techniques of, 574-575  
   recurrent, 574  
   staging of, 572, 572t  
   surgery for, 573-574, 574t  
   treatment of, 572  
     algorithm for, 573f  
     complications of, 575  
     results of, 573-574
- Lipoma, spinal, 537
- Liposarcoma, 200, 1347-1349, 1350f

- Liposomal drug delivery, hyperthermia with, 382-384, 383f
- Liquid scintillator, 113-114, 113f
- Lithium fluoride (LiF) dosimeter, 112-113
- Liver
- imaging of
  - metastatic disease to, 195, 197f-198f
  - primary tumors of, 195, 196f
  - late effects of radiation on, 256t-257t, 271-272
  - dose-volume data on, 271
  - organ function and clinical significance and, 271
  - QUANTEC Review on, 271-272
- Liver cancer, 960. *see also* Hepatobiliary cancer
- Liver metastases, 432, 445-447
- boron neutron capture therapy for, 379
  - clinical manifestations of, 445
  - of colorectal cancer, 405
  - diagnosis of, 445-446
  - of non-small cell lung cancer, 816
  - patient evaluation in, 445
  - radiation for, 446
  - treatment of, 446-447
- Liver tolerance, 447
- Liver toxicity, radiation-induced, 271-272
- Liver transplantation, 967
- Liver tumors, primary malignant, in children. *see* Primary malignant liver tumors
- (PMLTs), in children
- LL-2, for B-cell lymphoma, 409.e1t
- LMP1, pediatric nasopharyngeal carcinoma and, 1497
- Lobular carcinoma in situ (LCIS), 1303-1305
- biopsy of, 1304
  - breast-conservation therapy for, 1304t
  - failure rates with, 1304
  - histology of, 1303
  - molecular markers of, 1304
  - treatment algorithm for, 1305f
  - treatment recommendations for, 1304
- Local pain, in oropharyngeal cancer, 604
- Local recurrence map, 943f
- Locally multiply damaged sites, 44
- Locally unresectable disease, pancreatic cancer, 948-951
- chemotherapy *versus* chemoradiation therapy in, 949t
  - EBRT with or without IOERT for, 941.e1t
  - neoadjuvant therapy for, 951
  - stereotactic body radiation therapy for, 956t
- Locoregional disease, cancer, 1028
- Locoregional radiation failures, 615
- Log-rank statistic, for survival analysis, 248-249, 248f, 248t-249t
- Low anterior resection (LAR), 166
- Low-dose-rate (LDR) brachytherapy, 277
- high-dose-rate brachytherapy and, 279-280
- LRHL. *see* Lymphocyte-rich classical Hodgkin lymphoma (LRHL)
- Lumbosacral nerve roots, tolerance of, 531-532
- Lung, late effects of radiation on, 256t-257t, 263-266
- organ function and clinical significance and, 263
  - and pneumonitis and fibrosis, 263-265
  - and pulmonary function, 266
- Lung cancer, 191
- after radiotherapy for breast cancer, 1326
  - biology of, 789
  - conformal radiotherapy for, 318-320
  - epidemiology, 788
  - follow-up for, 193
  - imaging strategies for, 191-192, 192f
  - non-small cell. *see* Non-small cell lung cancer (NSCLC)
- Lung cancer (*Continued*)
- PET of, 209-210, 210f
  - radioimmunotherapy of
    - with chemotherapy, 406, 405.e2t-405.e4t
    - monoclonal antibodies for, 402.e2t-402.e4t, 402.e6t
    - pretargeting with, 408, 408.e3t  - screening for, 193
  - small cell. *see* Small cell lung cancer (SCLC)
  - staging of, 193
    - and workup, 789-790  - stereotactic body radiation therapy for, 430
- Lung Cancer Study Group (LCSG) trial, 819
- Lung-endobronchial brachytherapy, 285, 286f
- Lung metastases, 447-448
- of Ewing's sarcoma, 1418-1419
  - treatment of, 447-448
- Lung toxicity, 264t-265t
- Luteinizing hormone-releasing hormone (LHRH)
- agonists, for prostate cancer, 1077
  - metastatic, 1085
  - toxicity of, 1078
  - analogues, 1040
- Lutetium-177 (<sup>177</sup>Lu), with chemotherapy, 406
- Lyman NTCP model, 309
- Lymph node dissection
- elective nodal treatment to, 782
  - for gastric cancer, 911-912
- Lymph node involvement (LNI)
- in cervical cancer, 1176
  - endometrial cancer, 1210, 1210t
  - in prostate cancer
    - and clinical target volumes, 1087
    - computed tomography of, 1053
    - and elective nodal irradiation, 1087
    - management of, 1080
    - as predictive factors, pathologic, 1046
    - for staging, 1044
    - symptoms and signs of, 1052  - in soft-tissue sarcoma, 1351, 1352t
  - in testicular cancer, 200
- Lymph vessels and nodes, of head and neck, 676f
- Lymphadenectomy, for endometrial cancer, 1209
- Lymphangioma, pediatric, 1493-1494
- adjuvant therapy for, 1486, 1494
  - biologic characteristics of, 1486
  - clinical manifestations of, 1493
  - etiology and epidemiology of, 1493
  - evaluation for, 1493
  - incidence of, 1486
  - irradiation techniques for, 1494
  - locally advanced, 1486, 1494, 1494f
  - palliation for, 1487, 1494
  - pathology of, 1493
  - pathways of spread of, 1493
  - primary therapy for, 1486, 1494
  - staging of, 1486, 1493
  - treatment algorithms, controversies, challenges, and future possibilities for, 1494
- Lymphedema
- after breast-conservation therapy, 1325
  - with melanoma, 782-783, 783t
- Lymphoblastic lymphomas, pediatric, 1461t, 1462
- Lymphocyte predominant (LP) cells, 1508
- Lymphocyte-rich classic Hodgkin's disease (LRCHD), 1508
- Lymphocyte-rich classical Hodgkin lymphoma (LRHL), 1466
- Lymphocyte-rich thymoma, 868f
- Lymphoid diseases, of orbit, 1377
- Lymphoid malignancies
- basic issues in, 1501
  - molecular basis of, 1501
  - pathological classification of, 1501
  - staging of, 1501-1502
  - treatment of, 1502-1504
- Lymphoma(s), 450
- B-cell. *see* B-cell lymphoma(s)
  - basic issues in, 1501
  - bone, 1540
  - breast, 1540
  - Burkitt, and *c-MYC*, 1528-1529
  - cutaneous, 1541-1542, 1542f
  - extradural, 1530
  - extranodal, 1530
  - follicular, 1504, 1534-1536, 1535t
  - gastric, 1544-1545
  - Hodgkin's. *see* Hodgkin's lymphoma
  - imaging of, 193, 193f
  - intraocular. *see* Intraocular lymphoma
  - large cell. *see* Large cell lymphoma(s)
  - marginal zone, 1536-1537
  - molecular basis of, 1501
  - non-Hodgkin's. *see* Non-Hodgkin's lymphoma (NHL)
  - orbital. *see* Orbital lymphoma
  - pathological classification of, 1501
  - pediatric, 1455-1463
    - Burkitt's, 1461, 1461t
    - large cell, 1461t, 1462
    - lymphoblastic, 1461t, 1462
    - non-Hodgkin's. *see* Non-Hodgkin's lymphoma (NHL)  - PET scan for, 211
  - radioimmunotherapy for, 409-413, 409.e1t-409.e2t
    - radiobiology of, 401  - salivary gland, 1544
  - of small bowel, 194-195
  - small lymphocytic, 1534
  - spinal cord, 537, 538f
  - staging of, 1501-1502
  - T-cell. *see* T-cell lymphoma(s)
  - thyroid, 726, 729, 1544
  - treatment of, 1502-1504
- Lymphomatoid papulosis, 1562
- Lymphovascular space invasion (LVSI), in endometrial cancer, 1205-1207
- Lynch syndrome, 979
- endometrial cancer and, 1204
- ## M
- M component, 1547
- M protein, 1547
- MACIS scoring system, 719, 719f
- Macromolecular drug delivery, hyperthermia with, 382-384, 383f
- Macular degeneration, 1376
- age-related. *see* Age-related macular degeneration (AMD)
- Magnetic induction heating, 387t, 388-389
- Magnetic resonance imaging (MRI), 186
- in breast cancer screening, 1289
  - for cervical carcinoma, 202
  - for conformal radiotherapy, 298-299, 299b
  - for head and neck tumors, 191
  - for hepatocellular carcinoma, 195, 196f
  - for oropharyngeal cancer, 605-606
  - for prostate cancer, 1053-1054, 1054f
  - tumor hypoxia and, 52
- Magnetic resonance spectroscopy (MRS), 187
- high-grade tumors and, 187-191
  - for prostate cancer, 319, 1054, 1054f

- Magnetic resonance thermal imaging (MRTI), 390-391, 390f
- Malignant epithelial tumors, World Health Organization (WHO) classification of, 1022
- Malignant fibrous histiocytoma (MFH), 537-538, 1347
- Malignant melanoma. *see* Melanoma
- Malignant pleural mesothelioma (MPM), incidence of, 865
- Malignant salivary gland tumors (MSGTs), radiation-induced, 699
- Malnutrition, perioperative care of, 162
- MALT lymphoma. *see* Mucosa-associated lymphoid tissue (MALT) lymphomas
- Mammography, in breast cancer screening, 1289
- Manchester principles, for cervix cancer, 277
- Manchester system  
for gynecologic implants, 142, 142f-143f, 143t  
for interstitial implants, 142-143, 143f, 143t
- Mantle cell lymphoma, 1526, 1528  
advanced, 1537  
localized, 1537  
relapsed and refractory, 1537
- Margin status, of breast cancer, 1315-1316, 1315t
- Marginal zone lymphoma, 1536-1537
- "Marginally resectable" cancer, 1006
- Marker-based strategy design, 250, 251f
- Marker-by-treatment interaction design, 250, 250f
- Masaoka staging system, 790  
for thymoma, 790t, 871t
- Mass absorption coefficient, 106
- Mass attenuation coefficient, 102, 104, 104f
- Mass number, 94
- "Massive-dose technique", 5
- Mastectomy, 163  
for breast cancer, 1291, 1295-1296  
*versus* breast-conserving therapy, 1311, 1313.e1t  
for ductal carcinoma in situ, 1308  
radiation therapy after, 1334-1336, 1334t-1335t  
and breast reconstruction, 1339-1342  
with neoadjuvant chemotherapy, 1336-1337, 1336t  
techniques for, 1338, 1339f-1341f
- Matrix dose calculation algorithm, 306t
- Matter, 93-95  
atomic and nuclear structure of, 93-94, 94f, 94t  
interactions of ionizing radiation with, 100-109, 100f  
nomenclature for, 93-94, 94t  
nuclides and radionuclides, 94-95, 94t, 95f  
photons in, 95  
standard model of, 93-94, 94t
- Maxillary sinus(es), 677f, 678-680, 681t
- Maxillary sinus cancer  
adjuvant radiotherapy for, 694f  
etiology and epidemiology of, 674  
IMRT for, 692, 693f-695f, 693t  
irradiation techniques and tolerance for, 692-693, 693f-695f, 693t  
manifestation, patient evaluation, and staging of, 682t, 683  
pathology of, 679, 681t  
primary therapy for, 686-687, 687t, 687.e1f  
treatment algorithm for, 696, 697f
- Maximum tolerated dose (MTD), 240
- MDM4 amplification, 1438
- Mean heart dose, 267
- Mean lethal dose (LD<sub>50</sub>) assay, 13, 30
- Mechlorethamine hydrochloride (HN2), for mycosis fungoides, 1566
- Median dose effect principle, 68-69, 69f
- Mediastinal large B-cell lymphomas (MLBCLs), 1462
- Mediastinal staging, for lung cancer, 790, 816-817
- Mediastinoscopy, 210
- Mediastinum, soft-tissue sarcoma of, 1367
- Medical Research Council (MRC), 911-912
- Medroxyprogesterone, for prostate cancer, 1085
- Medullary thyroid cancer, radioimmunotherapy for, 402t  
monoclonal antibodies for, 402t  
pretargeting with, 408, 408.e3t
- Medullary thyroid carcinoma (MTC), 720-721  
cause-specific survival with, 720-721, 721f  
etiology and epidemiology of, 716, 716t  
familial, 562, 717  
pathology of, 717  
prognostic factors for, 721  
staging of, 718, 718t  
treatment algorithm for, 729
- Medulloblastoma, 1391-1393, 1391f  
craniospinal irradiation for, 1392, 1393f-1395f  
diagnosis of, 1391-1392  
proton beam radiotherapy for, 364, 365f  
risk-stratification system for, 1392  
treatment of, 1392
- Megavoltage (MV) imaging, 314
- Megestrol, for prostate cancer, 1077, 1085
- Melanoma, 777-787  
acral lentiginous, 778-779  
adjuvant therapy for, 777, 783-784  
amelanotic, 778  
anal, 1023  
biologic characteristics of, 777, 779  
clinical trials for, 786  
desmoplastic, 781-782  
diagnostic algorithm for, 781t  
with distant disease, 783-784  
etiology and epidemiology of, 778  
evaluation for, 779-781, 781t  
hyperthermia for, 384, 393t, 394  
interferon alpha-2b for, 783  
lentigo maligna, 778  
locally advanced, 777, 784  
with lymph node metastases  
elective nodal treatment to, 782  
therapeutic nodal approaches to, 782, 783t  
metastatic to brain, 378  
with nodal metastases, prognostic feature for, 779  
nodular, 778  
ocular. *see* Ocular melanoma  
pagetoid, 778  
palliation of, 784  
pathology of, 778-779  
patterns of spread of, 779, 779f, 780t  
presentation of, 778-779  
prevention and early detection of, 778  
primary therapy for, 777, 781-784  
for distant disease, 783-784  
for primary tumor, 781-782, 781t-782t  
for regional nodes, 782-783, 783t  
prognostic feature for, with nodal metastases, 779, 780t  
radiation therapy techniques for, 784-786  
for bulky or inoperable nodal disease, 786  
patient care during and after, 786  
setup, field arrangement, and dose-fractionation schedule for, 785-786  
target volume for, 784-785, 784f-785f  
radioimmunotherapy for, monoclonal antibodies for, 402.e2t-402.e4t  
sentinel lymph node biopsy for, 781, 781t  
of soft parts, 1351
- Melanoma (*Continued*)  
staging of, 777, 779-781, 781t  
superficial spreading, 778  
treatment algorithms for, 786  
elective nodal treatment, 786  
therapeutic nodal approaches for, 786, 786f  
vaginal, 1262  
vulvar, 1232, 1252-1253, 1252.e1f, 1253.e1t-1253.e2t  
staging of, 1253  
treatment of, 1253  
types of, 1253
- Melphalan, 70
- Memorial Sloan-Kettering Cancer Center, 1002
- Meningioma(s), 483  
anaplastic/malignant, 484t, 488-489  
atypical, 484t, 488, 488f, 488.e1f  
benign, 484t  
therapy for, 485-488  
definitive EBRT for, 486, 487f, 486.e1f  
postoperative radiotherapy for, 485, 486f  
stereotactic radiosurgery for, 486-488, 487t  
surgery for, 485, 485t  
biology of, 484  
cavernous sinus, 486.e1f  
clinical manifestations of, 485, 493f  
convexity, 485  
defined, 483  
dural tail and, 489  
etiology and epidemiology of, 483-484  
grading of, 484, 484t  
hyperostosis and, 489  
imaging of, 485  
incidence of, 483  
incidentally detected, 488.e1  
locally advanced, 483  
optic nerve sheath. *see* Optic nerve sheath meningioma  
orbital, 544-545  
palliation for, 483  
pathology and pathways of spread of, 484-485, 484t, 484.e1f  
patient evaluation in, 485  
prevention and early detection of, 484  
radiation-induced, 489.e1  
radiotherapy for  
external beam  
definitive, 486, 487f, 486.e1f  
postoperative, 485, 486f  
suggestions for, 490t  
techniques and tolerance in, 489-490  
toxicities of, 489  
stereotactic, hypofractionated, 488.e1  
radiotherapy for, proton beam, 362  
recurrent, 485-486  
response assessment of, 490  
spinal, 527t, 535  
staging of, 485  
stereotactic radiosurgery for, 422-424, 424f, 486-488  
results of, 487t  
suggestions for, 490t  
toxicities of, 489-490  
surgery for, 485, 485t  
therapy for  
adjuvant, 483  
benign histology of, 485-488  
in higher risk patients, 488-489  
primary, 485-489  
systemic, 489  
treatment of  
algorithm for, 490-491, 490f  
clinical trials of, 490-491



- 6-Mercaptopurine, hypoxanthine and, 172f  
Merkel cell carcinoma (MCC)  
  biology and pattern of spread of, 767  
  diagnostic and treatment algorithms for, 776  
  irradiation techniques for, 774-775  
  setup, field arrangement, and dose  
  fractionation schedule, 775, 775f  
  target volume, 774  
  presentation and pathology of, 767, 767f  
  staging of, 769  
  treatment of, 771-772, 772f  
Mesenteric mesenchymal tumors, of pancreas, 937  
Mesoblastic nephroma, 1424, 1424t  
 $\pi$ -Meson radiotherapy, 370, 370f  
Mesons, 93  
Mesorectal fascia (MRF), 994  
Mesorectum, 1012, 998.e1f  
Mesothelioma, 883-892  
  chemotherapy for, 885-886  
  clinical evaluation of, 883-884  
  epidemiology, 789  
  etiology and epidemiology of, 883  
  imaging of, 883-884  
  IMRT and, 891  
  intrapleural photodynamic therapy for, 886  
  radiation therapy for  
  after extrapleural pneumonectomy,  
  887-888, 888t  
  after pleurectomy or decortication, 886  
  alone, 886  
  combined with surgery, 886  
  computed tomographic simulation for,  
  889  
  curative, 886  
  intensity-modulated, 890-892, 891f-893f,  
  891t  
  palliative, 888-889  
  patient immobilization and setup, 889  
  target volume delineation, 889-890  
  three-dimensional conformal, 890  
  rationale for irradiation of, 886  
  staging of, 883-884, 885t  
  invasive, 884  
  and workup, 790-791  
  surgery for, 884-885  
  combined with radiation, 886  
  extrapleural pneumonectomy, 884-885  
  pleurectomy, 884  
  radiation after, 886  
  treatment of, 884-892  
MET gene, 908  
Meta-Analysis of Chemotherapy on Head and  
  Neck Cancer (MACH-NC), 611  
Metaiodobenzylguanidine (MIBG)  
  for routine imaging, 213-214  
  therapy, 214-215  
Metal oxide-silicon semiconductor field effect  
  transistor (MOSFET) detectors, 113, 113f,  
  129-130  
  remote reporting, 130  
Metastable state, 138  
Metastasis(es)  
  bone. *see* Bone metastases  
  brain. *see* Brain metastases  
  hyperthermia and, 384  
  liver. *see* Liver metastases  
  lung, 447-448  
  to pituitary gland, 517  
  in small cell lung cancer, treatment of, 805  
  spinal cord compression due to, 441-443,  
  442f, 442t  
Metastatic cervical lymph nodes, 394  
  imaging of, 741  
  CT for, 741, 742f  
  MRI for, 741, 743f  
Metastatic cervical lymph nodes (*Continued*)  
  PET for, 742, 744f  
  ultrasonography for, 741-742  
Metformin, 56  
Methotrexate, 70, 176, 181t  
  tetrahydrofolate and, 172f  
Methyl-CCNU, 71  
Methyl diphosphonate (MDP), 212-213  
O-6-Methylguanine-DNA methyltransferase  
  (MGMT), 183  
  in high-grade gliomas, 474  
  in low-grade gliomas, 454  
mFOLFOX6, for rectal cancer, 1000  
Microcystic adnexal carcinoma (MAC),  
  768  
Microenvironment, 47  
Micropapillary carcinomas, 1268  
Microsatellite instability (MSI)  
  in colorectal cancer, 979, 993  
  in endometrial cancer, 1204  
Microspheres, 215  
Microtubule targeting, 71  
Microwave array heating, 387t  
Microwave waveguide heating, 387t, 388f  
Midazolam, in endometrial cancer, 1203-1229  
Middle jugular nodes, 740t  
Milk production, after irradiation, 1325  
Million electron volts, 93, 96t  
Million volts, 96t  
Minimally invasive esophagectomy (MIE),  
  849  
Minor salivary gland cancers  
  pathways of spread of, 702-703  
  surgery for, 706  
  target volume delineation for, 711  
Mismatch repair, 9  
Misonidazole, 25, 25f, 25t, 56-57  
  as radiosensitizer, 54, 54t  
Mitogen-activated protein kinase (MAPK), 46,  
  47f  
Mitomycin C (MMC), 56, 57f, 71, 171  
  for anal cancer, 72  
  for anal carcinoma, 1025-1027, 1026t-1027t  
  with 5-fluorouracil, 72.e1  
Mitosis, cytotoxic drugs and, 176  
Mitotic catastrophe, 11, 67  
Mitotic delay, 18  
Mitotic harvest technique, 16  
Mitoxantrone, 72, 1085  
MLH1 gene, 908-909  
Mobetron, 338, 339f  
Mobile units, for intraoperative radiotherapy,  
  338  
  INTRABEAM, 333, 338, 333.e1f  
  Mobetron, 338, 339f  
  NOVAC 7, 332  
Mohs' surgery, for lip cancer, 574  
Moist desquamation, 1324, 1324f  
Molecular biology, 41-50  
  anabolic signaling pathways in, 46-47, 47f  
  basic concepts and techniques of radiation  
  sciences in, 49  
  DNA double-stranded break response in,  
  42-46  
  essential steps in tumor progression in, 41  
  ionizing radiation-induced programmed cell  
  death pathways in, 46  
  normal tissues in, 49, 49f  
  radiation and RNA world in, 47  
  radiation therapy and radiation biology in,  
  41-42  
  replicative senescence in, 46  
  targeting molecular pathways in, 48  
Molecular chaperones, of small cell lung cancer,  
  800  
Molecular prediction, 77-78  
Molecular targeted agents  
  integration of, 793  
  for salivary gland tumors, 710, 710.e1t  
Molecular targeting, for head and neck tumors,  
  567-568  
Molecular tumor progression model, 561  
Molecularly targeted agents, for oropharyngeal  
  cancer, 616  
Monitor unit (MU), 128  
Monoclonal antibody(ies) (Mabs), 176-177,  
  399, 402.e2t-402.e4t  
  imaging, for prostate cancer, 1055  
  for multiple myeloma, 1552  
  for neuroblastoma, 402t, 1452  
Monoclonal gammopathies, 1547  
Monoclonal gammopathy of undetermined  
  significance, 1548-1550  
Monoclonal protein, 1547  
Monotherapy, for oropharyngeal cancer, 612  
Monte Carlo algorithm, 306t  
MOPP therapy, for Hodgkin's lymphoma,  
  1475  
  advanced-stage, 1516-1517  
  early-stage, 1510-1511  
Morbus Dupuytren, 1379-1380  
Morbus Ledderhose, 1379-1380  
Morphea, postirradiation, 1324  
MOSFET detectors, 113, 113f, 129-130  
  remote reporting, 130  
Motion, 301-302  
MPDL3280A, 81t-82t  
MR-PET systems, 187  
MRC. *see* Medical Research Council (MRC)  
MRE11, 45  
MRF. *see* Mesorectal fascia (MRF)  
MSH2 gene, 908-909  
MSI. *see* Microsatellite instability (MSI)  
mTOR inhibitors, 87  
mTOR overexpression, 1207  
Mucinous cyst adenocarcinomas, ovarian,  
  1268  
Mucinous cystic neoplasms, of pancreas, 937  
Mucoepidermoid carcinomas (MECs), 700,  
  1022-1023  
Mucosa-associated lymphoid tissue (MALT)  
  lymphomas, 1527t, 1528, 1536-1537  
  advanced stage, 1537  
  gastric, 1536  
  orbital, 1536  
  of thyroid, 726  
  treatment of, 1504  
Mucositis, oral  
  with oral cavity cancer, 571  
  with oropharyngeal cancer, 624  
  with salivary gland tumors, 712  
  with total body irradiation, 345  
Multidetector CT, 207  
Multidisciplinary care (MDC), and pancreatic  
  cancer, 935  
Multidisciplinary teams, in rectal cancer, 1016.  
  e6  
Multifraction survival curve, 15, 15f  
Multileaf collimator, 98-99, 99f  
  for conformal radiotherapy, 132-133  
  leaf sequencing for, 313, 314f  
  shaping with, 303-304, 303f-304f  
  dynamic, 296, 313  
  segmental, 296, 313  
Multimodality therapy, for pancreatic  
  adenocarcinoma, 164-165  
Multiple detector-row CT (MDCT) scanning, of  
  oropharyngeal cancer, 606.e2  
Multiple endocrine neoplasia (MEN)  
  type 1 (MEN 1), 878  
  type 2A (MEN2A), 562  
  type II, 716

- Multiple-field techniques, for gastric cancer, 923-928
- Multiple myeloma, 1547-1555  
 biologic characteristics of, 1547  
 bone involvement in, 1549, 1549f  
 clinical manifestations of, 1548-1550, 1549f  
 epidemiology of, 1547  
 etiology of, 1547  
 evaluation for, 1548-1550  
 future directions with, 1554  
 imaging in, 1549, 1549f  
 incidence of, 1547  
 and monoclonal gammopathy of undetermined significance, 1548-1550  
 palliation for, 1554  
 pathology and molecular genetics of, 1548, 1548f  
 plasmablastic, 1548  
 primary therapy for, 1547  
 prognostic factors of, 1547  
 radiation therapy for, 1554  
 refractory and relapsing, 1547  
 solitary plasmacytoma and, 1553-1554  
 staging of, 1547, 1550, 1550t  
 stem-cell transplantation for, 1552  
 supportive treatment for, 1553  
 therapy for, 1550-1554, 1550t  
   maintenance, 1552-1553  
   novel, 1551-1552  
   treatment of, 1504
- Multiple sclerosis, MR spectroscopy and, 187-191
- "Multiply-damaged site" hypothesis, 7
- Mutually exclusive, defined, 69
- Myasthenia gravis, 868-869
- MYCN oncogene, amplification of, 1448
- Mycosis fungoides, 1529, 1542, 1556-1576  
 Alibert-Bazin, 1562  
 autologous or allogeneic bone marrow transplant for, 1568  
 biology of, 1557-1558, 1558f  
 clinical manifestations of, 1559-1562, 1561f  
 and cutaneous T-cell lymphoproliferative disorders, 1562-1563  
 diagnostic testing for, 1565  
 with erythroderma  
   clinical manifestations of, 1561, 1561f  
   histopathology of, 1558  
   total skin electron beam therapy for, 1570  
 etiology and epidemiology of, 1557  
 evaluation for, 1564-1565, 1564t  
 folliculotropic, 1562  
 follow up for, 1571  
 granulomatous slack skin as, 1562  
 immunosuppression and infection in, 1575, 1575f  
 incidence of, 1556  
 locally advanced, 1556  
 lymph node involvement in, 1561  
 pagetoid reticulosis (Woringer-Kolopp disease) as, 1562  
 palliation for, 1556, 1570-1575  
 patch phase  
   clinical manifestations of, 1559, 1561f  
   histopathology of, 1558, 1560f  
   total skin electron beam therapy for, 1569-1570, 1569t  
 pathology of, 1558-1559  
   classification of, 1559t  
   histopathology in, 1558, 1560f  
   immunophenotyping of skin lesions in, 1558-1559  
 T-cell receptor gene rearrangement in, 1559  
 transformation to large cell histology in, 1559
- Mycosis fungoides (*Continued*)  
 pathways of spread of, 1558-1559  
 Pautrier's microabscess in, 1558, 1560f  
 physical examination for, 1564  
 plaque phase of  
   clinical manifestations of, 1559, 1561f  
   histopathology of, 1558, 1560f  
   total skin electron beam therapy for, 1569-1570, 1569t  
 premycotic phase of, 1559, 1561f  
 prevention and early detection of, 1557, 1557t  
 primary therapy for, 1556, 1565-1570, 1565t  
 prognosis of, 1563-1564  
 radiotherapy for, 1568-1570  
   dose of, 1568-1569  
   limited superficial, 1569  
   node, viscera and blood, 1572  
   target volumes in, 1571  
   techniques of, 1571-1575  
 Sézary syndrome in, 1561-1562  
   diagnosis of, 1561t  
   Sézary cells in, 1560f  
   skin-directed therapy for, 1566  
   staging of, 1556, 1563-1564, 1563t-1564t  
   systemic therapy for, 1567-1568  
 total skin electron beam therapy for. *see* Total skin electron beam therapy (TSEBT)  
 treatment controversies, problems, challenges, and future possibilities in, 1575-1576  
 tumeur d'emblée in, 1561  
 tumor phase of, 1559-1561, 1560f-1561f  
 variants of, 1562  
 visceral involvement in, 1561
- Myelitis, radiation-induced, in non-small cell lung cancer, 836
- Myelodysplastic syndrome (MDS), after total body irradiation, 349, 349f
- Myeloma  
 multiple. *see* Multiple myeloma  
 plasmablastic, 1548
- Myelopathy  
 after total body irradiation, 349  
 radiation, 532t, 538
- Myelosuppression, 412-413
- Myxofibrosarcoma, 1349-1350
- Myxoid liposarcoma, 1348, 1350f
- N**
- NaF-PET/CT, 213
- Nasal cavity, 675-678, 677f-680f, 675.e1f
- Nasal cavity tumors  
 carcinoma as  
   etiology and epidemiology of, 673-674  
   manifestation, patient evaluation, and staging of, 681, 682t  
   pathology of, 675  
   primary therapy for, 685-686, 685t-686t  
 EBRT for, 689  
 esthesioneuroblastoma as. *see also* Esthesioneuroblastoma  
 ethmoid sinus cancer as, primary therapy for, 686  
 IMRT for, 690, 690t  
 irradiation techniques and tolerance for, 689-692  
   dose fractionation schedule in, 692  
   setup and field arrangement for, 692, 692f, 692.e1f  
   target volume in, 689-690, 690f-691f, 690t, 690.e1f  
 manifestation, patient evaluation, and staging of, 681, 682t  
 primary therapy for, 685-686, 685t-686t
- Nasal cavity tumors (*Continued*)  
 radiotherapy for, adjuvant, 690, 690f, 690t  
 treatment algorithms for, 696, 696t
- Nasal fossa, 675
- Nasal septum, 675, 675.e1f
- Nasal tumors, radiotherapy for, proton beam, 362-363
- Nasal vestibule tumors  
 brachytherapy for, 689, 689f, 689.e1f  
 irradiation for, 688-689  
   external beam, 689, 688.e1f  
   setup, field arrangement, and dose fractionation schedule of, 689  
   target volume, 688-689, 688.e1f  
 manifestation, patient evaluation, and staging of, 681  
 pathology of, 675, 676f-677f, 675.e1f  
 primary therapy for, 683-684, 683t-684t  
 treatment algorithms for, 696, 696t
- Nasopharyngeal Cancer Study Group of Hong Kong, 638
- Nasopharyngeal carcinoma (NPC), 629-648  
 anatomy and pathways of spread of, 631-633, 632f  
 biology of, 629, 633  
 brachytherapy for, 641, 642f  
 combined-modality therapy for, 636-639  
 EBV and, 562, 567, 630, 633  
 etiology and epidemiology of, 629-630  
 evaluation of, 633-636, 634f  
 field modifications and boost techniques for, 641  
 fractionation for, 638  
 incidence of, 629  
 intensity-modulated radiotherapy for, 636, 638-639, 639t, 641-645, 643t, 644f-647f, 645t  
 irradiation for  
   conventional, 641  
   plus chemotherapy, 636-638, 637t  
   techniques of, 640-645  
   treatment fields in, 641, 641f  
 locally recurrent or persistent, 629, 639-640  
 manifestations of, 633-636  
 molecular biology of, 633  
 molecular genetics of, 562  
 pathology of, 631, 631t  
 prevention and early detection of, 630  
 primary therapy for, 629, 636-639  
 prognostic markers for, 567  
 radiotherapy for  
   complications of, 645t  
   dose for, 643-644, 645b  
   single-modality therapy for, 636  
   staging of, 629, 633-636, 635t  
   treatment algorithm and future possibilities for, 645-646, 647f
- Nasopharyngeal fibroma, juvenile, 1376
- Nasopharyngeal tumors, radiotherapy for, proton beam, 362-363
- Nasopharynx, 631, 632f
- National Cancer Institute (NCI), 896-897
- National Comprehensive Cancer Network (NCCN), 1016.e1
- Nausea and vomiting, with total body irradiation, 345, 345.e1t
- NCCN. *see* National Comprehensive Cancer Network (NCCN)
- NCCTG. *see* North Central Cancer Treatment Group (NCCTG)
- Neck  
 control of, 751-756, 755f  
 imaging of, 741-742, 742f-744f  
 lymphatic system of, 738-741, 739f, 740t  
 target volumes in, 747-749, 748t

- Neck dissection, postradiation, for oropharyngeal cancer, 614
- Neck irradiation, complications of, 760
- Neck management, 738-762
- irradiation techniques for, 751
  - late complications after, 759-760
  - for oropharyngeal cancer, 613-614
    - adjuvant radiation or chemoradiation, 613-614
  - for recurrent disease, 760-761
  - for salivary gland tumors, 706
  - for stage N0 disease
    - after neck node dissection, 754-755, 755*t*
    - after radiotherapy, 755-756, 756*t*
  - for stage N1 to N3 disease, 756-759
    - after primary radiotherapy, 757-758, 757*t*-758*t*
    - after surgery alone, 756-757, 756*f*
    - postoperative irradiation and chemoradiation in, 758, 758*t*-759*t*
    - postradiotherapy neck node dissection in, 759
- Neck node delineation, 751
- of clinical target volume, 751, 752*t*-753*t*, 754*f*
  - levels in, 751, 752*t*-753*t*
- Neck node dissection, 749-751
- complications of, 759-760
  - definitions and terminology for, 749, 749*t*
  - neck control after
    - for stage N0 disease, 754-755, 755*t*
    - for stage N1 to N3 disease, 756-757, 756*f*
  - postradiotherapy, indications for, 758-759
  - radical, 749, 749*t*, 750*f*
    - extended, 749*t*, 750
    - modified, 749, 749*t*, 750*f*
  - neck control after, 756-757, 756*f*
  - selective, 749-750, 749*t*, 750*f*
  - neck control after, 754-755, 755*t*
- Neck node metastases
- clinical and radiologic assessment of, 743-745, 745*t*
  - in contralateral neck, 747
  - incidence and distribution of, 743-747
  - pathologic, 745-747, 746*t*
  - for skip metastases, 747
  - staging of, 742-743, 745*t*
- Neck tumors. *see* Head and neck tumors
- Necrosis, 11
- with chemoradiation, 67
- Negatron, 137-138
- Negatron decay, 137, 137*f*
- Nelson's syndrome, 516
- Neoadjuvant androgen deprivation (NAAD), 1069
- Neoadjuvant chemotherapy, 175
- Neon ion radiotherapy, 370
- Neoneurogenesis, and salivary gland tumors, 701
- Neoplastic transformation, 32
- Nephrectomy, for renal cell carcinoma
- partial, 1145
  - radical, 1143-1145, 1145*t*
    - laparoscopic, 1145
- Nephroblastoma, 1422
- Nephrogenic rests, 1424
- Nephrogenic systemic fibrosis (NSF), 186-187
- Nephroma, mesoblastic, 1424, 1424*t*
- Nephropathy, contrast media-induced, 186
- Nephroureterectomy, laparoscopic, 1147
- Nervous system toxicity, 348-349
- Neural cell adhesion molecule (NCAM), 1547-1548
- Neuroblastoma, 1447-1454
- biology of, 1447
  - bone metastases of, 1452
  - classification of, 1447, 1448*t*, 1450*t*
- Neuroblastoma (*Continued*)
- clinical manifestations of, 1449
  - clinical trials for, 1452
  - etiology and epidemiology of, 1447
  - evaluation of, 1449
  - high-risk, 1451-1452
  - intermediate-risk, 1450-1451, 1450*t*
  - irradiation techniques for, 1452-1453, 1452*f*
  - late effects of therapy for, 1453
  - low-risk, 1450, 1450*t*
  - MIBG therapy for, 1452
  - palliation for, 1452
  - pathology of, 1448-1449
  - pathways of spread of, 1448-1449
  - prevention and early detection of, 1447-1448
  - primary therapy for, 1449-1452
  - radioimmunotherapy for, 402*t*
  - recurrent, 1452
  - risk stratification of, 1448, 1450*t*
  - staging of, 1447, 1449, 1449*t*-1450*t*
  - therapy for, 1447
  - treatment algorithm for, 1449-1450, 1451*f*
  - very-low-risk, 1450
- Neurocognitive impairment, 348-349
- Neurocytoma(s), 460-461, 537
- Neuroendocrine carcinoma, of larynx and hypopharynx, 661
- Neuroendocrine malignancies
- metaiodobenzylguanidine therapy in, 214-215
  - octreotide derivatives in, 214
- Neuroendocrine markers, in small cell lung cancer, 800
- Neuroendocrine sequelae, of acute lymphoblastic leukemia, 1460
- Neuroendocrine tumors, 866
- imaging of, 213-214
  - of pancreas, treatment of, 947*e1t*
- Neuroepithelial tumors, dysembryoplastic, 461
- Neurofibromatosis, soft-tissue sarcoma and, 1346
- Neurofibromatosis 2, vestibular schwannoma with, 497-498
- Neutrino, 93, 94*t*
- Neutron(s)
- in atomic structure, 93, 94*f*
  - charged particle interactions of, 108
  - physical characteristics of, 94*t*
- Neutron activation, 108
- Neutron number, 94
- Neutron production, 368
- Neutron radiotherapy, 373-380
- boron. *see* Boron neutron capture therapy (BNCT)
  - californium 252 brachytherapy as, 379
  - fast. *see* Fast neutron radiotherapy
  - for salivary gland tumors, 708
- Next-generation sequencing, 78
- NF-κB. *see* Nuclear factor kappa B (NF-κB)
- NF2 gene, 484
- Nibrin (NBN), 45
- Nicotinamide, 56, 57*f*
- Nilotinib (Tasigna), 81*t*-82*t*
- Nilutamide, for prostate cancer, 1085
- Nimorazole, 54, 54*t*, 55*f*
- Nitrogen mustard, 70, 171, 1566
- Nitroheterocyclics, 26
- Nitroimidazole, 24
- multicenter randomized trials for, 54*t*
- 2-Nitroimidazole, 25*f*, 25*t*
- Nitrosoureas, 71
- NK/T cell lymphoma, of nasal type, 1526, 1526*b*, 1529, 1530*f*, 1541, 1541*f*
- Nodal irradiation, for breast cancer stages I-II, 1318-1319
- axillary, 1318, 1321-1322, 1321*f*-1322*f*
  - doses, 1323
  - internal mammary, 1318-1319, 1322, 1318*e1t*, 1322*e1f*
  - supraclavicular, 1318, 1321-1322, 1321*f*-1322*f*
- Nodal metastasis, 604
- prediction of, 164
- Node-negative require pelvic irradiation, 1000
- Nodular lymphocyte predominant Hodgkin's disease, treatment for, 1503
- Nodular lymphocyte predominant Hodgkin's lymphoma (nLPHL), 1508, 1519-1520
- pediatric, 1466, 1482-1483
- Nodular sclerosing Hodgkin lymphoma, 1466
- Nomenclature Committee on Cell Death (NCCD), 67
- Nonchromaffin paragangliomas, 1375
- Nonclonogenic assays, in vivo, 13-14
- Nondysgerminoma, ovarian, 1279-1280
- Nongerm cell testicular tumors, 1133-1134
- Non-germinomatous germ cell tumors (NGGCT), 1398
- Non-Hodgkin's lymphoma (NHL), 1524-1546
- assessment of response with, 1541
  - B-cell, with *c-MYC* and *BCL-2*, 1528
  - BCL-2* and, 1527, 1527*t*
  - biologic characteristics of, 1524, 1526-1529
  - bone, 1540
  - breast, 1540
  - chemotherapy for, principles of, 1533, 1534*t*
  - classification of, 1526, 1526*b*
  - clinical manifestations of, 1529-1530
  - cutaneous, 1541-1542, 1542*f*
  - diffuse large B-cell
    - advanced, 1538
    - cutaneous, 1542
    - localized, 1537-1538, 1538*f*
    - relapsed and refractory, 1538-1540
    - RT management of, 1545
    - testicular, 1540
  - etiology and epidemiology of, 1524-1525, 1525*t*
  - evaluation for, 1530-1531, 1530*f*, 1531*b*
  - extradural, 1530
  - extranodal, 1530
  - follicular, 1527
    - advanced, 1535-1536
    - localized, 1534-1535, 1535*f*, 1535*t*
    - RT management of, 1545
  - follow-up for, 1541
  - gastric, 1544-1545
  - history and physical examination for, 1531
  - imaging studies for, 1531
  - laboratory tests for, 1531
  - large cell, anaplastic, 1526, 1527*f*, 1529, 1540
  - MALT, 1536-1537
    - advanced stage, 1537
    - gastric, 1536
    - orbital, 1536
    - treatment of, 1504
  - mantle cell, 1526, 1528
    - advanced, 1537
    - localized, 1537
    - relapsed and refractory, 1537
  - NK/T cell, 1526, 1526*b*, 1529, 1530*f*, 1541, 1541*f*
  - orbital, 1543, 1543*f*-1544*f*
  - palliation for, 1524, 1542-1543
  - pathologic diagnosis of, 1531
  - pathology of, 1526-1529
  - pediatric, 1461-1462, 1461*t*
    - biology of, 1455
    - Burkitt's, 1461, 1461*t*
    - classification of, 1455

- Non-Hodgkin's lymphoma (NHL) (*Continued*)
- cranial irradiation for, 1462
  - epidemiology of, 1455
  - large cell, 1462
  - late sequelae of, 1455
  - lymphoblastic, 1462
  - radiation therapy for, indications of, 1455
  - relapse and palliation for, 1455
  - staging of, 1455, 1461, 1461*t*
  - therapy for, 1455
  - urgent radiotherapy for, 1462
  - phenotypic characteristics of, 1527*t*
  - prevention and early detection of, 1525-1526
  - primary therapy for, 1524
  - principles of management of, 1532-1534, 1533*f*
  - prognostic factors in, 1532, 1532*t*
  - radiation therapy for
    - to abdominal structures, 1544-1545
    - changing practice in, 1545
    - effects on reproductive system, 1545
    - for palliation, 1542-1543
    - pelvic, 1545
    - principles of, 1533
    - technical aspects of, 1543-1545
    - to thoracic structures, 1544, 1544*f*
  - radioimmunotherapy for, 411
  - salivary gland, 1544
  - salvage therapy for, 1524
  - small lymphocytic, 1534
  - staging of, 1524, 1531-1532
  - surgery for, 1533-1534
  - T-cell, 1540
  - thyroid, 1544
  - treatment of, 1503-1504
  - Waldeyer's ring, 1544
- Nonhomologous end joining (NHEJ), 9, 44, 45*f*
- Noninvasive breast brachytherapy (NIBB), 285
- Noninvolved normal tissue, 320
- Nonionizing radiation, 96*t*
- Nonmutually exclusive, defined, 69
- Nonreceptor tyrosine kinases (NRTKs), 46, 47*f*
- Nonrhabdomyosarcoma soft-tissue sarcoma (NR-STS)
- biologic characteristics and pathology of, 1404, 1404*t*
  - clinical manifestations of, 1404-1405, 1404*f*
  - evaluation and risk classification for, 1406
  - interstitial brachytherapy for, 1410
  - primary therapy for, 1407, 1407*f*-1408*f*
  - radiation therapy for
    - indications and outcomes of, 1409
    - techniques of, 1409-1410, 1410*t*
    - timing of, 1411
  - staging of, 1405*t*, 1406
- Non-seminoma, 1121, 1124
- chemotherapy with or without retroperitoneal node dissection, 1132
  - primary therapy for, 1131-1132
  - residual retroperitoneal mass and, 1132
  - stage I
    - management of, 1132
    - surveillance in, 1132*e1t*
  - stage II, management of, 1132
  - stage III, management of, 1132
  - treatment algorithm for, 1137-1138, 1137*f*
- Non-small cell lung cancer (NSCLC), 788, 809-842
- adjuvant therapy for, 809
  - biologic characteristics of, 809
  - biology of, 789
  - chemoradiation for, 828*t*
  - chemotherapy for
    - adjuvant, 825*t*
    - combining radiation therapy and, 828-829
    - postoperative, 824-826, 825*t*
- Non-small cell lung cancer (NSCLC) (*Continued*)
- classification of, International Staging System, 818*t*
  - clinical manifestations of, 816-819
  - controversies in, 840-841
  - cytologic and molecular screening in, 813
  - early detection and prevention of, 812-813
  - early-stage disease, 819-826
    - adjuvant therapy for, 822, 822*t*
    - definitive radiation therapy for, 819-821, 821*t*
    - postoperative chemotherapy for, 824-826, 825*t*
    - postoperative radiation therapy for, 822-824, 823*f*
    - stereotactic body radiation therapy for, 820*t*, 821-822
  - epidemiology of
    - etiology and, 810-811
    - pathology and, 809
  - evaluation of
    - for extrathoracic metastases, 817
    - local control, 831
    - patient, 816-819
    - pulmonary function, 819*t*
  - fractionation for, 829-830
    - accelerated, 830-831
    - hyper-, 830
    - local control with, 831
    - physical considerations in, 831
  - growth factors of, 811-812
  - imaging of, 192-193
  - locally advanced, 809
  - lymph node metastases of, 816
  - molecular biology of, 811-812
  - molecular targeted agents of, 829-831
    - EGFR inhibitors, 829
  - neoadjuvant therapy for, 809, 826*t*
  - normal tissue toxicity considerations with, 791
  - with oligometastatic disease, 838
  - palliation for, 809, 836-840, 837*t*
    - chemotherapy, 836-838
    - with oligometastatic disease, 838
  - pathology and pathways of spread of, 813-815, 815*f*
  - PET of, 210, 210*f*
  - potentially resectable disease, 826-827
    - preoperative treatment, 826-827, 826*t*
  - primary therapy for, 819-828
    - for early-stage disease, 809
  - prognostic and predictive factors for, 814*t*
  - prophylactic cranial irradiation for, 824, 824*t*
  - radiation dose for, 829-830
  - radiation therapy for
    - beam energy in, 835
    - choice of beam direction in, 835
    - definitive, 819-821, 821*t*
    - dose escalation, 829-830
    - individualized, 834-835
    - integration of molecular targeted agents with, 829-831
    - palliative, 838-840, 838*t*, 840*t*
    - proton beam, 364, 835
    - radical, 821*t*
    - stereotactic, 821-822
    - surgical resection, 819
    - target volumes, 831-834
    - technique, 831-835
    - toxicity and, 835-836, 835*t*
  - rates and patterns of relapse after resection of, 822*t*
  - research funding for, 841*t*
  - staging of, 809, 816-819
- Non-small cell lung cancer (NSCLC) (*Continued*)
- mediastinum, 816-817
  - radiographic procedures in, 816
  - tumor-node-metastasis stage grouping, 817-819, 818*t*
  - and workup, 789
  - stereotactic body radiation therapy for, 821-822
  - stereotactic radioablation of, 820*t*
  - surgical resection in, 819
    - of cardiopulmonary evaluation, 819, 819*t*
  - treatment considerations for, 792-793
  - unresectable stages IIIA and IIIB disease, 826*t*, 827-828
- Non-small cell lung carcinoma, 75-76, 76*t*
- Nonsteroidal anti androgens, for prostate cancer, 1077
- Non-tobacco-associated lung cancer (NTLC), and non-small cell lung cancer, 810
- Normal tissue control probability (NTCP), 309
- Normal tissues
- $\alpha/\beta$  ratios for, 37*t*
  - in conformal radiotherapy, 300-301
  - damage of, from hyperthermia, 384, 391
  - growth kinetics of, 27-30, 28*t*
  - protection, in chemoradiation, 65, 65*t*
  - radioprotectors, 26-27
  - radiotherapy and, 49, 49*f*
  - tolerance, with nasopharyngeal carcinoma, 644-645
- North Central Cancer Treatment Group (NCCTG), 802, 830
- NOVAC 7 mobile linear accelerator, 332
- NSD model, 35
- NTCP modeling, 261
- Nuclear factor kappa B (NF- $\kappa$ B)
- in Hodgkin's lymphoma, 1507
  - hyperthermia and, 386
  - ionizing radiation and, 49, 49*f*
- Nuclear medicine, 206-216
- antibody-based imaging agents in, 213
  - cellular imaging in, 213
  - imaging
    - bone scans as, 1054-1055
    - monoclonal antibody imaging as, 1055
    - positron emission tomography imaging as, 1055
  - positron emission tomography, 206, 207*f*
  - targeted imaging in, 212
  - targeted radionuclide therapy, 214-215
  - other, 215
  - therapy-enhancing strategies in, 215
- Nuclear Regulatory Commission (NRC), 145-146
- Nucleons, 93
- Nucleoside analogs, 176
- Nucleotide excision repair, 9, 44
- Nuclides, 94-95, 94*t*, 95*f*
- Nutritional deficiencies, in oropharyngeal cancer, 600*e1*
- Nutritional support, with gastric cancer, 929-930
- O**
- Obesity
- and prostate cancer, 1040
  - and renal cell carcinoma, 1140
- Obinutuzumab (Gazyva), 81*t*-82*t*
- Obsessive-compulsive disorder, 422
- Obstructing rectal cancers, 994
- Occipital nodes, 740*t*
- Octreotide derivatives, in neuroendocrine malignancies, 214



- Ocular lymphoma  
 pathology of, 544  
 primary and adjuvant therapy for, 550  
 pseudo-, 543
- Ocular melanoma  
 algorithm for treatment of, 549f  
 biology of, 543, 543.e1f, 543.e1t  
 clinical manifestations of, 545-548  
 enucleation for, 549  
 evaluation of, 545-548, 546f-547f, 547t  
 local resection for, 549  
 locally advanced, 553  
 observation for, 549  
 pathology of, 544, 544.e1f  
 photocoagulation for, 549  
 primary and adjuvant therapy for, 549-550  
 radiotherapy for, 550, 550t, 550.e1f  
   charged particle, 550  
   proton beam, 359  
 transpupillary thermotherapy for, 549
- Ocular metastasis  
 presentation of, 548, 548.e1f  
 primary and adjuvant therapy for, 550
- Ocular tumors, 541-560  
 adjuvant therapy for, 541, 549-553  
 biology of, 541, 543-544  
 clinical manifestations of, 545-549  
 etiology and epidemiology of, 541-543  
 evaluation of, 545-549, 545f  
 IMRT for, 555, 558f-559f  
 irradiation techniques for, 553-558  
   for anterior lesions, 555, 556f  
   for bilateral lesions, 555  
   plaque irradiation as, 553-554, 554f, 554.e1f-554.e2f  
   for skin lesions, 554  
   tolerance issues with, 555-558  
   for unilateral lesions, 554-555, 555f-557f  
 locally advanced, 541, 553  
 palliation of, 541, 553  
 pathology and pathways of spread of, 544-545  
 patient evaluation for, 545-549, 545f  
 prevention and early detection of, 543  
 primary therapy for, 541, 549-553  
 staging of, 541, 545-549
- Odynophagia, acute, 860
- Ofatumumab (Arzerra), 81t-82t
- Off-axis profiles, 154, 155f
- Ohngren's line, 678-679
- Olaparib, 88
- Olfactory bulbs, 677f
- Olfactory neuroblastoma. *see* Esthesioneuroblastoma
- Olfactory region, 675
- Oligoastrocytic tumors, 453t
- Oligoastrocytomas, 453t  
 anaplastic, 475  
 imaging of, 457f  
 mixed, 453, 457f  
 observation for, 457f  
 prognostic and predictive molecular factors for, 454  
 recurrent, 462f
- Oligodendroglial tumors, 453t
- Oligodendrogliomas, 453t  
 anaplastic, 475  
 chemotherapy for, 459f  
 observation for, 457f  
 prognostic and predictive molecular factors for, 454  
 radiation toxicities with, 465f
- Oligometastases, for stereotactic body radiation therapy for, 430-431
- Oligometastatic disease, non-small cell lung cancer and, 838
- Oliparib, 175
- Oncocytic carcinoma, 719-720
- Oncogene addiction, 171
- Oncogenes, 561, 799
- Oncotype DX assay, for breast cancer, 1294
- One-stage design, 241-242, 242t
- Ophthalmologic toxicity, after radiation, 260
- Opioids, 435
- Optic chiasm, late effects of radiation on, 256t-257t, 260  
 dose-volume data on, 260  
 organ function and clinical significance and, 260  
 QUANTEC Review on, 260
- Optic nerve(s)  
 late effects of radiation on, 256t-257t, 260  
 dose-volume data on, 260  
 organ function and clinical significance and, 260  
 QUANTEC Review on, 260  
 radiation injury of, 558
- Optic nerve glioma  
 etiology and epidemiology of, 542  
 IMRT for, 555  
 pathology of, 545
- Optic nerve sheath meningioma  
 etiology and epidemiology of, 542  
 evaluation of, 548  
 IMRT for, 555, 559f  
 pathology of, 544-545  
 presentation of, 548, 548.e1f  
 primary and adjuvant therapy for, 550-551  
 therapy for, 486
- Optic nerve tumors, 541-560  
 adjuvant therapy for, 541, 549-553  
 biology of, 541, 543-544  
 clinical manifestations of, 545-549  
 etiology and epidemiology of, 541-543  
 IMRT for, 555, 558f-559f  
 irradiation techniques for, 553-558  
   for anterior lesions, 555, 556f  
   for bilateral lesions, 555  
   plaque irradiation as, 553-554, 554f, 554.e1f-554.e2f  
   for skin lesions, 554  
   tolerance issues with, 555-558  
   for unilateral lesions, 554-555, 555f-557f  
 locally advanced, 541, 553  
 palliation of, 541, 553  
 pathology and pathways of spread of, 544-545  
 patient evaluation for, 545-549, 545f  
 prevention and early detection of, 543  
 primary therapy for, 541, 549-553  
 staging of, 541, 545-549
- Optic neuropathy, and nasopharyngeal carcinoma, 645
- Optic pathway glioma  
 evaluation of, 548, 548.e1f  
 pathology of, 545  
 primary and adjuvant therapy for, 551  
 proton beam radiotherapy for, 361
- Optically stimulated luminescent dosimeters (OSLD), for external beam treatment verification, 129
- Oral care, 571
- Oral cavity, 570-596
- Oral cavity cancer  
 biologic characteristics of, 570  
 of buccal mucosa. *see* Buccal mucosa cancer  
 distribution of, 571t  
 etiology and epidemiology of, 570-571  
 and locally advanced disease, 570  
 molecular biology of, 571  
 oral care for, 571  
 palliation for, 570
- Oral cavity cancer (*Continued*)  
 prevention and early detection of, 571  
 staging evaluation of, 570  
 therapy for  
   primary, 570  
   radiotherapy alone as, 570
- Oral cavity implants, at base-of-tongue, 288-289
- Oral cavity shields, 774, 774f
- Oral cavity squamous cell carcinomas  
 metastatic neck nodes from, 745t  
 target volumes in neck for, 747, 748t
- Oral hygiene, in oropharyngeal cancer, 600.e1
- Oral mucositis  
 acute, with salivary gland tumors, 712  
 with oral cavity cancer, 571  
 with total body irradiation, 345
- Oral tongue cancers, 581-585  
 advanced, 582-583, 585  
 early, 582, 584-585, 584f  
 evaluation of, 581-582  
 manifestations of, 581-582  
 moderately advanced, 582, 585  
 pathology of, 581, 582f  
 staging of, 581-582  
 techniques of irradiation for, 584-585  
 treatment of, 582-583, 582f  
   complications of, 585, 585t  
   results of, 583-584, 583t-584t
- Oral toxicity, 345-346
- Orbicularis oris muscle, 571
- Orbit, 678f  
 benign disorders of, 1376-1378
- Orbital lymphoma, 1377, 1543, 1543f-1544f  
 biology of, 543-544  
 etiology and epidemiology of, 542  
 evaluation of, 548  
 locally advanced, 553  
 palliation for, 553  
 pathology of, 544  
 presentation of, 548, 548.e1f  
 staging of, 548
- Orbital meningioma, 544-545
- Orbital metastases, 542
- Orbital pseudolymphoma, 543
- Orbital pseudotumor  
 biology of, 544  
 defined, 542  
 etiology and epidemiology of, 542-543  
 evaluation of, 549  
 pathology of, 545  
 presentation of, 549  
 primary and adjuvant therapy for, 551
- Orbital retinoblastoma, 1438
- Orbital tumors, 541-560  
 adjuvant therapy for, 541, 549-553  
 biology of, 541, 543-544  
 clinical manifestations of, 545-549  
 etiology and epidemiology of, 541-543  
 IMRT for, 555, 558f-559f  
 irradiation techniques for, 553-558  
   for anterior lesions, 555, 556f  
   for bilateral lesions, 555  
   plaque irradiation as, 553-554, 554f, 554.e1f-554.e2f  
   for skin lesions, 554  
   tolerance issues with, 555-558  
   for unilateral lesions, 554-555, 555f-557f  
 locally advanced, 541, 553  
 palliation of, 541, 553  
 pathology and pathways of spread of, 544-545  
 patient evaluation in, 545-549, 545f  
 prevention and early detection of, 543  
 primary therapy for, 541, 549-553  
 staging of, 541, 545-549

- Orbitopathy, endocrine, 1376  
 Orchiectomy, radical inguinal, 1128  
 Organ at risk (OAR), 126  
 Organ shielding, 355  
 "Organ-sparing" approach, for oropharyngeal cancer, 597  
 Organic nitroxides, 25f, 25t, 26, 57, 57f  
 Oropharyngeal cancer, 597-628  
   biologic characteristics of, 597, 600-601  
   brachytherapy for, 623-624  
   epidemiology of, 598-600  
   etiology of, 598-600  
     HPV in, 599-600, 599t  
   evaluation for, 604-605, 605f, 605t, 605.e1f  
   fractionation for, 616-618, 617t  
     accelerated  
       with dose reduction, 617, 617t-618t  
       without dose reduction, 617, 617t-618t  
     hyper, 616, 617t-618t  
     schedules for, 618t  
   HPV in, 563  
   imaging studies of, 605-606  
     selection of, 605-606  
     technique of, 606  
   incidence of, 597  
   irradiation techniques for, 616-626  
   locally advanced, 597-598, 611-616  
     biologic therapy for, 613  
     chemotherapy for, 611-613  
     neck management in, 613-614  
   manifestations of, 604-607  
   metastatic  
     cytotoxic chemotherapy for, 615-616  
     imaging of, 606  
     molecularly targeted agents for, 616  
   molecular biology of, 600-601  
   nodal involvement in, 604, 604.e1f  
   imaging of, 606  
   of oropharyngeal wall  
     pathways of spread of, 603-604  
     therapy for, 611  
   pathologic findings of, 601, 601.e1f  
   pathways of spread of, 601-604, 601f-602f  
   prevention and early detection of, 600  
   primary therapy for, general principles of, 607  
   quality of life with, 626  
   radiation treatment planning for, 618-623  
     with conventional radiation, 619-620, 619f  
     with intensity-modulated radiation therapy, 620-623, 622f, 622t-623t  
     with unilateral radiation, 620, 621f  
   recurrent  
     cytotoxic chemotherapy for, 615-616  
     locoregional, 614-615  
     molecularly targeted agents for, 616  
     reirradiation for, 615  
     salvage surgery for, 614-615  
   risk factors of, 600.e1  
   of soft palate  
     pathways of spread of, 601-602, 602f  
     therapy for, 611  
   staging of, 597, 604-607, 606t  
   surgery for, 607-608, 608t  
   therapy for, 597, 607-611  
   of tongue base, 604, 604f, 610-611, 610.e1t  
   of tonsillar region  
     pathways of spread of, 602-603, 603f  
     therapy for, 608-610, 609t, 609.e1t  
   treatment algorithm, challenges, and future possibilities in, 626-627, 627f  
   treatment-related side effects for, 624-626, 624.e1f  
     acute toxicities of, 624, 624.e1f  
     late toxicities of, 624-626  
   Oropharyngeal squamous cell carcinoma  
     nodal display in, imaging of, 742f-743f  
     target volumes in neck for, 747-748, 748t  
   Oropharyngeal wall, oropharyngeal cancer of, 603-604, 611  
   Oropharynx, 597, 598f  
     malignant tumors of, 597  
     normal CT of, 601f  
     normal MRI of, 602f  
   Orteronel, for prostate cancer, 1085  
   Ossification, heterotopic, 1381-1383, 1382f  
   Osteoradionecrosis, 625  
   Osteosarcoma, 1412  
     adjuvant therapy for, 1412  
     advanced, 1412, 1420  
     biologic characteristics of, 1412  
     clinical manifestations of, 1413-1414  
     etiology and epidemiology of, 1412  
     evaluation of, 1413-1414  
     incidence of, 1412  
     local therapy for, 1419-1420  
     palliation for, 1412, 1420  
     pathology of, 1413  
     pathway of spread of, 1413, 1413f  
     prevention and early detection of, 1412  
     primary therapy for, 1412, 1419  
     staging of, 1412-1414, 1414t  
     treatment of, 1419-1420  
     treatment planning techniques for, 1420  
   Outcomes  
     defined, 228  
     relating structure and process to, 233-236  
     studies of, 231-233, 232f-233f  
       interregional variations, 233, 234f, 234t  
       population-based, 232f, 235, 235b  
       socioeconomic status and, 233, 233f  
   Outcomes research  
     legitimate roles of, 234-236  
     limitations of, 233-234  
     when randomized trial not feasible, 234-235  
       evaluating adoption and generalizability of clinical trial results, 235-236, 235b  
   Ovarian cancer, 1172, 1264-1283  
     adjuvant therapy for, 1264  
     advanced-stage, 1272-1276, 1273f-1274f  
       chemotherapy for, 1275-1276  
       consolidative intraperitoneal radioactive chromic phosphate suspension (<sup>32</sup>P) for, 1277, 1277t  
       radiation therapy for, 1276-1277  
     biologic characteristics of, 1264, 1266-1267  
     biologic factors of, 1267  
     CA 125 in, 1266, 1268-1269  
     challenges and future possibilities in, 1282-1283  
     clear cell, 1268  
     clinical manifestations of, 1268  
     clinicopathologic factors of, 1267  
     early-stage  
       chemotherapy for, 1270  
       external beam irradiation for, 1271-1272, 1271t  
       fertility-sparing therapy for, 1270  
       intraperitoneal radioactive chromic phosphate suspension (<sup>32</sup>P) for, 1270-1271  
       radiation therapy for, 1270-1272  
       surgery for, 1270  
     endometrioid, 1268  
     environmental risk factors of, 1265  
     epidemiology of, 1265, 1265f  
     epithelial, 1269-1272  
       advanced-stage, 1272-1276, 1273f-1274f  
       early-stage, 1270  
   Ovarian cancer (*Continued*)  
     etiology of, 1265-1266  
     evaluation and diagnosis of, 1268-1269  
     external beam irradiation for  
       early-stage, 1271-1272, 1271t  
       technique for, 1281-1282, 1281f  
     genetic factors of, 1266  
     histologic classification of, 1267-1268  
     hormonal factors of, 1265-1266  
     incidence of, 1264, 1265f  
     intraoperative irradiation for, 1278-1279  
     intraperitoneal chemotherapy for, 1275  
     intraperitoneal radioactive chromic phosphate suspension (<sup>32</sup>P) for  
       advanced-stage, 1277, 1277t  
       early-stage, 1270-1271  
     irradiation techniques for, 1281-1282, 1281f  
     micropapillary, 1268  
     molecular targeting agents for, 1276-1277  
     mucinous cyst adenocarcinomas as, 1268  
     nonepithelial, 1279-1281  
       germ cell, 1279-1280, 1279.e1t  
       sex cord and stroma, 1280-1281  
     palliation of, 1264-1265  
     pathogenesis of, 1267  
     pathways of spread of, 1267  
     prevention and early detection of, 1264, 1266  
     primary therapy for, 1264  
     prognostic factors for, 1266-1267  
     radiation therapy for, 1264  
     radioimmunotherapy of  
       with chemotherapy, 406, 405.e2t-405.e4t  
       intraperitoneal delivery of, 408, 408.e4t  
       monoclonal antibodies for, 402.e2t-402.e4t, 402.e6t  
     recurrent, 1277-1279  
       intraoperative irradiation for, 1278-1279  
       palliative radiation therapy for, 1279  
       secondary cytoreductive surgery for, 1278  
     screening for, 1266  
     serous, 1267-1268  
     staging of, 1264, 1269, 1269t  
     surgery for  
       early-stage, 1270  
       fertility-sparing therapy, 1270  
       relapse, 1278  
     transitional cell, 1268  
     treatment algorithm for, 1282, 1282f  
   Ovarian germ cell tumors, 1279-1280, 1279.e1t  
   Ovarian sex cord tumors, 1280-1281  
   Ovarian stromal tumors, 1280-1281  
   Ovarian transposition, MOPP chemotherapy and, 1475  
   Ovarian tumors, primary, 203, 203f  
   Overkill effect, 20  
   Oxaliplatin, 71  
     for colon cancer, 983  
     for esophageal cancer, 855  
     regimens, concurrent, 1003-1004  
   Oxaliplatin-based preoperative chemoradiation, 1003.e1t  
   Oxazaphosphorines, 70-71  
   Oxygen effect, 20-24, 21f  
     mechanistic aspects of, 21-22, 22f  
     reoxygenation in tumors and, 22-23  
     tumor hypoxia and, 21, 23  
     measurement of, 23-24, 23f  
   Oxygen electrodes, 23-24, 23f  
   Oxygen enhancement ratio (OER), 21, 22f  
     linear energy transfer and, 19-20

- Oxygen k-curve, 22, 22f  
 Oxygen partial pressure (pO<sub>2</sub>), distribution of, tumor hypoxia and, 52, 53f  
 Oxy-hemoglobin dissociation curve, 56
- P**
- p16 gene, 846  
 p53 gene. *see* TP53 gene  
 Paclitaxel, 67, 71, 176, 181t, 901  
   for endometrial cancer, 1220.e1, 1218.e1  
   for ovarian cancer, 1275  
   radioimmunotherapy with, 406  
 Pagetoid reticulosis, 1562  
 Paget's disease, 1305-1306  
   breast-conservation therapy for, 1305, 1305t  
   differential diagnosis of, 1305  
   presentation of, 1305  
   treatment algorithm for, 1306, 1306f  
   of vulva, 1253.e3, 1253.e3f  
 Pain, sciatic, 994  
 Pair production, 105, 105f  
 Paired survival curve technique, 21  
 Palatine (faucial) tonsils, 602  
 Palatoglossus muscle, 601-602  
 Palatopharyngeal muscle, 601-602  
 Palbociclib, 81t-82t  
 Palladium-103 (<sup>103</sup>Pd), in brachytherapy, 281, 281t  
 Pamidronate, 434  
   for multiple myeloma, 1553  
 Pancoast tumors, 192-193  
 Pancreas, 937, 938f  
 Pancreatic adenocarcinoma, 934  
   multimodality therapy for, 164-165  
   proton beam radiotherapy for, 364  
 Pancreatic cancer, 934-959  
   adjuvant therapy for, 934, 943-946  
   present status of, 946  
   biologic characteristics of, 934-936  
   borderline resectable, 947-948  
   comparison of radiographic definitions of, 947.e1t  
   chemoradiation for, 948-950  
   adjuvant, 943-944  
   alternate radiation and approaches, 950-951  
   gemcitabine-based, 945  
   interferon-based, 944-945  
   newer regimens for, 944-946  
   nonrandomized studies, 944t  
   randomized studies, 944t  
   using IMRT or SBRT, 945-946  
   chemotherapy for, 948-952  
   adjuvant, 946  
   outcomes in, 944t  
   alternate regimens, 950  
   novel combination, 946  
   palliative, 952  
   clinical manifestations of, 939-941  
   epidemiology of, 935  
   etiology of, 935  
   evaluation of, 939-941, 940f  
   familial, 935  
   genetic mutations in, 936.e1t  
   incidence and epidemiology of, 934  
   intraoperative radiotherapy for, 326, 330-332, 331t-332t, 955  
   IOERT plus EBRT or CRT, 951  
   irradiation for  
     intraoperative, 951  
     techniques and tolerance, 953-955  
   locally advanced, 947-953, 947.e1t  
   locally unresectable, stereotactic body radiation therapy in, 956t  
   metastatic, 934, 951-953  
   Pancreatic cancer (*Continued*)  
     molecular biology of, 935-936, 936.e1t  
     molecular mechanisms of, 934  
     motion management of, 953-954  
     neoadjuvant therapy for, 946-947, 947.e1t  
       in borderline resectable, 948t  
       CRT plus IOERT, 951  
       in locally unresectable disease, 951  
     palliation of, 934, 947-953  
       symptom, 952  
     pathology of, 937  
     pathways of spread of, 937-939, 938f  
     patient evaluation in, 939-940  
     prevention and early detection of, 935  
     primary therapy for, 934, 941-947  
       surgery of, 941-943  
     radiation delivery in, 954-955  
     radiation therapy for  
       intensity-modulated, 950-951, 954  
       palliative, 952  
       proton beam, 955  
       stereotactic body, 950-951  
       toxicity and dose constraints to normal tissues, 955, 957t  
     staging of, 939-941, 941b  
       evaluation, 934  
     stenting for, 952-953  
     stereotactic body radiation therapy for, 430, 955  
     surgery for, 941-943  
       palliative, 952-953  
       patterns of failure after, 942-943, 943f  
       prognostic factors, 941-942  
     systemic therapy of, 934  
     treatment of  
       algorithm, challenges, and future directions of, 956-958, 957f  
       recommendations for rare tumors, 947.e1t  
     treatment planning for, 954-955  
       simulation and, 953-954  
     unresectable and locally advanced disease, 934  
     vaccination and immunotherapy strategies in, 946  
 Pancreatic intraepithelial neoplasia (PanIN), 937  
 Pancreatic neoplasms, classification, 937  
 Pancreatic tumors  
   diagnostic algorithm for, 940f  
   primary, 195, 198f-199f  
 Pancreaticoduodenectomy, 934, 941  
 Pancreatoblastoma, 937  
   treatment of, 947.e1t  
 PanIN. *see* Pancreatic intraepithelial neoplasia (PanIN)  
 Panitumumab, 81t-82t, 178, 1004  
 Panniculitis-like T-cell lymphoma ( $\alpha/\beta$  type), subcutaneous, 1562-1563  
 Papillary thyroid carcinoma (PTC), 718-719  
   cause-specific survival with, 718, 719f  
   etiology and epidemiology of, 716, 716t  
   pathology of, 717  
   presentation of, 718  
   prognostic factors for, 719  
   receptor tyrosine kinases in, 562  
   relapse of, 718-719  
   staging of, 718, 718t  
   treatment algorithm for, 728-729  
 Papillion technique, 1005  
 Papillon radiotherapy, 287  
 Paragangliomas, nonchromaffin, 1375  
 Parallel functioning organs, 254-255, 255f  
 Parallel-opposed fields  
   for lip cancers, 574-575, 575f  
   for pelvis, 131f-132f  
 Parallel-plate chamber, 112  
 Paraneoplastic syndromes  
   and small cell lung cancer, 800, 800t  
   and thymic tumors, 867, 868b  
 Paraprotein, 1547  
 Paraproteinemias, 1547  
 Pararectal nodes, 994  
 Paratracheal nodes, 739f, 740t  
 Paris system, 142-143, 143f, 143t  
 Parkinsonism, 422  
 Parotid gland malignancy, 704-705, 710, 704.e1f  
 Parotid nodes, 740t  
 Partial response, 5  
 Particle(s), 93-94  
   fundamental, 93, 94t  
   mass of, 94  
   physical characteristics of, 94t  
 Particle beam therapy. *see* Charged particle radiotherapy  
 Particle interactions  
   heavy charged, 108  
   heavy uncharged (neutrons), 108  
   light charged (electrons), 107-108, 107f  
   summary of, 108-109  
 Particle range, 106-107  
 Particle therapy. *see* Charged particle radiotherapy  
 Paterson-Parker system, 142-143, 143f  
 Pathologic fractures  
   of acetabulum, 436  
   distribution of, 436, 436t  
   of femoral neck-intertrochanteric area, 436  
   of humerus, 436  
   predicting risk of, 436, 436t  
   prophylactic fixation of, 436  
   of spine, 436-437  
 Patient-derived xenografts, 78  
 Patient-equivalent phantom, 130  
 Patient treatment chart, 316  
 Pautrier's microabscess, 1558, 1560f  
 Pazopanib, 81t-82t, 85-86, 179-180  
   for renal cell carcinoma, 1152  
   for soft-tissue sarcoma, 1370  
 PCV therapy, for low-grade gliomas, 459-460  
 PD-1 inhibitors, 89-90  
 PDL-1 inhibitors, 89-90  
 Pediatric nasopharyngeal cancer, 1497-1499  
   adjuvant therapy for, 1486, 1498-1499  
   biology of, 1486, 1497  
   clinical manifestations of, 1497  
   etiology and epidemiology of, 1497  
   evaluation for, 1497  
   incidence of, 1486  
   irradiation techniques for, 1499  
   locally advanced, 1486  
   pathology of, 1497  
   pathways of spread of, 1497  
   primary therapy for, 1486, 1498-1499  
   staging of, 1486, 1497, 1498t  
   treatment algorithms, controversies, challenges, and future possibilities in, 1499  
   treatment-related toxicity in, 1499t  
 Pediatric tumors, rare, 1486-1500  
 Pelvic gastrointestinal cancers, irradiation tolerance of, 903-904  
 Pelvic irradiation, node-negative require, 1000  
 Pelvic lymph nodes, metastatic involvement of, 1023  
 Pelvic soft-tissue sarcomas, 333-334, 334t, 334.e1t  
 Pelvic tumors, hyperthermia for, 393t, 394  
 Pembrolizumab, 81t-82t, 89-90  
 Pemetrexed, 70, 886  
 Pencil beam scanning, 368, 369f

- Penile bulb, late effects of radiation on, 256*t*-257*t*, 273  
 dose-volume data on, 273  
 organ function and clinical significance and, 273  
 QUANTEC Review on, 273
- Penile cancer, 1037, 1160-1170  
 adjuvant therapy for, 1160  
 biologic characteristics of, 1160-1161  
 brachytherapy for, 282, 1163, 1164*t*, 1166-1168  
   interstitial, 1166-1168, 1167*f*  
   molds, 1166  
   patient selection for, 1164  
 clinical manifestations of, 1161-1163  
 diagnostic algorithm for, 1162*f*, 1161*e1f*  
 etiology and epidemiology of, 1160-1161  
 external beam  
   irradiation for, 1166, 1166*f*  
   radiation therapy for, 1163, 1164*t*  
 incidence of, 1160  
 irradiation techniques and tolerance for, 1166-1169  
   acute reaction, 1168  
   late reactions, 1168-1169  
 locally advanced, 1160, 1164-1165  
 lymph node assessment of, 1161-1163, 1163*e1f*  
 molecular biology of, 1161  
 node-positive, 1164-1165, 1165*f*  
 palliation of, 1160, 1164-1165  
 pathology and pathways of spread of, 1161  
 patient evaluation for, 1161-1163  
 prevention and early detection of, 1161  
 primary therapy for, 1160, 1163-1164  
 radiation therapy for, 1163-1164  
   patient selection for, 1164, 1165*f*  
 risk factors for, 1160-1161  
 staging of, 1160-1163, 1162*t*  
 surgery for  
   as primary therapy, 1163  
   for salvage, 1164  
 treatment algorithm, controversies, and challenges in, 1169-1170, 1169*f*
- Penis, 1160
- Pentoxifylline, 61
- Penumbra  
 of electron beams, 122, 122*f*  
 of photon beams, 119-120
- Percent depth dose (PDD), 115, 115*f*, 153, 155*f*  
 curve, 153*f*, 154  
 for electron beams, 120, 121*f*, 121*t*  
   effect of energy on, 121-122, 121*f*-122*f*, 121*t*  
 for photon beams, 116, 116*f*, 116*t*  
   effect of energy on, 118, 118*f*  
   effect of field size on, 118-119, 119*f*
- Percent labeled mitosis (PLM) technique, 28, 29*f*
- Percutaneous ablation, for hepatocellular carcinoma, 967
- Perflexion unit, 148, 150*f*
- Perfluorocarbons, 56
- Perfusion imaging (PI), 187  
 of brain tumors, 191
- Perfusion-limited hypoxia, 23
- Pericardial effusion, 837*t*
- Pericarditis, after radiotherapy for breast cancer, 1325
- Perineural invasion (PNI), by salivary gland tumors, 703, 703*f*, 712
- Perioperative care  
 of malnutrition, 162  
 of oncology patient, 162-163
- Peripheral neuropathy, with intraoperative radiotherapy, 330, 330*t*, 330*e1t*
- Peripheral T-cell lymphoma, 1529
- Peritoneal reflection, 994
- Pertuzumab, 81*t*-82*t*, 178
- PET/CT, for lung cancer, 193
- Peyronie's disease, 1379
- Pharmacodynamics, 180
- Pharmacogenomics, 183
- Pharmacokinetics, 180
- Pharyngeal walls, 652-653  
 tumors of, 611, 653
- Pharyngolaryngeal squamous cell carcinomas, metastatic neck nodes from, 745*t*
- Pharynx, late effects of radiation on, 256*t*-257*t*, 262-263
- Phase I trials, 240-241  
 newer designs, 241  
 traditional cohorts-of-3 design, 240-241
- Phase II/III design, 243
- Phase II trials, 241-243  
 randomized design, 242-243  
 traditional single-arm  
   one-stage design, 241-242, 242*t*  
   two-stage design, 242, 242*t*
- Phase III intergroup trial, 986
- Phase III trials, 243-246  
 current topics in, 249-251  
   adaptive design in, 250-251  
   biomarkers, 250, 250*f*-251*f*  
   surrogate end points, 249-250  
 intent to treat in, 244-246, 244*f*-245*f*  
 monitoring ongoing trials in, 246  
 rationale for randomization in, 243  
 stratification of treatment assignments in, 243-244
- Phosphatidylinositol-3-kinase (PI3K) pathway, 178, 179*f*
- Phosphorus-32 (<sup>32</sup>P)  
 for bone metastases, 440*t*-441*t*  
 in radioimmunotherapy, 414  
 techniques for, 1282
- Photochemotherapy, extracorporeal, 1567-1568
- Photocoagulation, for retinoblastoma, 1436-1437
- Photodisintegration, 105, 105*f*, 109
- Photodynamic therapy, intrapleural, 886
- Photoelectric effect, 103-104, 103*f*-104*f*, 109
- Photoelectron, 103, 103*f*
- Photon, 93-95, 96*t*  
 Compton, 104
- Photon beam radiation, 116-120  
 with beam modifiers, 120, 120*f*  
 dose characteristics of, 116-118, 116*t*-117*t*, 117*f*  
   dose profile as, 116, 117*f*, 117*t*  
   isodose lines as, 117-118, 117*f*  
   effect of energy on, 118, 118*f*-119*f*, 118*t*  
   effect of field size on, 118-119, 119*f*  
   penumbra of, 119-120, 119*f*
- Photon dose calculation methods, 127-128
- Photon interactions, 100-106  
 attenuation and transmission as, 100-101, 100*f*-101*f*  
 beam quality and, 101, 102*f*  
 coherent scattering as, 103, 103*f*  
 Compton effect as, 103*f*, 104-105  
 distribution of secondary electrons as, 105-106  
 pair production as, 105, 105*f*  
 photodisintegration as, 105, 105*f*  
 photoelectric effect as, 103-104, 103*f*-104*f*  
 summary of, 106  
 total absorption coefficient, 106  
 total attenuation coefficient for, 106, 106*f*  
 with x-rays and gamma rays, 102-105
- Photophoresis, 1567-1568
- Phyllodes tumor, 1367
- Physical wedge, 120
- Physics, 93-147  
 of brachytherapy, 136-145  
 of buildup phenomenon, 114-115, 114*f*  
 of dose relationships, for external beams, 115-116  
 of electron beams, 120-123  
 of external beam treatment planning and dosimetry, 125-129, 125*f*-126*f*  
 of external beam treatment simulation, 123-125  
 of external beam treatment verification, 129-130, 129*f*  
 of general techniques for external beam treatments, 130  
 of imaging, 133-135  
 of ionization and its fate, 109  
 of matter, 93-95  
 physical definitions in, 93-95, 94*f*-95*f*, 94*t*, 96*t*  
 of quality assurance, 146  
 of radiation detection and measurement, 111-114  
 of radiation production, 95-100, 96*f*  
 of radiation protection, 145-146, 145*t*  
 of radiation quantities and measurement, 109-114  
 of radiation quantities and units, 109-111, 111*t*  
 of radiotherapy photon beams, 116-120, 116*t*-117*t*, 117*f*  
 of stereotactic radiosurgery and radiotherapy, 135-136  
 of three-dimensional conformal radiotherapy, 130-133, 134*f*  
 of total-body procedures, 136, 136*f*  
 of treatment machines, 95-100, 96*f*
- PI3 kinase, as target for cancer therapy, 178-179, 179*f*
- PI3K/Akt/mTOR pathway, 83*f*, 87
- PI3K/mTOR pathway, 454
- Pian fungoides*, 1556
- Picture archiving and communications systems (PACS), 187
- Pigmented villonodular synovitis, 1381
- PIK, 46-48
- PIK3CA* mutations, 1207
- Pimonidazole, 54, 54*t*
- Piriform sinus(es), 652-653
- Piriform sinus tumors, pathways of spread of, 653
- Pituitary adenoma(s)  
 with acromegaly. *see* Acromegaly  
 adjuvant therapy for, 502  
 anatomy of, 504-505, 504*f*  
 biologic characteristics of, 502  
 classification of, 505  
 clinical manifestations of, 505-506  
 clinical trials for, 518-519  
 epidemiology of, 503  
 etiology of, 502-503  
 gonadotropin-secreting, 517  
 locally advanced, 502, 517  
 macro-, 505  
   imaging of, 507, 507*f*  
   nonfunctioning, 510, 510*f*  
 medical therapy for, 508-509  
   with acromegaly, 513  
   for nonfunctioning adenoma, 510  
   for prolactinoma, 512  
 micro-, 505  
   nonfunctioning, 510, 510*f*  
 in Nelson's syndrome, 516  
 nonfunctioning, 510-511



- Pituitary adenoma(s) (*Continued*)  
 laboratory assessment of, 506  
 macro-, 510, 510f  
 medical therapy for, 510  
 micro-, 510, 510f  
 radiation therapy for, 510-511, 511t  
 stereotactic radiosurgery for, 510-511, 511t  
 surgery for, 510  
 treatment algorithms for, 510, 510f  
 palliation for, 502, 517  
 pathology of, 505  
 pathways of spread of, 504-505, 504f  
 patient evaluation in, 506-507, 507f  
 prevention and early detection of, 503  
 primary therapy for, 502, 507-510  
 prolactinoma as. *See* Prolactinoma  
 radiation therapy for, 509-510  
   with acromegaly, 514, 514t  
   morbidity due to, 517-518  
   for nonfunctioning adenoma, 510-511, 511t  
   for prolactinoma, 512  
   techniques of, 517  
 staging of, 502, 507  
 stereotactic radiosurgery for, 509-510, 509f  
   with acromegaly, 514, 514t  
   in Cushing's disease, 516, 516t  
   morbidity due to, 517-518  
   for nonfunctioning adenoma, 510-511, 511t  
   for prolactinoma, 512, 512t  
   techniques of, 517  
 surgery for, 507-508  
   with acromegaly, 513  
   for nonfunctioning adenoma, 510  
   for prolactinoma, 511-512  
   thyroid-stimulating hormone-secreting, 516  
   treatment algorithms for, 518-519
- Pituitary carcinomas, 517
- Pituitary gland, 504, 504f  
 metastases to, 517
- Pituitary shielding, 641f
- Pituitary tumors, 502-520  
 aggressive, 517  
 anatomy of, 504-505, 504f  
 biology of, 502-504  
 classification of, 505  
 clinical manifestations of, 505-506  
 epidemiology of, 503  
 etiology of, 502-503  
 pathology of, 505  
 pathways of spread of, 504-505, 504f  
 patient evaluation in, 506-507, 507f  
 prevention and early detection of, 503  
 primary therapy for, 502, 507-510  
 staging of, 502, 507  
 stereotactic radiosurgery for, 422
- Placental leukocyte alkaline phosphatase (PLAP), 1126
- Planning organ at risk volume (PRV), 126
- Planning target volume (PTV), 125-126, 126f, 300, 300f, 317, 861, 974, 1014
- Plantar warts, 1380
- Plaque brachytherapy, for retinoblastoma, 1439-1440, 1440f-1441f
- Plaque irradiation, 553-554, 554f, 554.e1f-554.e2f
- Plasma cell malignancies, 1504
- Plasma cell neoplasms, 1547-1555
- Plasmablastic myeloma, 1548
- Plasmacytoma, 1549f, 1553-1554
- Plastic reconstruction surgical techniques, for  
 sinonasal cancer, 694-695
- Platinum analogs, 171
- Pleomorphic sarcoma, undifferentiated, 1349
- Pleura, soft-tissue sarcoma of, 1367
- Pleural effusion, 837t
- Pleurectomy, 884
- Pleuropulmonary blastoma, pediatric, 1492-1493  
 adjuvant therapy for, 1486, 1493  
 biology of, 1486, 1492  
 clinical manifestations of, 1492-1493  
 etiology and epidemiology of, 1492  
 evaluation for, 1492-1493  
 incidence of, 1486  
 irradiation techniques for, 1493  
 locally advanced, 1486, 1493  
 palliation for, 1487, 1493  
 pathology of, 1492  
 pathways of spread of, 1492  
 prevention and early detection of, 1492  
 primary therapy for, 1486, 1493  
 staging of, 1486, 1492-1493  
 treatment algorithms, controversies, challenges, and future possibilities for, 1493
- Pneumonectomy, extrapleural, 884-885
- Pneumonitis  
 after radiotherapy for breast cancer, 1325  
 after total body irradiation, 346, 346f  
 late effects of radiation and  
   dose-volume data on, 263-265, 264t-265t  
   QUANTEC Review on, 265-266  
 in non-small cell lung cancer, 835-836, 835t
- Pneumonopathy, after total body irradiation, 346
- Podophyllotoxins, 72
- Polarographic electrodes, 52, 53f
- Polish trial, 1005, 1005t
- Poly (ADP-ribose) polymerase (PARP)  
 inhibitors, 9, 77-78  
   DNA repair and, 87-88, 88f, 88t  
 Polymerase chain reaction (PCR), of human  
   papillomavirus infection, 599
- Polymorphisms, 180
- Pomalidomide, 180, 1551
- Ponatinib, 177
- Popcorn cells, 1508
- Population-based outcomes studies, 232f, 235, 235b
- Portal imaging, 129, 129f
- PORTEC-3 trial, in endometrial cancer, 1227
- Positive interaction, 68
- Positive radial (circumferential) margins, rectal  
 cancers, 1001
- Positron, 206
- Positron decay, 137-138, 137f
- Positron emission mammography (PEM), 214
- Positron emission tomography (PET), 206, 207f  
 application of, in other malignancies, 212  
 attenuation corrected, 206, 207f  
 basic physics of, 206-208  
   of breast cancer, 212  
   with brown fat, 209  
   for colorectal cancer, 211, 212f  
   with diabetes, 208  
 general aspects of tumor visualization in, 208, 209f  
 for head and neck cancers, 210-211  
 indications for, 209-214  
 for lymphoma, 211  
 misalignment in, 206-207, 207f  
 with MRI, 207-208  
 multidetector CT in, 207  
 patient preparation for, 208-209  
 potential pitfalls in, 208b  
 for prostate cancer, 1055  
 quantification in, 209  
 tumor hypoxia and, 52
- Positron emission tomography/computed  
 tomography (PET/CT)  
 basic physics of, 206, 207f  
 for tumor staging, 161
- Positronium, 137-138
- Postcricoid pharynx, 653
- Postcricoid tumors, 653
- Posterior triangle nodes, 740, 740t
- Postirradiation morphea, 1324
- Postoperative radiotherapy (PORT)  
 for meningiomas, 485, 486f  
 for non-small cell lung cancer, 822-824, 823f  
 for salivary gland tumors, 706-707, 706t-707t, 707b
- Posttransplant lymphoproliferative disorder (PTLD), 349, 349f  
 lymphoma and, 193
- Potential doubling time, 28t, 29-30
- Potentially lethal damage repair, 14-16, 16f
- Powers of ten, 4-5, 5f
- Practice patterns  
 financial incentives and disincentives and, 231  
 physicians' beliefs and, 230-231  
 program structure and, 230, 230f  
 quality indicators in, 231, 232f  
 reason for variation in, 229-231  
 research on, 229-231  
 scientific evidence and, 230
- Precision radiotherapy, for head and neck  
 tumors, 565-567
- Predictive marker, 250
- Prednisone, for prostate cancer, 1085
- Pregnancy, breast-conservation therapy and, 1314
- Prelymph nodes, 739f, 740t
- Preoperative short-course radiation *versus*  
 chemoradiation, 1004-1005
- Prescription isodose, 125
- Pretargeting, 407-408, 408.e3t
- Primary anal melanoma, 1023
- Primary central nervous system lymphoma (PCNSL), 1539-1540
- Primary dose, 116
- Primary malignant liver tumors (PMLTs), in  
 children  
 adjuvant therapy for, 1488  
 biology of, 1487  
 clinical manifestations of, 1487-1488  
 etiology and epidemiology of, 1487  
 evaluation for, 1487-1488  
 irradiation techniques for, 1488  
 locally advanced, 1488  
 palliation for, 1488  
 pathology of, 1487  
 pathways of spread of, 1487  
 primary therapy for, 1488  
 staging of, 1487-1488, 1487t, 1488f  
 treatment algorithms, controversies, challenges and future possibilities for, 1488-1489
- Primary mediastinal B-cell lymphoma (PMBL), 1528, 1539
- Primary unresectable disease, rectal cancer, 1007-1009, 1008t
- Primitive neuroectodermal tumors, supratentorial, 1393  
 medulloblastoma as, 1393  
 pineoblastoma as, 1393
- Procabazine, 71
- Process, 229-236  
 defined, 228  
 outcome and, 233-236  
 practice patterns in, 229-231  
 quality assurance processes and, 229

- Proctitis, after brachytherapy, 1069  
 Prodromal syndrome, 30-31  
 Progestational agents, for prostate cancer, 1085  
 Progesterone receptor (PR), in breast cancer, 1292  
 Prognostic marker, 250  
 Programmed cell death, 11  
   ionizing radiation-induced, 46  
 Programmed cell death protein 1 (PD-1), 89  
 Progression-free survival (PFS), 250  
 Prolactinoma, 511-512  
   laboratory assessment of, 506  
   medical therapy for, 512  
   radiation therapy for, 512  
   stereotactic radiosurgery for, 512, 512*t*  
   surgery for, 511-512  
   treatment algorithm for, 511, 511*f*  
 Proliferating cell radiosensitizers, 26  
 Prophylactic cranial irradiation, 793  
   for L-SCLC and E-SCLC, 803-804, 807  
   in small cell lung cancer, 794  
 Prophylactic surgery, for ovarian cancer, 1266  
 Proportion of treatment effect (PTE), 250  
 ProstaScint (capromab pendetide), 213, 1055  
 Prostate  
   anatomy of, 1042-1043  
   histology of, 1043  
   primary tumors of, 200-201, 201*f*  
 Prostate biopsy, postirradiation, 1073  
 Prostate cancer, 1035-1036, 1038-1095  
   active surveillance for, 1057, 1057*e1t*  
   adjuvant therapy for, 1038  
   androgen deprivation for  
     and brachytherapy, 1069  
     effects on staging of, 1046  
     for metastatic disease, 1085  
     radiation therapy plus, 1077-1078, 1078*t*-1079*t*  
     salvage, 1082-1083  
     toxicity of, 1078-1079  
   biologic characteristics of, 1038, 1046-1050  
   brachytherapy for, 277*f*, 280-282, 281*f*, 281*t*, 1067-1073  
     and androgen ablative therapy, 1069-1070  
     complications of, 1071-1073  
       lower gastrointestinal, 1072  
       sexual function, 1072-1073, 1073*f*  
       urinary, 1071-1072, 1072*f*  
     dosimetry during, 1090  
     EBRT and, 1068-1069, 1069*t*  
     high-dose rate, 1070-1071  
       outcomes of, 1073  
     indications for boost, 281-282  
     isotope selection for, 1068  
     monotherapy, indications for, 281  
     outcomes of, 1071  
     patient selection for, 1067-1068, 1068*f*  
     post-implant dosimetry for, 1070, 1070*t*  
     prostate biopsy after, 1073  
     ultrasound localization for, 1087*e1*  
   chemotherapy for, 1085  
     adjuvant, 1080  
   clinical symptoms and signs of, 1051-1052  
   conformal radiotherapy for, 319  
     treatment goals and rationale for, 321  
   diagnostic imaging of, 1053-1055  
     computed tomography for, 1053  
     magnetic resonance imaging for, 1053-1054, 1054*f*  
     nuclear medicine for, 1054-1055  
     ultrasonography for, 1053  
   early detection of, 1041-1042, 1042*e1t*  
   epidemiology of, 1038-1039  
   etiology of, 1039-1040  
   expectant management for, 1056-1057  
   extraprostatic extension of  
     Prostate cancer (*Continued*)  
       and clinical target volumes, 1087, 1088*f*  
       as predictive factor, 1046-1047  
       in staging, 1044-1045  
       grading of, 1043-1044, 1044*f*  
       as predictive factor, 1048-1049  
       histology of, 1043  
       appearance of, 1043  
       postirradiation, 1045-1046  
       history and physical examination for, 1052-1053  
       hormonal therapy for, 1085, 1085*e1b*  
       IMRT for, 1058  
       *versus* proton therapy, 1065-1066, 1067*f*  
       incidence of, 1038  
       irradiation techniques for, 1086-1092  
         external-beam, 1086-1090  
         and brachytherapy, 1090-1091, 1090*f*-1091*f*  
         clinical target volumes for, 1087, 1088*f*  
         planning target volumes for, 1087-1088  
         treatment planning and delivery for, 1089-1090, 1089*f*  
       postoperative, 1091-1092  
         treatment technique, 1091-1092, 1092*f*, 1092*t*-1093*t*  
       as primary therapy, 1086-1091  
       laboratory evaluation of, 1055  
         acid phosphatase in, 1055  
         prostate-specific antigen in, 1055  
       local therapy for, 1057-1058, 1058*f*  
       locally advanced, 1036, 1038, 1077-1084  
         adjuvant chemotherapy for, 1080  
         radiation therapy for, 1077-1083  
         adjuvant, 1080-1082, 1081*t*  
         androgen deprivation plus, 1077-1078, 1078*t*-1079*t*  
         postoperative, 1080-1083  
         scope of, 1079-1080  
         toxicity of, 1080  
       regional lymph node positive disease (pN+), 1080  
       surgery for, 1077  
   lymph node involvement of  
     and clinical target volumes, 1087  
     computed tomography of, 1053  
     management of, 1080  
     as predictive factors  
       pathologic, 1046  
     in staging, 1044  
     symptoms and signs of, 1052  
   metastatic, 1084-1086  
     bisphosphonates for, 1086  
     bone-directed therapies, 1086  
     chemotherapy for, 1085  
     hormonal therapy for, 1085, 1085*e1b*  
     immunotherapy for, 1086  
     radiotherapy for, 1086  
       systemic, 1086  
     symptoms and signs of, 1052  
   molecular biology of, 1046  
   morphologic variants of, 1043  
   nodal involvement in, 1047  
   overdiagnosis of, 1056  
   palliation of, 1038  
   particle beam therapy for, 1065-1067  
     carbon ion therapy as, 1066*e1*  
     proton therapy as, 1065-1067  
       clinical outcomes of, 1066  
       future applications of, 1066-1067  
       historical perspective of, 1065*e1*  
       *versus* IMRT, 1065-1066, 1067*f*  
       radiobiology and second malignancies with, 1066  
     technical issues with, 1065-1066, 1066*f*-1067*f*  
     Prostate cancer (*Continued*)  
       pathology of, 1043-1046  
       predictive factors for, 1046-1050  
         clinical endpoints as, 1047-1050  
         models using, 1050*e1*  
         pathologic endpoints as, 1046-1047, 1046*e1t*-1046*e2t*  
         patient-related factors, 1047-1048  
         and prognostic models using, 1050, 1051*f*-1052*f*  
       prevention of, 1040  
       primary therapy for, 1038, 1056-1077  
         irradiation techniques, 1086-1091  
         quality of life after, 1075-1077, 1076*f*  
       prostatic intraepithelial neoplasia and, 1040, 1043  
       radical prostatectomy for, 1057, 1073  
       radioimmunotherapy for  
         with chemotherapy, 406, 405*e2t*-405*e4t*  
         with external beam radiotherapy, 406  
         with HuJ591, 407  
         monoclonal antibodies for, 402*e2t*-402*e4t*, 402*e6t*  
       radiotherapy for, 1058-1073  
         adjuvant, 1080-1082, 1081*t*, 1083*t*  
         androgen deprivation plus, 1077-1078, 1078*t*-1079*t*  
         external beam, 1058-1065  
           biochemical relapse with, 1059-1060, 1059*f*, 1060*t*, 1059*e1t*  
           complications of, 1063-1065, 1063*t*, 1064*f*  
           dose escalation in, 1060, 1061*t*  
           hypofractionation and treatment duration in, 1060-1062, 1062*t*, 1062*e1t*, 1062*e3t*  
           for metastatic disease, 1086-1090  
           organ-confined disease, 1074, 1074*t*-1075*t*  
           planning target volumes for, 1087-1088  
           results with, 1059  
           screening recommendations for, 1042  
           staging of, 1038, 1053  
           surgical therapy for, 1073-1075  
         fast neutron, 375, 375*f*  
         general principles of, 1058  
         for locally advanced disease, 1077-1083  
         postirradiation local salvage therapy for, 1084  
         salvage radiotherapy for, 1082-1083  
           adverse effects of, 1083  
           for biochemical relapse, 1082-1083  
           for clinically apparent local recurrence, 1083, 1083*e1t*  
           outcomes after biochemical relapse, 1082-1083, 1083*t*, 1084*f*  
           surgery *versus*, 1057-1058  
         risk factors for, 1039, 1039*e1b*  
           age as, 1039  
           body habitus as, 1040  
           dietary as, 1039  
           environmental exposure as, 1040*e1*  
           hereditary, 1039  
           hormonal, 1039  
           other lifestyle factors as, 1040*e1*  
           precancerous lesions as, 1040  
           racial and ethnic as, 1039  
           vasectomy as, 1040*e1*  
         risk groupings for, 1049, 1049*t*  
         seminal vesicle invasion by  
           and clinical target volumes, 1087  
           as predictive factor, 1047  
           in staging, 1045  
           ultrasound of, 1045

- Prostate cancer (*Continued*)  
 staging of  
   magnetic resonance imaging for, 1053-1054  
   pathologic, 1044-1045, 1045*t*  
   workup, 1056, 1056*f*  
 for stereotactic body radiation therapy for, 430  
 surgical margins in  
   as predictive factor, 1048  
   as risk factors, 1045  
 surgical therapy for  
   complications of, 1074-1075  
   general principles of, 1073-1074  
   for locally advanced disease, 1077  
   for organ-confined disease, 1074, 1074*t*-1075*t*  
   radiotherapy *versus*, 1057-1058  
 treatment algorithm and future directions for, 1093, 1094*f*  
 tumor of, category of, 1048  
 Prostate carcinoma, radiotherapy for, proton beam, 363-364  
 Prostate-specific antigen (PSA)  
   after radiotherapy, 1059.e1  
   and bone scans, 1054-1055  
   in failure definitions after local therapy, 1050  
   in laboratory evaluation, 1055  
   as predictive factor, 1049-1050, 1049*t*, 1059.e1*t*  
   for staging, 1047  
 Prostate-specific antigen density (PSAD), 1042, 1042.e1  
 Prostate-specific antigen doubling time (PSADT), 1049  
   and salvage radiotherapy, 1082  
 Prostatectomy, radical, 1057, 1073  
   complications of, 1074-1075  
   general principles of, 1073-1074  
   for locally advanced disease, 1077  
   minimally invasive techniques for, 1073  
   for organ-confined disease, 1074, 1074*t*-1075*t*  
 Prostatic acid phosphatase (PAP), 1055  
 Prostatic hyperplasia, benign, 1039  
 Prostatic intraepithelial neoplasia (PIN), 1040, 1043  
 Prostatism, 1051  
 PROSTAVAC vaccine, 1086.e1  
 Proteasome, 42-43  
   inhibition of, 179  
 Protein, as hyperthermia target, 382  
 Proteomics, 49  
   chemotherapy-radiation interactions in, 78  
 Proton(s)  
   in atomic structure, 93, 94*f*  
   charged particle interactions of, 108, 108*f*  
   high-energy, 100  
   physical characteristics of, 94*t*  
 Proton beam radiotherapy  
   for acoustic neuroma, 363  
   active scanning in, 368, 369*f*  
   for astrocytoma, 361-362  
   for benign meningioma, 362  
   for breast cancer, 366  
   for carcinoma of prostate, 363-364  
   cost comparisons for, 369  
   delivery techniques for, 367-368, 367*f*-368*f*  
   development of, 358-359, 360*t*  
   for gastrointestinal tumors, 364  
   for head and neck tumors, 566  
   Proton beam radiotherapy (*Continued*)  
     for lung cancer, 364, 835  
     neutron production in, 368  
     for ocular (uveal) melanoma, 359  
     for optic pathway glioma, 361  
     for pancreatic cancer, 955  
     for paranasal sinus, nasal, and nasopharyngeal tumors, 362-363  
     for pediatric cancer, 364-366, 365*f*-367*f*  
     for prostate cancer, 1065-1067  
       clinical outcomes of, 1066  
       future applications of, 1066-1067  
       historical perspective of, 1065.e1  
       *versus* IMRT, 1065-1066, 1067*f*  
       radiobiology and second malignancies with, 1066  
       technical issues with, 1065-1066, 1066*f*-1067*f*  
     for sarcomas of skull base and spine, 359-361  
     second malignant tumor with, 368  
 Proton radiotherapy  
   for retinoblastoma, 1442, 1443*f*-1444*f*  
   for salivary gland tumors, 709  
   for sinonasal cancer, 695-696  
 Protracted venous infusion (PVI), 1000  
 Pseudocapsule, 1351  
 Pseudolymphoma, orbital, 543  
 Pseudo-progression, of high-grade gliomas, 476-477, 481  
 Pseudotumor orbitae, 1377-1378  
 Psoralen plus UVA (PUVA), 1566-1567  
 PTEN gene, 1207  
 PTEN phosphorylase, 178  
 Pterygium(ia), 291-292, 542, 544, 552, 552*t*, 1376-1377, 552.e1*f*-552.e2*f*  
 Pterygopalatine fossa, 678-679  
 Pterygopalatine ganglion, 678-679  
 PTV. *see* Planning target volume (PTV)  
 Pulmonary carcinoid, 878-883  
   biologic characteristics of, 879  
   biology of, 789  
   chemotherapy of, 881  
   clinical manifestations of, 880  
   epidemiology of, 788  
   etiology and epidemiology of, 878-879  
   incidence of, 788  
   irradiation techniques for, 881-883  
   locally advanced disease of, 881  
   medical treatment of, 881  
   molecular biology of, 879  
   palliation of, 881  
   pathology and pathways of spread, 879-880  
   patient evaluation in, 880  
   prevention and early detection of, 879  
   primary therapy of, 880-881  
   radiation therapy of, 881  
   results of therapy, 881  
   staging of, 880  
     and workup, 790  
   symptoms of, 880*t*  
   targeted agents of, 881  
   treatment of, 880-883  
     algorithm and controversies of, 883  
     considerations in, 795-796  
     results of, 882*t*  
 Pulmonary function, late effects of radiation and  
   dose-volume data on, 266  
   QUANTEC Review on, 266  
 Pulmonary function tests (PFTs), after total body irradiation, 346-347  
 Pulmonary metastases, of oropharyngeal cancer, 606  
 Pulmonary toxicity, of total body irradiation, 346-347, 346*f*  
 PUVA. *see* Psoralen plus UVA (PUVA)  
 PVI. *see* Protracted venous infusion (PVI)
- Q**  
 QALYs. *see* Quality-adjusted years of life (QALYs)  
 Quality, 217, 227-228  
   concepts of, 227-228  
   defined, 228  
   indicators of, 231, 232*f*  
   outcomes and, 231-233, 232*f*-234*f*, 234*t*  
     legitimate roles of, 234-236  
     limitations of, 233-234  
     relating structure and process to, 233-236  
     when randomized trial is not feasible, 234-235  
   process and, 229-236  
     outcome and, 233-236  
     practice patterns in, 229-231  
     quality assurance processes in, 229  
   structure of radiotherapy programs, 228  
     descriptive, 228  
     outcome and, 233-236  
     and practice patterns, 230, 230*f*  
   study of, 227-236  
     technology assessment in, 228-229  
 Quality-adjusted years of life (QALYs), 236  
 Quality assurance, 146, 229  
   for stereotactic radiosurgery, 154-158, 419  
   for total body irradiation, 351  
 QUANTEC initiative, 255-256, 256*t*-257*t*  
 Quantitation, of chromosome aberrations, 10-11  
 Quarks, 93, 94*t*  
 Quimby system, 142-143, 143*f*, 143*t*  
 Quinone antibiotics, 26
- R**  
 RACS Intergroup Trial, 1005  
 RAD 51, 45  
 RAD50, 45  
 Radiation  
   detection and measurement of, 111-114  
     gas-filled detectors for, 111-112, 112*f*, 112*t*  
     ionization chambers for, 112, 112*f*  
     solid-state detectors for, 112-114, 113*f*  
   quantities and units of, 109-111, 111*t*  
     dose as, 109-111, 110*f*  
     exposure as, 109  
     kerma as, 111  
 Radiation-associated injury  
   carcinogenesis as, 32-33  
   cataracts as, 31-32  
   cerebrovascular syndrome as, 31  
   functional subunits and volume effects in, 33-34  
   gastrointestinal syndrome as, 31  
   hematopoietic syndrome in, 31  
   molecular cascades and cytokines in, 33  
   prodromal syndrome as, 30-31  
   reirradiation tolerance as, 34  
   second malignancies as, 34  
   teratogenesis as, 31  
   whole body radiation syndromes as, 30-31  
 Radiation biology  
   in the 21st century, 39-40  
   biochemical repair of DNA damage and, 8-9  
   bioelectronic drugs in, 24-27, 25*t*  
   cell cycle in, 16-19, 17*f*-18*f*  
   cell survival curves and survival curve theory in, 11-14  
   cellular repair in, 14-16, 14*f*-15*f*  
   clinical, 27-39

- Radiation biology (*Continued*)  
 dose rate and dose fractionation effects, 34-35, 35f, 35t  
 early and late effects in normal tissues, 30-34  
 growth kinetics of normal tissues and tumors, 27-30, 28t  
 time-dose-fractionation relationships, 35-39  
 continuum of, 3, 4t  
 cytogenetic effects in, 10-11, 10f  
 defined, 2  
 densely ionizing radiation in, 19-20, 19f-21f  
 interaction with biological materials in, 6-7  
 levels of complexity, 3-4  
 oxygen effect in, 20-24, 21f-23f  
 radiation therapy and, 41-42  
 radioprotectors in, 24-27, 25t  
 radiosensitizers in, 24-27, 25t  
 radiotherapy-oriented  
   conceptual framework of, 2-5  
   first 50 years of, 5-6  
   powers of ten in, 4-5, 5f  
   second 50 years of, 6-27  
   therapeutic ratio in, 2-3, 3f  
   tissue heterogeneity in, 4
- Radiation carcinogenesis, 32-33  
 epidemiological studies in humans, 32-33  
 laboratory studies on, 32  
 and medical imaging procedures, risk from, 33  
 and prenatal irradiation, risk from, 33
- Radiation dose, tumor cell survival and, 4-5, 5f
- Radiation exposure  
 and salivary gland tumors, 699  
 and soft-tissue sarcoma, 1346  
 and thyroid cancer, 716
- Radiation-induced permanent growth arrest, 11
- Radiation modulation, 67f
- Radiation necrosis, 258
- Radiation oncologists, in oropharyngeal cancer, 600
- Radiation physics, stereotactic, 148-158  
 commissioning and quality assurance in, 154-158  
   dosimetric commissioning, 156-158, 157f  
   end-to-end target localization in, 154-155, 156f  
   Winston-Lutz test in, 154, 156f  
 detectors for small field measurements in, 153-154  
 dosimetric localization in, 149  
 hidden target test for, 155, 156f  
 history of, 148, 149f-150f  
 principles of, 148-149, 151f  
 radiosurgery beams, dosimetry of, 149-154  
   considerations for, 152-153  
   detector selection for, 152, 152f-153f  
   percent depth dose, 153, 153f  
   relative output factors in, 152, 153t  
 small field beam data, 154, 155f  
 stereotactic localization in, 149, 151f
- Radiation production, 95-100  
 by linear accelerators, 97-99  
   major electronic and beamline components of, 98t  
   multileaf collimator of, 98-99, 98t, 99f  
   photon spectra for, 99, 100f  
   schematic of, 98f  
   treatment machine geometry for, 96f  
 by other accelerators, 100  
 by radioactive decay, 96-97, 97f  
 treatment machine geometry for, 96f
- Radiation protection, physics of, 145-146, 145t
- Radiation protectors, 58-61  
 modifiers of oxygen supply as, 61, 61f  
 others, 61  
 sulfhydryl-containing compounds as, 58-61, 59f-60f, 60t
- Radiation safety, of stereotactic body radiation therapy, 427-428
- Radiation sciences, 49
- Radiation source licenses, 146
- Radiation target volumes, thoracic neoplasms, 793
- Radiation Therapy Oncology Group (RTOG), 639, 821-822, 1036  
 study, 600
- Radiative interactions, 107-108
- Radical competition model, 22, 22f
- Radical neck dissection (RND), 749, 749t, 750f  
 extended, 749t, 750  
 modified, 749, 749t, 750f  
 neck control after, 756-757, 756f
- Radioactive decay, 96-97, 97f, 139f  
 in brachytherapy, 137-138, 137f  
 mathematics of, 138-139  
 schematics of, 139-140, 140f-141f, 140.e1f-140.e2f
- Radioactive iodine (RAI) therapy, for thyroid cancer, 723-724
- Radioactive labeling, for measuring tumor hypoxia, 24
- Radioactive somatostatin, tumor staging with, 795-796
- Radiobiology  
 of stereotactic body radiation therapy, 428-430  
 of stereotactic radiosurgery, 420-422, 423f, 423t  
 of targeted radionuclide therapy, 401
- Radiochromic film, 113, 130
- Radiocolloids, 215
- Radiofrequency heating, ablation, for renal lesions, 1145
- Radiofrequency phased array heating, 387t, 389, 389f
- Radioiodine remnant ablation (RRA), for thyroid cancer, 715, 723
- Radiomitigators, 51
- Radionuclide(s), 94-95, 95f  
 in positron emission tomography, 206  
 for targeted radionuclide therapy, 400-401, 400t
- Radionuclide bone scintigraphy, in prostate cancer, 1055, 1055f
- Radionuclide therapy, systemic, for bone metastases, 440-441, 440t-441t
- Radioprotectors, 24-27, 25t, 58-61  
 modifiers of oxygen supply as, 61, 61f  
 normal tissue, 26-27  
 others, 61  
 sulfhydryl-containing compounds as, 58-61, 59f-60f, 60t
- Radiosensitization, 63, 67-68  
 tumor hypoxia and, 51
- Radiosensitizers, 24-27, 25t  
 angiogenesis as  
   clinical studies of, 86-87  
   preclinical studies of, 86  
 chemotherapy drugs as, 26  
 EGFR family inhibitors as  
   clinical studies of, 84-85  
   preclinical studies of, 84  
 hypoxic cell, 24-25, 53-55, 54t, 55f  
 mTOR inhibitors as, 87  
 oxygenation status and, measurement of, 24  
 PARP inhibitors as, 88
- Radiosensitizers (*Continued*)  
 PI3K/Akt/mTOR pathway and, 83f, 87  
 proliferating cell, 26
- Radiotherapy  
 accessibility of, 218-227  
 efficiency of, 236-237  
 hyperthermia and  
   with chemotherapy, 391  
   clinical, 391  
   factors to consider for, 385  
   phase III clinical trials of, 392-394, 393t  
   rationale for, 384-385  
   “thermal enhancement ratio” for, 385  
   quality of, 227-236  
   underutilization of, 227
- Radium-223 (Xofigo), 81t-82t
- Radium-226 (<sup>226</sup>Ra)  
 in brachytherapy, 142  
 in teletherapy, 96
- Radium-233, 1086.e1
- Radium therapy, 5
- Raloxifene, for breast cancer, 1290, 1291t
- Ramucirumab (Cyramza), 81t-82t
- Randomized design, 242-243
- Range compensator, 367, 367f
- Range modulation, 367, 367f
- Rapamycin analogs, 87
- RAPIDO Trial, 1007.e1
- RAS genes  
 in bladder cancer, 1099  
 in non-small cell lung cancer, 811
- $\alpha/\beta$  ratios, 36-37, 37t
- RB gene, in bladder cancer, 1098-1099
- RB1 genes  
 in non-small cell lung cancer, 811  
 in retinoblastoma, 1433-1434  
 in soft-tissue sarcoma, 1347
- R-CHOP chemotherapy, for diffuse large B-cell lymphoma, 1503
- Reactive oxygen species (ROS), 46-47
- Real-time remote monitoring, 134-135
- Receptor tyrosine kinases (RTKs)  
 activation by ionizing radiation of, 46, 47f  
 chemotherapy and, 177-178  
 in head and neck tumors, 562, 567
- Recoil protons, 7, 19
- Recombinant antibodies, 403, 404f
- Recombinant human thyroid stimulating hormone (rhTSH), 214
- Rectal bleeding, 1023
- Rectal cancer, 992-1018. *see also* Colorectal cancer  
 adjuvant therapy for, 992  
   primary and, 998-1006  
   resectable disease, 998-1006  
 analyses, 899, 900t  
 anatomy and pathways of spread, 994, 994.e1f  
 biologic characteristics of, 992-994  
 brachytherapy for, 287-288, 288f  
 chemoradiation for, 73-74, 74t  
   adjuvant, 999-1004  
   followed by local excision, 1006  
   imaging after, 995  
   with positive radial (circumferential) margins, 1001  
   postoperative, 999-1000  
   preoperative *versus*, 1003  
   preoperative, 1000-1004  
   alternate regimens and issues, 1003-1004  
   distance from anal verge, 1001, 1001.e1t  
   impact of tumor response to, 1004  
   for locally advanced disease, 1006-1007  
   oxaliplatin-based, 1003.e1t  
   prospective series, 1002-1003  
   randomized trials, 1003  
   retrospective series, 1002



Rectal cancer (*Continued*)

RTOG phase II, 1004  
 sphincter preservation with, 1001-1002  
 surgery needed, 1002-1003  
 randomized trials of preoperative  
   short-course radiation *versus*, 1005*t*  
 targeted biologic agents, 1004  
 chemotherapy for  
   adjuvant irradiation without, 998-999  
   postoperative, 1000-1001  
   sequential, 1004  
   sphincter preservation, 1002  
 clinical manifestations of, 994  
 decision supportive tools for, 1016-1017  
 delineation recommendations and,  
   1012-1013, 1014*f*, 1012.*e1f*  
 diagnostic algorithm for, 994, 995*t*  
 distance from anal verge, 1002.*e1f*  
 etiology and epidemiology of, 992-993  
 evaluation of, 994-998  
   staging, 992  
 histopathology of, 994  
 IGRT for, 1014-1015  
 imaging of, 994-995, 995.*e1t*, 1016.*e2f*  
   after chemoradiation, 995  
 IMRT for, 1014-1015, 1014*f*  
 incidence of, 992  
 irradiation for  
   endocavitary, 1005  
   fractionation, modality, and dose, 1015  
   postoperative, 998  
   preoperative, 998-999  
     short-course preoperative, 998-999, 999*t*  
   techniques of, 1012-1016  
     patterns of relapse that define radiation  
       portals, 1012  
     tolerance of, 1012-1016  
   three-dimensional treatment planning and  
     delineation recommendations for,  
       1012-1013, 1014*f*, 1014.*e1f*, 1012.*e1f*  
   two-dimensional irradiation field design  
     in, 1012, 1012*f*-1013*f*  
 local excision for, 1006  
   alone, 1006  
   followed by postoperative therapy, 1006,  
     1006.*e1t*  
   preoperative therapy followed, 1006  
   sphincter function, 1006  
 locally advanced, 992, 1006-1012  
   intraoperative radiation therapy for, 1007,  
     1008*t*  
 locally recurrent, 1009, 1010*t*  
   intraoperative irradiation, 992  
   irradiation alone for, 1011  
 metastatic  
   screening for, 995  
   treatment of patients with, 1011-1012  
 methods to reduce toxicity, 1015-1016  
 molecular biology of, 993-994  
 multidisciplinary teams, 1016.*e6*  
 node-negative require pelvic irradiation, 1000  
 nonoperative treatment of, 1002.*e1t*  
 obstructing, 994  
 palliation of, 992, 1006-1012  
 pathology and pathways of spread of, 994  
 pooled analyses, 899, 899*t*-900*t*  
 postoperative, 998  
   role of concurrent, 1000-1001  
 posttreatment assessment of, 998  
 preoperative  
   prospective clinical assessment, 1002  
   short-course, 1004-1005  
   treatment fields for, 1013*f*  
 pretreatment evaluation and, 994-995,  
   995.*e1t*  
 prevention and early detection of, 993

Rectal cancer (*Continued*)

primary therapy for, 992  
 primary unresectable, irradiation for,  
   1007-1009, 1008*t*  
 prognostic factors for, 1006  
 radiation for  
   interval between short-course and surgery,  
     1004  
   selective use of, 1001  
   therapy, local excision with or without,  
     1005-1006  
 randomized trials for, 1005  
 sandwich technique for, 998  
 screening for early detection of, 993  
 sphincter preservation with  
   alternative methods for, 1005-1006  
   endocavitary irradiation, 1005  
   preoperative chemoradiation for,  
     1001-1002  
 staging of  
   evaluation, 992  
   sensitivity and specificity of ERUS, pelvic  
     CT and MRI, 995.*e1t*  
   TNM, 995-998  
     AJCC, 997*t*  
     clinical, 996-998  
 surgery for, reirradiation followed by,  
   1009-1011  
 surgical quality, recording of, 998  
 targeted biologic agents for, 1004  
 tethered, 1006  
 treatment algorithms, controversies,  
   problems, challenges, and future  
   possibilities for, 1016-1017, 1016*f*,  
   1016.*e2f*  
 tumor regression grading, 998  
 Rectal fossa, 1013  
 Rectum, 994, 996*f*  
   adenocarcinoma of, therapy, 165-167, 167*t*  
   late effects of radiation on, 256*t*-257*t*,  
     269-271  
   dose-volume data on, 269-271, 270*t*  
   organ function and clinical significance  
     and, 269  
   QUANTEC Review on, 271  
 5 $\alpha$ -Reductase inhibitors, 1040  
 Reese-Ellsworth grouping system, 1435, 1435*t*  
 Reference point, 126  
 Referred pain, in oropharyngeal cancer, 604  
 Regorafenib (Stivarga), 81*t*-82*t*, 85-86  
 Regrowth delay assay, 13-14  
 Reirradiation  
   for nasopharyngeal carcinoma, 639-640  
   for oropharyngeal cancer, 615  
   for recurrent high-grade gliomas, 478  
 Reirradiation tolerance, 34  
 Relative biological effectiveness (RBE), 19-20,  
   20*f*  
   factors influencing, 20, 20*f*-21*f*  
   of fast neutron radiotherapy, 373  
 Relative movement method, 29  
 Relative output factors, 152, 153*t*, 154, 155*f*  
 Renal cancer, radioimmunotherapy of,  
   monoclonal antibodies for, 402.*e2t*-402.*e4t*,  
   402.*e6t*  
 Renal cell carcinoma (RCC), 196, 199*f*,  
   1139-1159  
   adjuvant irradiation for, 1146-1147, 1146*t*  
   adjuvant therapy for, 1139  
   biologic characteristics of, 1139, 1142  
   chemotherapy for  
     adjuvant, 1147  
     for metastatic disease, 1151-1152  
   classification of, 1141  
   clinical manifestations of, 1143  
   clinical trials for, 1157-1158

Renal cell carcinoma (RCC) (*Continued*)

etiology and epidemiology of, 1140  
 grading system of, 1141  
 immunotherapy for  
   adjuvant, 1147  
   for metastatic disease, 1151-1152  
 incidence of, 1139  
 intensity-modulated radiation therapy for,  
   1152, 1153*f*-1156*f*, 1152.*e1f*  
 irradiation for  
   primary, 1145-1146  
   techniques and tolerance to, 1152-1155  
 locally advanced, 1139, 1149-1150  
 intraoperative irradiation containing  
   approaches for, 1149-1150  
 neoadjuvant irradiation for, 1149, 1149*t*  
 metastatic, 1150-1152  
   bone and soft-tissue, 1151  
   brain, 1151, 1151*t*  
   solitary, 1150-1151  
 molecular biology of, 1142  
 molecularly targeted treatment for  
   adjuvant, 1147  
   axitinib for, 1152  
   bevacizumab for, 1152  
   everolimus for, 1152  
   for metastatic disease, 1151-1152  
   pazopanib for, 1152  
   sorafenib for, 1152  
   sunitinib for, 1152  
   temsirolimus for, 1152  
 palliation of, 1139, 1150-1152  
 pathology of, 1141  
 pathways of spread of, 1141  
 patient evaluation for, 1143, 1143*b*  
 pediatric, 1426  
 predictive features for, 1141  
 prevention and early detection of, 1141  
 primary therapy for, 1139, 1143-1147  
 radiotherapy for  
   for salvage treatment, 1152-1155, 1155.*e1f*  
   stereotactic body, 1151  
   treatment-related toxicity of, 1155  
 staging of, 1139, 1143, 1144*t*  
 surgery for, 1143-1145  
 treatment algorithm, conclusions, and future  
   possibilities for, 1156-1158, 1158*f*  
 Renal pelvis cancer, 1036-1037, 1140  
   adjuvant irradiation for, 1147-1148, 1148*t*  
   adjuvant therapy for, 1139  
   topical, 1149  
   biologic characteristics of, 1139, 1142  
   chemotherapy for, adjuvant, 1148-1149  
   clinical manifestations of, 1143  
   epidemiology of, 1140  
   etiology of, 1140-1141  
   grade and nodal status of, 1144*t*  
   IMRT for, 1155  
   incidence of, 1139  
   irradiation for  
     primary, 1147  
     techniques and tolerance to, 1155-1156,  
       1157*f*, 1156.*e1f*  
   locally advanced, 1139, 1150  
   metastatic, 1152  
   molecular biology of, 1142  
   palliation of, 1139, 1152  
   pathology of, 1141-1142  
   pathways of spread of, 1142  
   patient evaluation for, 1143  
   prevention and early detection of, 1141  
   primary therapy for, 1139, 1147-1149  
   staging of, 1139, 1143  
   surgery for, 1147  
   treatment algorithm, conclusions, and future  
     possibilities for, 1158

- Renal toxicity, 270*t*, 272  
 of radioimmunotherapy, 413-414, 414.e1*f*  
 of total body irradiation, 347-348
- Reoxygenation, 22-23
- Replicative senescence, 46
- Repopulation  
 with chemoradiation, 66  
 in tumors and normal tissues, 30
- Reproductive function, altered, 348
- Resected node-positive colon cancers, 901-902
- Resection margin, circumferential, 998, 998.e1*f*
- Respiratory cycle, 134
- Respiratory misregistration, 206-207, 207*f*
- Respiratory motion, 953
- RET* gene, 562
- RET* proto-oncogene, 717
- Reticulosis, pagetoid, 1562
- Retina, radiation and, 556-558
- Retinoblastoma, 1433-1446  
 bilateral, 1433  
 biology of, 1433  
 chemotherapy for, 1437  
 clinical manifestations of, 1434-1436  
 early detection of, 1434  
 etiology and epidemiology of, 1433  
 evaluation of, 1434-1436  
 exophytic, 1435  
 extraocular, 1438-1439  
 genetic counseling for, 1434  
 incidence of, 1433  
 International Classification of, 1435, 1436*b*  
 intraocular, 1435, 1435*f*  
 bilateral, 1437-1438, 1445*f*  
 intravitreal and intraarterial chemotherapy for, 1437  
 primary therapy for, 1437-1438, 1438*f*  
 unilateral, 1437, 1445*f*  
 metastatic, 1439  
 pathology of, 1434  
 pathways of spread of, 1434  
 prevention of, 1434  
 primary therapy for, 1436-1437  
 radiation therapy for, 1437  
 external beam, 1441-1442  
 long-term effects of, 1442-1443  
 plaque brachytherapy, 1439-1440, 1440*f*-1441*f*  
 proton, 1442, 1443*f*-1444*f*  
 stereotactic, 1440-1441  
 techniques of, 1439-1442  
 Reese-Ellsworth grouping system for, 1435, 1435*t*  
 staging of, 1433, 1436*b*  
 surgery for, 1436-1437  
 treatment of  
 algorithms, controversies, problems, and future possibilities for, 1444-1445, 1445*f*  
 modalities of, 1433  
 principles of, 1436-1437  
 trilateral, 1434-1435, 1439  
 tumor suppressor gene, in cervical cancer, 1176-1177  
 unilateral, 1433
- 13-cis-Retinoic acid, 630
- Retinoids  
 for mycosis fungoides, 1567  
 for nasopharyngeal carcinoma, 630  
 for non-small cell lung cancer, 813
- Retroauricular nodes, 740*t*
- Retromolar trigone, 590-591
- Retromolar trigone cancer  
 early, 591-592  
 irradiation techniques for, 592  
 locally advanced, 592  
 manifestations of, 591
- Retromolar trigone cancer (*Continued*)  
 pathology of, 591, 591*f*  
 staging of, 591  
 treatment of, 591-592  
 algorithm for, 591*f*  
 complications of, 592  
 results of, 592, 592*t*
- Retroperitoneal lymph node dissection (RPLND)  
 for nonseminoma, 1132.e1  
 for seminoma, 1128
- Retroperitoneal organs, primary tumors of, 195-200, 198*f*-199*f*
- Retroperitoneal sarcomas, 1363-1366  
 adjuvant radiation therapy for, 1364-1366, 1364*t*, 1366*f*  
 classification of, 1363-1364  
 surgery for, 1364  
 treatment and diagnostic algorithm for, 1365*f*
- Retroperitoneal soft-tissue sarcoma  
 intraoperative radiotherapy for, 333-334, 334*t*, 334.e1*t*  
 management of, 167-168, 168*f*-169*f*
- Retropharyngeal lymph nodes, 740*t*, 745
- Retrostyloid space, 749
- Reverting postmitotic (RPM) cells, 27
- Rexinoids, 1566
- RF beacons, 314
- Rhabdoid tumor, of kidney, 1424-1426, 1424*t*, 1425*f*  
 chemotherapy for, 1430
- Rhabdomyosarcoma (RMS), 1367-1368  
 alveolar, 1367, 1406  
 biologic characteristics and pathology of, 1404  
 clinical manifestations of, 1404, 1404*f*  
 embryonal, 1367, 1406  
 evaluation and risk classification for, 1406  
 of female genitourinary tract, 1408-1409, 1409*f*  
 interstitial brachytherapy for, 1410  
 of orbit, 1408  
 in parameningeal sites, 1408, 1409*f*  
 paratesticular, 1409  
 pleomorphic, 1367  
 primary therapy for, 1406-1407  
 radiation therapy for  
 indications and outcomes of, 1407-1409, 1408*t*  
 proton beam, 364, 366*f*  
 techniques of, 1409-1410, 1410*f*, 1410*t*  
 timing of, 1410-1411  
 staging of, 1405-1406, 1405*t*-1406*t*
- Rhenium 186, 440*t*-441*t*, 441
- Rheumatologic disorders, breast-conservation therapy and, 1314
- Rituximab (Rituxan), 81*t*-82*t*
- RNA, 47
- Robbins classification, 738, 740*t*
- Rodent ulcer, 764
- Roentgen, 109
- Roentgen-to-gray conversion coefficient, 110
- Romidepsin, 81*t*-82*t*, 180, 1567
- Rotational intensity-modulated radiation therapy, 351
- Rotterdam Nasopharynx Applicator, 641
- Rotter's nodes, 1285, 1286*f*
- RSU-1069, 56-57, 57*f*
- RTOG. *see* Radiation Therapy Oncology Group (RTOG)
- S**
- Salivary gland(s), 676*f*, 698  
 after total body irradiation, 345  
 late effects of radiation on, 256*t*-257*t*, 261-262
- Salivary gland(s) (*Continued*)  
 dose-volume data on, 261  
 organ function and clinical significance and, 261  
 QUANTEC Review on, 262  
 malignancies, 698-714. *see also* Salivary gland tumors (SGTs)
- Salivary gland tumors (SGTs)  
 adjuvant therapy for, 698  
 biologic characteristics of, 698-701  
 classification of, 701, 701*b*  
 dysregulation and, 700  
 early stage, 698  
 etiology and epidemiology of, 698-699  
 evaluation for, 703-704, 704*b*  
 genetic and molecular biology of, 699-701  
 irradiation techniques for, 710-713  
 locally advanced, 698, 707-710  
 altered fractionation for, 708  
 chemoradiation for, 709-710  
 definitive radiotherapy for, 707-708  
 molecular targeted agents for, 710, 710.e1*t*  
 neutrons and heavy charged particle therapy for, 708  
 palliation for, 710  
 proton radiotherapy for, 709  
 stereotactic radiosurgery for, 708-709
- lymphoma as, 1544  
 manifestations of, 703, 703*f*  
 microenvironment of, 701  
 mutation analysis of, 700  
 neck management for, 706  
 palliation for, 698, 710  
 pathology of, 701-702, 701*b*, 702*t*  
 pathways of spread of, 702-703, 702*t*  
 prevention and early detection of, 699  
 primary therapy for, 698, 704-707, 705*f*  
 radiotherapy as, 706-707  
 surgery as, 704-706  
 prognostic factors for, 701, 702*t*  
 radiotherapy for  
 definitive, 707  
 fast neutron, 373-375, 374*f*  
 staging of, 698, 704, 704*t*  
 treatment of  
 algorithm for, 713, 713*t*  
 side effects of, 712-713
- Samarium 153, 441, 441*t*
- Sample size calculation, 239
- Sanazole, 54
- Sarcoma(s)  
 of bone, pediatric, 1412-1421  
 adjuvant therapy for, 1412  
 advanced, 1412  
 biologic characteristics of, 1412  
 clinical manifestations of, 1413-1414  
 etiology and epidemiology of, 1412  
 evaluation of, 1413-1414  
 Ewing's sarcoma. *see* Ewing's sarcoma  
 incidence of, 1412  
 osteosarcoma. *see* Osteosarcoma  
 palliation for, 1412  
 pathology of, 1413  
 pathway of spread of, 1413, 1413*f*  
 prevention and early detection of, 1412  
 primary therapy for, 1412  
 staging of, 1412-1414, 1414*t*  
 brachytherapy for, 289-290, 290*f*, 290*t*  
 Ewing's. *see* Ewing's sarcoma  
 of skull base, 359-361  
 soft-tissue. *see* Soft-tissue sarcoma (STS)  
 of spinal cord, 359-361, 537-538  
 synovial, 1350  
 uterine, treatment of, 1220  
 vaginal, 1262  
 of vulva, 1253, 1253.e2*f*

- Sarcomatoid carcinoma, of larynx and hypopharynx, 651, 661
- Satraplatin, 71
- SBRT. *see* Stereotactic body radiation therapy (SBRT)
- Scandinavian Prostate Cancer Group-4 trial, 1056
- Scanditronix MM50 Racetrack Microtron, 296
- Scars, hypertrophic, 1380
- Scatter-air ratio, 116
- Scatter dose, 116
- Scatter integration, 306*t*
- Schiller-Duval bodies, 1489
- Schwannoma(s), spinal, 538
- Schwarz, Gottwald, 51
- Sciatic pain, 994
- Scintillation detectors, 113-114
- Sclera, radiation and, 556
- Scleroderma, 1324
- Screening phase II design, 243
- Sebaceous carcinoma, 767-768
  - biology and pattern of spread of, 768
  - presentation and pathology of, 767-768
- Second malignancies
  - radiation-induced, 34
  - with radioimmunotherapy, 415
- Second solid tumors, with acute lymphoblastic leukemia, 1460
- Secondary decay processes, 138
- Secondary malignant tumors, from radiation, 349-350, 349*f*
- SEER analysis, 918
- Segmental multileaf collimator, 296, 313
- Selective estrogen receptor modulators (SERMs), for breast cancer, 1290
- Selective internal irradiation, for liver metastases, 446-447
- Selective node dissection (SND), 749-750, 749*t*, 750*f*
  - neck control after, 754-755, 755*t*
- Selenium, for non-small cell lung cancer, 813
- Semiconductor diamond detectors, 154
- Seminal vesicle invasion (SVI)
  - and clinical target volumes, 1087
  - as predictive factor, 1047
  - in staging, 1045
  - ultrasound of, 1045, 1053
- Seminal vesicles, 1042-1043
- Seminoma, 1036, 1121, 1124, 1128-1131
  - anaplastic, 1124
  - pediatric, 1489, 1489*t*
  - spermatocytic, 1124, 1135
- stage I
  - follow-up protocol for, 1129*t*
  - irradiation techniques for, 1135-1137
  - management of, 1128-1130
  - radiation therapy for, 1129-1130, 1129*t*
    - adjuvant chemotherapy for, 1130
    - dose of, 1136
    - reduction in treatment volume, 1135-1136, 1136*f*
    - target volume, 1135
  - retroperitoneal lymph node dissection for, 1130
  - surveillance for, 1128-1129, 1128*f*, 1128*t*
- stage II
  - irradiation techniques for, 1135-1137
  - management of, 1130-1131, 1131*t*
  - radiation dose for, 1136-1137
  - reduction in radiation treatment volume, 1136, 1136*f*
    - residual retroperitoneal mass and, 1131
- stage III, management of, 1131
- treatment algorithm for, 1137-1138, 1137*f*
- Senescence, 11
- Sensitizer enhancement ratio (SER), 24-25
- Sentinel lymph node biopsy (SLNB), 164, 164*f*
  - for breast cancer, 1314
  - for cutaneous carcinoma, 771
  - for floor-of-mouth neoplasms, 577
  - for head and neck tumors, 749-751
  - for melanoma, 781, 781*t*
- Sentinel lymph node surgery, for breast cancer, 1296
- Serial organs, 254-255, 255*f*
- Serial tomotherapy, 296
- Serous carcinoma, 1205, 1267-1268
- Sertoli cell tumors, 1133-1134
- Sestamibi, 214
- Sex cord tumors, ovarian, 1280-1281
- Sexual dysfunction, penile cancer and, 1169
- Sexually transmittable infectious agents, 1020
- Sézary syndrome, 1529, 1557-1558, 1561-1562
  - diagnosis of, 1561*t*
  - Sézary cells in, 1560*f*
- Shake-off technique, 16
- Shell outs, 1351
- Shielding, 355
- Short-course preoperative irradiation, 998-999, 999*t*, 1004.e1
- Short tracks, in energy deposition, 6-7, 7*f*
- Shoulder mobility, after axillary irradiation, 1325
- “Shrinking-field” technique, 619-620
- Shrinking-field (boost) techniques, 327
- Signal transduction inhibitors, 177
- Silicon (SiLi) detector, 114
- Simple hyperplasia, 1205
- Simpson grades of resection, 485, 485*t*
- Simulation, of external beam treatment, 123-125
  - computed tomographic, 124-125
  - conventional radiographic/fluoroscopic simulator description and components, 123-124
  - conventional simulation procedures and immobilization in, 124
  - purpose of, 123
  - treatment setup of, 123
    - SAD treatment as, 123, 123*f*
    - SSD treatment as, 123, 123*f*
- Simultaneous integrated boost (SIB) technique, 321-322
- “Single-hit” breaks, 10
- Single-modality therapy, for nasopharyngeal carcinoma, 636
- Single nucleotide polymorphism (SNP) arrays, 78
- Single-photon-emission computed tomography (SPECT), 212
  - for unknown head and neck primary site, 731-732, 732*t*
- Single-stranded break repair, 9
- Sinonasal cancer, 673-697
  - adjuvant therapy for, 673, 690, 690*t*
    - biologic characteristics of, 673-681, 675*t*
    - chemotherapy for
      - concurrent, 688
      - neoadjuvant, 688
    - classification of, 674-675, 675*t*
    - etiology and epidemiology of, 673-674
    - evaluation of, 681-683
    - follow-up after, 696
    - IMRT for, 690, 690*t*
    - incidence of, 673
    - irradiation techniques and tolerance for, 688-694
    - locally advanced, 673, 688
      - palliation for, 688
    - primary radiotherapy for, 688
    - manifestation of, 681-683
    - of maxillary sinus. *see* Maxillary sinus cancer
- Sinonasal cancer (*Continued*)
  - of nasal cavity and ethmoid air cells. *see* Ethmoid sinus tumors; Nasal cavity tumors
  - of nasal vestibule. *see* Nasal vestibule tumors
  - new therapy directions and clinical studies for, 694-696
  - palliation for, 673
  - pathology of, 674-681, 675*t*
  - pathways of spread of, 674-681, 675*t*
  - patient care for, 693-694
  - prevention and early detection of, 674
  - primary therapy for, 673, 683-688
  - side effects with, 692, 693*t*
  - staging of, 673, 681-683, 682*t*
  - surgical techniques for, 694-695, 694.e1*f*
  - treatment algorithms for, 696, 696*t*, 697*f*
- Sinonasal undifferentiated carcinoma (SNUC)
  - IMRT for, 692, 695*f*
  - pathology of, 680-681
  - primary therapy for, 686
- Sinuses, 673-674, 674*f*, 675*b*, 673.e1*f*
  - change with age of, 674, 674.e1*f*
- Sinusoidal obstructive syndrome (SOS), 347
- Skeletal scintigraphy, 433
- Skin, benign diseases of, 1378-1380
  - desmoid, 1378-1379
  - Dupuytren's contracture (morbus Dupuytren) and morbus Ledderhose, 1379-1380
  - gynecomastia, 1380
  - keloids and hypertrophic scars, 1380
  - Peyronie's disease, 1379
  - plantar warts, 1380
- Skin cancer. *see also* Cutaneous carcinoma
  - brachytherapy for, 289, 289*f*
  - eyelid. *see* Eyelid skin cancers
- Skin erythema, 345
- Skin reaction assay, 13
- Skin thickening, after breast-conservation therapy, 1324
- Skip metastases, 747
- Skull base sarcomas, 359-361
- SMAD4 gene, 936, 936*f*
- Small bowel, late effects of radiation on, 256*t*-257*t*, 268-269
  - dose-volume data on, 269
  - dose and, 269
  - dose-volume and, 269
  - organ function and clinical significance and, 268
- Small bowel tumors, 194-195
- Small cell lung cancer (SCLC), 798-808
  - biologic characteristics of, 798
  - chemotherapy for, 794, 803
  - clinical manifestations of, 800-801
  - clinical trials for, 807
  - epidemiology of, 788, 798
  - etiology of, 798
  - evaluation of, patient, 800-801
  - imaging of, 193
  - incidence of, 798
  - irradiation techniques for, 805-806
  - metastatic, 804-805
  - molecular biology of, 798-800, 799*t*
  - palliation of, 801-804
  - paraneoplastic syndromes associated with, 800, 800*t*
  - pathology and pathways of spread of, 800
  - prevention and early detection of, 798-800
  - primary therapy of, 798
    - locally advanced disease, 801-804
  - prophylactic cranial irradiation for, 794, 803-804
  - radioimmunotherapy of, 408, 408.e3*t*
  - radiotherapy for

- Small cell lung cancer (SCLC) (*Continued*)  
 dose, 802  
 for extensive-stage disease, 804-805  
 fractionation, 802-803, 802*t*  
 normal tissue considerations with, 805-806  
 timing of, 794  
 treatment volumes for, 805-806  
 recurrent, management of, 804-805  
 role of surgery, 803  
 sequencing and timing of TRT and chemotherapy, 801  
 staging of, 800-801  
 evaluation, 798  
 and workup, 789  
 thoracic radiotherapy dose and fractionation for, 793-794  
 treatment of  
 algorithm for, 807, 807*f*  
 considerations in, 793-794  
 volume of, 794
- Small interfering RNA, 47-48
- Small lymphocytic lymphoma, 1534
- Smokeless tobacco (snuff), 570
- Smoking. *see* Cigarette smoking
- Smoking cessation, with cervical cancer, during radiotherapy, 1183
- Snuff, 570
- Sodium iodine (NaI) scintillation detectors, 113, 113*f*
- Soft palate, oropharyngeal cancer of, 601-602, 602*f*, 611
- Soft-tissue metastases, renal cell carcinoma in, 1151
- Soft-tissue necrosis, after surgery, for breast cancer, 1324-1325
- Soft-tissue sarcoma (STS), 1345-1372  
 aggressive fibromatosis as, 1368-1369  
 angiosarcoma as, 1367  
 biologic characteristics of, 1345  
 brachytherapy for, 1357, 1357*f*  
 doses of, 1361  
 of breast, 1367  
 from breast cancer radiotherapy, 1326  
 chemotherapy for, 1362-1363  
 adjuvant, 1362-1363  
 neoadjuvant, 1363  
 radiation and, 1363  
 classification of, 1347, 1349*b*  
 clear cell, 1351  
 clinical manifestations of, 1351  
 dermatofibrosarcoma protuberans as, 1347, 1368  
 diagnosis of, 1352-1353  
 with distant metastasis, 1351  
 chemotherapy for, 1370, 1370*f*  
 palliation for, 1369-1370  
 salvage treatment for, 1369-1370  
 early detection of, 1346  
 environmental factors of, 1346  
 epidemiology of, 1345  
 epithelioid, 1351  
 etiology of, 1346  
 evaluation of, 1351-1352, 1352*f*  
 Ewing's sarcoma as, 1368, 1368*f*  
 fast neutron radiotherapy for, 376  
 gastrointestinal stromal tumors as, 1350-1351, 1366  
 with genetic alterations, 1347, 1348*f*  
 grading of, 1347  
 of head and neck, 1366-1367  
 hereditary factors of, 1346  
 hyperthermia for, 395, 395*t*  
 image-guided RT for, 1357-1358  
 imaging of, 1352, 1353*f*  
 immunologic factors of, 1346
- Soft-tissue sarcoma (STS) (*Continued*)  
 intensity-modulated RT for, 1357, 1357*f*, 1362*t*  
 intraabdominal, 1363-1366  
 karyotypes of, 1347  
 leiomyosarcoma as, 1350  
 liposarcoma as, 1347-1349, 1350*f*  
 local disease in, 1351  
 local recurrence of, 1369, 1369*f*  
 malignant fibrous histiocytoma as, 1347  
 metastasis of, 1353-1354, 1354*f*  
 myxofibrosarcoma as, 1349-1350  
 palliation for, 1345-1346, 1369-1370  
 pathologic subtypes of, 1347-1351  
 pathology of, 1345, 1347-1351  
 pathways of spread of, 1351  
 pediatric, 1367-1369, 1403-1411  
 adjuvant therapy for, 1403  
 biologic characteristics of, 1403  
 clinical manifestations of, 1404-1405  
 epidemiology of, 1403-1404  
 evaluation and risk classification for, 1406  
 incidence of, 1403  
 nonrhabdomyosarcoma. *see* Nonrhabdomyosarcoma soft-tissue sarcoma (NR-STS)  
 primary therapy for, 1403, 1406-1407  
 radiation therapy for, 1407-1411, 1408*t*, 1410*f*, 1410*t*  
 rhabdomyosarcoma. *see* Rhabdomyosarcoma  
 staging of, 1403, 1405-1406  
 pleomorphic sarcoma as, undifferentiated, 1349  
 prevention of, 1346  
 primary therapy for, 1345, 1354-1363, 1355*f*  
 pseudocapsule of, 1351  
 radiation therapy for  
 adjuvant, 1355-1356  
 indications for, 1356, 1356*f*  
 timing of, 1356-1357  
 type of, 1357-1358, 1357*f*  
 alone, 1362  
 chemotherapy and, 1363  
 doses of, 1359-1361  
 external beam, 1357, 1357*f*  
 intraoperative, 1364  
 morbidity of, 1361-1362  
 target volume, 1358-1359, 1358*f*-1360*f*  
 regional lymph node involvement in, 1351, 1352*t*  
 retroperitoneal. *see* Retroperitoneal sarcomas;  
 Retroperitoneal soft-tissue sarcoma  
 rhabdomyosarcoma as, 1367-1368  
 salvage treatment for, with local recurrence, 1369-1370, 1369*f*  
 staging of, 1345, 1354, 1354*t*  
 surgery for, 1354-1355  
 synovial, 1350  
 thoracic, 1367
- Soft-tissue ulceration/necrosis, penile cancer and, 1168, 1168*f*
- Soft wedge, 120
- Solid neoplasms, of pancreas, 937
- Solid-pseudopapillary (Hamoudi) tumor, treatment of, 947.e1*t*
- Solid-state detectors, 112-114  
 absolute dosimeters, 114  
 film as, 113, 113*f*  
 MOSFET, 113, 113*f*  
 scintillation detectors, 113-114  
 semiconductors as, 114  
 silicon diode, 154  
 thermoluminescent dosimeters, 112-113, 113*f*
- Solid tumors  
 chemotherapy for, 175-176  
 radioimmunotherapy of, 401, 402.e2*t*-402.e4*t*, 402.e6*t*
- Solitary plasmacytoma, 1553-1554
- Sorafenib, 81*t*-82*t*, 85-86, 179-180, 850  
 for hepatocellular carcinoma, 960, 972  
 for renal cell carcinoma, 1152
- Source-to-axis distance (SAD), as treatment setup, 123, 123*f*
- Source-to-skin distance (SSD)  
 effective, 122-123  
 as treatment setup, 123, 123*f*
- Spatial accessibility, 218, 218*b*
- Spatial cooperation, 65-66, 65*t*
- SPECT. *see* Single-photon-emission computed tomography (SPECT)
- Sphenoid sinus, 687-688
- Sphenopalatine fossa, 678-679
- Spinal canal chloroma, 536
- Spinal CNS brachytherapy, 291
- Spinal cord, 522-523, 523*f*  
 late effects of radiation on, 256*t*-257*t*, 259-260  
 dose-volume data on, 259  
 organ function and clinical significance and, 259  
 QUANTEC Review on, 259-260  
 location within, 523, 523*f*
- Spinal cord compression, 441-443  
 clinical manifestation of, 442  
 diagnosis of, 442  
 irradiation technique and dose for, 443  
 from non-small cell lung cancer, 837*t*  
 patient evaluation in, 442  
 treatment of, 442-443, 442*f*, 442*t*
- Spinal cord nerve roots, tolerance of, 531-532
- Spinal cord tumor(s), 521-540  
 anatomic distribution of, 522*t*-523*t*, 523  
 anatomy and, 522-523, 523*f*  
 astrocytoma as, 532-533, 532*f*  
 biology of, 522  
 in children, 1400  
 chloroma as, 536  
 chondrosarcoma as, 527*t*, 536  
 chordoma as, 527*t*, 535-536  
 classification by location of, 523, 523*f*  
 clinical manifestations of, 524-526, 524*f*  
 ependymoma as, 527*t*, 533-535, 534*f*  
 with drop metastases, 534*f*  
 myxopapillary, 533, 534*f*  
 pathology of, 533  
 prognostic factors of, 533-534  
 sacral, 534*f*  
 treatment and outcomes of, 534-535  
 epidemiology and etiology of, 521-522  
 epidermoid tumor as, 536-537  
 extradural, 523*f*  
 extramedullary, 523*f*, 528  
 hemangioblastoma as, 537, 537*f*  
 incidence of, 521  
 intradural, 523*f*, 528  
 intramedullary, 523*f*, 528  
 lipoma as, 537  
 locally advanced, 521  
 lymphoma as, 537, 538*f*  
 meningioma as, 527*t*, 535  
 neurocytoma as, 537  
 palliation for, 521  
 pathology of, 523  
 pathways of spread of, 523  
 patient evaluation in, 524-526  
 cerebrospinal fluid examination in, 526  
 clinical workup in, 524-526, 524*f*-525*f*  
 histologic confirmation of disease in, 526  
 neuroimaging in, 526



- Spinal cord tumor(s) (*Continued*)  
 prevention and early detection of, 522  
 pseudotumor mimicking, 523, 524f  
 sarcoma as, 537-538  
 schwannoma as, 538  
 staging of, 524-526  
 teratoma as, 538  
 therapy for, 521, 526-528  
   algorithm for, 539, 539f  
   chemotherapy as, 528  
   complications of, 538-539  
   IMRT as, 529  
   for locally advanced disease, 528  
   and outcome, 526, 527t  
   for palliation, 528  
   radiation, 528  
     fractionation of, 531, 532t  
     general principles of, 528  
     techniques of, 529-531, 530f-532f  
     tolerance to, 531-532, 532t  
     treatment volumes in, 528-529, 529t  
   stereotactic radiosurgery as, 531  
   surgery as, 526-528, 527t  
   by tumor type, 532-539  
   vertebral hemangioma as, 538  
 Spinal sarcomas, 359-361  
 Spindle cell variant, of oropharyngeal cancer, 601  
 Spine  
   imaging of, 191  
   metastases to, 436-437  
 Split-dose damage recovery, 14, 14f  
 Spot scanning, 368, 369f  
 Spread-out Bragg peak dose distribution, 358, 359f  
 Spurs, in energy deposition, 6-7, 7f  
 Squamous cell carcinoma (SCC), 192-193  
   of base of tongue, 610, 610.e1t  
   of bladder, 1098  
   cervical, 1174  
   cutaneous  
     biology and pattern of spread of, 766, 766f  
     diagnostic and treatment algorithms for, 775-776, 775f  
     etiology and epidemiology of, 763  
     infiltrating, 765-766  
     presentation and pathology of, 765-766, 765f-766f  
     in situ, 765, 765f-766f  
     staging of, 769  
     superficial, 765  
   of eyelid, 541, 544, 549  
   fast neutron radiotherapy for, 376  
   of gingiva, 588  
   of lips, 572  
   of oral tongue, 581  
   oropharyngeal, 597, 601  
   of pharyngeal wall, 611  
   of renal pelvis and ureter, 1141-1142  
   of tonsillar region, 602  
   treatment of  
     for perineural invasion, 771  
     primary tumor, 769-771, 770f  
     for regional nodes, 771, 771f  
     sentinel lymph node biopsy in, 771  
   vaginal, 1232, 1232f  
 Standard two-dimensional (2D) planning, 304-305  
 Standardized uptake value (SUV), 209  
 Stanford V regimen, for Hodgkin's lymphoma  
   advanced-stage, 1517-1518, 1517.e1t  
   early-stage, 1511  
 Statistician, 239-240  
   investigator and, interaction between, 240  
 Statistics, 239-252  
   use of, 239-240  
 Stem-cell transplantation. *see also*  
   Hematopoietic stem cell transplant (HSCT)  
   for multiple myeloma, 1552  
 Stereotactic body radiation therapy (SBRT), 135-136, 254, 296-297  
   beam arrangement for, 428, 428f  
   clinical indications and outcomes of, 430-431  
     for hepatocellular cancer, 430  
     for lung cancer, 430  
     for oligometastases, 430-431  
     for pancreatic cancer, 430  
     for prostate cancer, 430  
   clinical radiobiology of, 428-430  
   defined, 427  
   dose of  
     constraints of, 428-430  
     *versus* tumor control, 429  
   immobilization devices for, 427, 428f  
   for liver metastases, 447  
   for lung metastases, 447-448  
   for nasopharyngeal carcinoma, 640  
   for non-small cell lung cancer, 820t, 821-822  
   for pancreatic cancer, 950-951, 954f, 955  
     locally unresectable, 956t  
   physics of, 135-136  
   safety considerations for, 427-428  
   technical aspects of, 427-428, 428f  
 Stereotactic radiation therapy (SRT), for  
   childhood central nervous system tumors, 1390  
 Stereotactic radioablation, of lung tumors, 820t  
 Stereotactic radiosurgery (SRS), 135-136  
   clinical outcomes of, 422-425  
     for arteriovenous malformations, 422  
     for brain metastases, 424-425, 425t  
     for functional disorders, 425, 425f  
     for meningiomas, 422-424, 424f  
     for pituitary tumors, 422  
   definition of, 419-420  
   for meningiomas, 422-424, 424f  
   for nasopharyngeal carcinoma, 640  
   physics of, 148-158  
     commissioning and quality assurance in, 154-158  
     dosimetric commissioning, 156-158, 157f  
     end-to-end target localization in, 154-155, 156f  
     Winston-Lutz test in, 154, 156f  
   detectors for small field measurements in, 153-154  
   dosimetric localization in, 149  
   hidden target test for, 155, 156f  
   history of, 148, 149f-150f  
   principles of, 148-149, 151f  
   radiosurgery beams, dosimetry of, 149-154  
     considerations for, 152-153  
     detector selection for, 152, 152f-153f  
     percent depth dose, 153, 153f  
     relative output factors in, 152, 153t  
     small field beam data, 154, 155f  
   stereotactic localization in, 149, 151f  
   quality assurance for, 419  
   radiobiology of, 420-422, 423f, 423t  
   for salivary gland tumors, 708-709  
   technical principles of, 419-420, 424f  
   for vestibular schwannomas, 424, 424f  
 Stereotaxis, 148  
 Steroids, for prostate cancer, 1085  
 Stockholm III trial, 1004  
 Stomach, late effects of radiation on, 256t-257t, 268-269  
   dose-volume data on, 269  
   dose and, 269  
   dose-volume and, 269  
 Stomach, late effects of radiation on  
   (*Continued*)  
   organ function and clinical significance and, 268  
   QUANTEC Review on, 269  
 Stomach cancer. *see* Gastric cancer  
 Stomach tumors, primary, imaging of, 194  
 Stopping power, 106-107  
 Stratification variables, 243-244  
 Stratified random assignment, 243-244  
 Streptavidin-biotin system, 407  
 Streptozotocin, 71  
 String theory, 93-94  
 Stromal tumors  
   gastrointestinal, 1350-1351  
   ovarian, 1280-1281  
 Strontium 89 (<sup>89</sup>Sr), 440-441, 440t-441t  
   analogue, 1086  
 Strontium-90 (<sup>90</sup>Sr), 292  
 Structure-specific endonucleases, 9  
 Strut-adjusted volume implant (SAVI) applicator, 284  
 Sturge-Weber syndrome, 1377  
 Subcutaneous fibrosis, after neck irradiation, 760  
 Subcutaneous panniculitis-like T-cell lymphoma ( $\alpha/\beta$  type), 1562-1563  
 Subependymomas, 461  
 Subglottic tumors, 652  
 Subglottis, 652  
 Sublethal damage repair, 14, 14f-15f  
 Sublingual glands, 575  
   malignancy, 706  
 Submandibular duct, 575  
 Submandibular glands, 575  
   malignancy, 705-706, 710, 711f  
 Submandibular nodes, 575, 738, 739f, 740t  
 Submental nodes, 738, 739f, 740t  
 Sulcus terminalis, 581  
 Sulfhydryl-containing compounds, 58-61, 59f-60f, 60t  
 Sunitinib, 179  
   as biologic modifier, 81t-82t, 85-86  
   for renal cell carcinoma, 1152  
 Superior mediastinal group, 607  
 Superior mesenteric artery (SMA), and  
   borderline resectable pancreatic cancer, 947.e1t  
 Superior mesenteric vein-portal vein (SMV-PV), and  
   borderline resectable pancreatic cancer, 947.e1t  
 Superior pharyngeal constrictor muscle, 602-603  
 Superior vena cava (SVC), 816  
   obstruction, 837t  
   syndrome, 805  
 Supportive treatment, for multiple myeloma, 1553  
 Supraclavicular nodal irradiation, 1318, 1321-1322, 1321f-1322f  
 Supraclavicular nodes, 740t  
   breast cancer involving, 1285-1287  
 Supraglottic tumors  
   bulky, 663  
   pathways of spread of, 652  
   presentation of, 654  
   primary radiation therapy for, 666-668  
   primary therapy for, 660-661, 660t  
   staging of, 656, 657t  
 Supraglottis, 652  
 Supratentorial primitive neuroectodermal tumors, 1393  
 Surface mold, 136  
 Surgery, 159-170, 722  
   for breast cancer, 163-164  
   early, 163-164, 164f

- Surgery (*Continued*)  
 goals of, 162  
 histologic diagnosis of, 159-161  
 for pancreatic adenocarcinoma, 164-165  
 perioperative care for, 162-163  
 radiation therapy and wound healing after, 163  
 for rectal adenocarcinoma, 165-167, 167*t*  
 for retroperitoneal soft-tissue sarcoma, 167-168, 168*f*-169*f*  
 role of, 159  
 for staging, 161-162  
 pancreatic malignancy, 161-162, 161*f*-162*f*  
 role of laparoscopy in, 161-162  
 for tonsillar region carcinomas, 610
- Surgical debulking, 162
- Surgical palliation, 162
- Surgical resection  
 for nasopharyngeal carcinoma, 639  
 for oropharyngeal cancer, 607
- Surrogate end points, 249-250
- Survival analysis, 246-249, 247*f*  
 bias in, 247  
 Cox proportional hazard model for, 249  
 example of, 246  
 Kaplan-Meier method for, 247-248, 247*f*  
 log-rank statistic, 248-249, 248*f*, 248*t*-249*t*  
 relapse history in, 246-247, 247*f*
- Survival curve, 247-248, 247*f*
- Swallowing  
 dose-volume data on, 262  
 QUANTEC Review on, 262-263
- Sweat gland carcinomas, 768
- Symmetrical exchanges, 10
- Syndecan-1, in multiple myeloma, 1548
- Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 800
- Synergism, 68
- Syngeneic transplant, 343
- Synovial sarcoma, 1350
- Synthetic lethality, 9-10, 77-78, 88
- Systemic radionuclide therapy, for bone metastases, 440-441, 440*t*-441*t*
- T**
- Tail of Spence, 1285
- Takahashi, Shinji, 294-296
- Tamoxifen  
 for breast cancer, 1290, 1291*t*, 1299-1300  
 for ductal carcinoma in situ, 1306-1307, 1309*t*, 1310
- Target motion, 134
- Target volume  
 definition of, 831-834  
 for stereotactic radiosurgery, 419-420
- Targeted agents, hyperthermia with, 385
- Targeted biologic therapies, for esophageal cancer, 849-851, 856*t*
- Targeted drugs, and drug administration schedules, 182
- Targeted imaging, in nuclear medicine, 212
- bone scanning and, 212-213
- Targeted radionuclide therapy (TaRT), 214-215, 399-418  
 antibodies with immunomodulatory or biologic activity in, 406-407  
 with autologous stem cell support, 403  
 chelators in, 400.e1  
 toxicities and, 413  
 clinical results of, 401  
 in combined modality approaches, 405-406, 405.e1*t*-405.e4*t*  
 with chemotherapy  
 for lymphoma, 409-410  
 for solid tumors, 405, 405.e2*t*-405.e4*t*
- Targeted radionuclide therapy (TaRT) (*Continued*)  
 with external beam radiotherapy, 406  
 with hyperthermia, 406.e1  
 dosimetry for, 415-416  
 with engineered immunoconstructs, 403-404, 404*f*  
 fractionation of, 403  
 with hyperthermia, 406.e1  
 low dose rate, 401  
 for lymphoma and leukemia, 409-413, 409.e1*t*, 409.e2*t*, 411.e3*t*  
 minimal tumor burden setting for, 404-405  
 to modify tumor environment, 404  
 monoclonal antibodies for, 399, 402.e2*t*-402.e4*t*  
 for nonhematologic malignancies, 401-409, 402.e2*t*-402.e4*t*, 402.e6*t*  
 optimization of, 416-417  
 antibody cocktails for, 417.e1  
 bifunctional antibodies for, 417.e1  
 clearing agent for, 417.e1  
 increasing tumor uptake for, 416-417  
 pretargeting for, 417  
 radiosensitizers and radioprotectors for, 417  
 regional or direct, 417.e1  
 other, 215  
 pretargeting in, 407-408, 408.e3*t*  
 radiobiology of, 401  
 radionuclide selection for, 400-401, 400*t*  
 regional administration of, 408-409, 408.e4*t*, 408.e6*t*  
 for solid tumors, 401, 402.e2*t*-402.e4*t*, 402.e6*t*  
 for thyroid diseases, 214  
 toxicities of, 413-415, 414.e1*f*  
 tumor targeting in, 399-400
- Targeted therapies, 171, 177  
 FDA-approved, 172*t*-173*t*  
 for thyroid cancer, 725-726  
 for vestibular schwannoma, 497
- Targeted toxicity level (TTL), 240
- Tasman Radiation Oncology Group (TROG), 1005
- Taxane regimens, in gastric cancer, 922
- Taxanes, 71  
 radioimmunotherapy with, 406
- T-cell lymphoma(s), 1540  
 CD30+ large cell cutaneous, 1562  
 cutaneous, 1542, 1556  
 pediatric, 1462  
 subcutaneous panniculitis-like ( $\alpha/\beta$  type), 1562-1563
- T-cell lymphoma/leukemia, adult, 1562
- T-cell lymphoproliferative disorders, CD30-positive, 1529
- T-cell receptor gene rearrangement, 1559
- Teletherapy, 96, 96*f*-97*f*  
 radiation sources for, 99
- Telomerase, 46, 799
- Temozolomide, 71, 88, 182, 408-409  
 for high-grade gliomas, 475, 481  
 for low-grade gliomas, 459
- Temporal modulation, 65*t*, 66
- Temsirolimus, 178-179  
 as biologic modifier, 81*t*-82*t*, 87
- Tendons, benign diseases of, 1378
- Teniposide, 72
- Tenth-value layer, 102
- Teratogenesis, 31
- Teratoma  
 immature, ovarian, 1280  
 pediatric, 1489, 1489*t*  
 of spinal cord, 538  
 testicular, 1124.e1
- Terminal ductal-lobular unit, breast cancer in, 1285
- Testicle, tumors arising in single, 1134-1135
- Testicular cancer, 1036, 1121-1138  
 adjuvant therapy for, 1121  
 biologic characteristics of, 1121, 1123  
 carcinoma in situ and, 1123-1124  
 central nervous system metastases of, 1135  
 chemotherapy complications in, 1133  
 clinical presentation of, 1125  
 etiology and epidemiology of, 1121-1123  
 germ cell tumors as. *see* Testicular germ cell cancer (TGCC)  
 in immunosuppressed patients, 1134  
 incidence of, 1121  
 irradiation techniques for, 1135-1137  
 molecular biology of, 1123  
 nongerm cell, 1133-1134  
 pathology of, 1123-1124, 1123*b*  
 pathways of spread of, 1124-1125, 1125*f*  
 patient evaluation for, 1126  
 primary therapy for, 1121, 1128-1135  
 radiation dose for, 1136-1137  
 staging of, 1121, 1126, 1127*t*  
 surgery for, 1128  
 treatment algorithms, conclusions, and future possibilities for, 1137-1138, 1137*f*  
 treatment-related side effects, 1132-1133  
 cardiovascular toxicity, 1133  
 gonadal toxicity, 1132-1133  
 psychological toxicity, 1133  
 radiation therapy toxicity, 1132-1133  
 second malignant tumor, 1133  
 tumor markers for, 1126
- Testicular diffuse large B-cell lymphoma, 1540
- Testicular germ cell cancer (TGCC)  
 bilateral, 1134-1135  
 classifications of, 1124*t*  
 environmental factors and, 1122-1123  
 heritability of, 1122  
 non-seminoma. *see* Non-seminoma  
 prevention and early detection of, 1123  
 seminoma. *see* Seminoma
- Testicular leukemia, 1459
- Testicular self-examination, 1123
- Testicular tumors  
 germ cell, 1490  
 primary, 200
- Tetrahydrofolate, methotrexate and, 172*f*
- Thalidomide, 180  
 for multiple myeloma, 1551
- Therapeutic index  
 for chemoradiation, 64-66, 64*f*  
 defined, 64-65  
 strategies to improve, 65
- Therapeutic ratio, 2-3, 3*f*
- Thermal dose, 391-392, 396, 396*f*  
 "Thermal enhancement ratio", 385
- Thermal isoeffect dose, 381-382, 382*f*
- Thermoluminescent dosimeters (TLD), 112-113, 113*f*  
 for external beam treatment verification, 129
- Thermometry  
 invasive, 389-390  
 noninvasive, 390-391, 390*f*
- Thermotolerance, 381, 382*f*
- Thiol free radical scavenger, 25*f*, 25*t*
- Thoracic esophagus, 846
- Thoracic neoplasms  
 biology of, 789  
 chemotherapy  
 regimen and schedule during radiotherapy, 792  
 sequencing and timing of RT and, 792

- Thoracic neoplasms (*Continued*)  
 epidemiology, 788-789  
 normal tissue toxicity considerations of, 791-792  
 postoperative radiotherapy of, 793  
 radiation dose escalation and fractionation, 793  
 radiation target volumes, 793  
 staging and workup of, 789-791  
 treatment considerations of, 792-796
- Thoracic radiation therapy (TRT), 807  
 L-SCLC with good performance status and, 807
- Thoracic soft-tissue sarcoma, 1367
- Thoracic tumors, uncommon, 865-894  
 adjuvant therapy of, 865  
 biologic characteristics of, 865  
 incidence of, 865  
 locally advanced disease of, 865  
 palliation of, 865  
 primary therapy of, 865  
 staging evaluation of, 865
- Thoracic wall brachytherapy, 286, 286f
- Thorium dioxide (Thorotrast), and maxillary sinus carcinoma, 674
- Three-dimensional conformal proton therapy (CPT), for sinonasal cancer, 696
- Three-dimensional conformal radiotherapy (3DCRT), 130-133, 134f, 294  
 image guidance for, 134  
 for mesothelioma, 890
- Three-dimensional treatment planning, 127, 127f
- Three-field plan, 132f
- 3D integration, 306t
- Thromboembolic complications, of surgery, 162-163
- Thymic carcinoids, 867  
 pathology and pathways of spread, 867-868, 868f  
 prevention and early detection of, 866-867  
 treatment of, 875
- Thymic carcinomas, 789  
 biologic characteristics of, 867  
 etiology and epidemiology of, 866  
 molecular biology of, 867  
 prevention and early detection of, 866-867  
 treatment of, 875, 876t, 877f-878f
- Thymic epithelial tumors, World Health Organization classification of, 866t
- Thymic neoplasms, epidemiology of, 788
- Thymic tumors, 866-878  
 biologic characteristics of, 867  
 biology of, 789  
 clinical manifestations and patient evaluation of, 868-869  
 diagnostic workup for, 869-871, 870f  
 etiology and epidemiology of, 866  
 irradiation techniques for, 875-877  
 locally advanced, 872  
 molecular biology of, 867  
 pathology and pathways of spread, 867-868, 868f  
 prevention and early detection of, 866-867  
 primary therapy, 880-881  
 prognostic factors of, 869  
 staging of, 871  
 and workup, 790  
 treatment of, 871-878  
 algorithm of, 877-878
- Thymoma. *see also* Thymic tumors  
 chemotherapy for, 872-875  
 combined-modality therapy for, 875  
 locally advanced, 872  
 Masaoka staging system for, 790t, 871t  
 palliation of, 872
- Thymoma (*Continued*)  
 radiation therapy for, 871-872  
 summary of adjuvant therapy results of, 873t-874t  
 surgery for, 871  
 targeted agents for, 875  
 treatment considerations of, 795
- Thymus gland, 866
- Thyroid cancer, 715-730  
 adjuvant therapy for, 715, 722-726  
 anaplastic. *see* Anaplastic thyroid cancer (ATC)  
 biologic characteristics of, 715, 717-721  
 etiology and epidemiology of, 716, 716t  
 evaluation for, 721-722  
 follicular. *see* Follicular thyroid carcinoma (FTC)  
 Hürthle cell, 719-720, 728-729  
 lymphoma as, 726, 729  
 manifestations of, 721-722  
 oncocytic, 719-720  
 palliative therapy for, 715-716  
 papillary. *see* Papillary thyroid carcinoma (PTC)  
 pathology of, 717  
 pathways of spread of, 717  
 prevention and early detection of, 717  
 primary therapy for, 715, 722-726  
 prognostic factors for, 717-721  
 risk factor for, 716  
 staging of, 715, 717-721, 718t  
 targeted radionuclide therapy for, monoclonal antibodies for, 402.e2t-402.e4t, 402.e6t  
 treatment algorithm for, 727-728, 729t  
 treatment tolerance in, 727  
 treatment volumes and doses for, 727, 728f  
 undifferentiated, 715-716
- Thyroid diseases, targeted radionuclide therapy and, 214
- Thyroid hormone, 722-723
- Thyroid lymphoma, 1544
- Thyroid-stimulating hormone-secreting adenomas, 516
- Thyroid suppression therapy, 722-723
- Thyroidectomy, 722
- Time-dose equivalents, for skin erythema, 6
- Time-dose-fractionation relationships, 35-39  
 linear-quadratic isoeffect model for, 35-36, 36f-37f  
 clinical applications of, 36-39  
 parameters of, 39t  
 reciprocal dose plot in, 35-36  
 summary of, 38t  
 NSD model for, 35
- Timer setting, 128
- Tirapazamine, 25f, 25t, 26, 57, 57f, 67
- Tissue-air ratio, 115, 115f
- Tissue heterogeneity, 4
- Tissue-maximum ratio, 115-116
- Tissue-phantom ratio, 115-116
- Tissue responses, to hyperthermia, 382
- TMPRSS2-ERG fusion gene, 1046
- TNFAIP3, 1507
- TNM disease extent, treatment algorithm by, 932
- TNM staging, 161
- Tobacco use. *see also* Cigarette smoking  
 and head and neck tumors, 561  
 and oral cavity cancer, 570  
 and oropharyngeal cancer, 598-600
- $\alpha$ -Tocopherol, for non-small cell lung cancer, 813
- Tomotherapy, 99
- Tongue, 581, 676f
- Tongue base tumors  
 evaluation for, 605, 605.e1f  
 pathways of spread of, 604, 604f  
 therapy for, 610-611, 610.e1t  
 brachytherapy as, 610-611  
 conventional radiation as, 619f  
 IMRT as, 622f
- Tonsillar carcinomas, HPV and, 562
- Tonsillar fossa, 602
- Tonsillar region carcinomas  
 pathways of spread of, 602-603, 603f  
 therapy for, 608-610, 609t, 609.e1t  
 surgery as, 610  
 unilateral radiation as, 609-610, 609t, 620, 621f
- Tonsillectomy, for unknown head and neck primary site, 732, 733t
- Tooth development abnormalities, 346
- Topoisomerase inhibitors, 71-72
- Topotecan, 72, 181t
- Tositumomab, in radioimmunotherapy, 410, 409.e1t
- Tositumomab I-131 (Bexxar), 81t-82t
- Total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO), 1209
- Total absorption coefficient, 106
- Total attenuation coefficient, 106, 106f
- Total body irradiation (TBI), 341-357  
 beam energy, angling, and production for, 351  
 beam spoilers in, 350, 350f  
 boosting in, 355  
 calibration and quality assurance for, 351  
 in children, 350-351  
 comparison of techniques of, 350-351, 350f  
 compensation in, 351  
 compensatory electron boosts for, 350, 350f  
 dose of, 353-354, 354.e1t-354.e2t  
 fractionation and, 354-355  
 for hematopoietic stem cell transplant. *see* Hematopoietic stem cell transplant (HSCT)  
 history of, 341-342, 342f  
 lateral field arrangements for, 350-351  
 in nonmalignant diseases, 355-356  
 opposed-parallel anterior-posterior (AP/PA) horizontal field setup for, 350, 350f  
 organ shielding during, 355  
 physical principles of, 350-351  
 physics of, 136, 136f  
 radiobiology of, 343-344  
 with radioimmunotherapy, 406  
 simulation and planning for AP/PA, 351  
 toxicity of  
 immediate, 344-345, 344t, 345.e1t  
 later, 345-350, 345f-346f, 349f
- Total marrow irradiation (TMI), 351
- Total mesorectal excision (TME), 166
- Total skin electron beam therapy (TSEBT)  
 clinical results for, 1569-1570, 1569t  
 depth dose curves for, 1574f  
 doses for, 1568  
 EORTC guidelines for, 1572t  
 film dosimetry for, 1574f  
 geometry of dual-field, 1572f  
 infections during, 1575, 1575f  
 node, viscera and blood radiotherapy with, 1572  
 physics of, 136  
 positions for, 1573, 1573f  
 target volumes for, 1571  
 techniques for, 1572-1574  
 toxicity of, 1570  
 treatment protocol for, 1574t  
 underdosing and overdosing in, 1573-1574, 1575t

- Total-skin electron treatment (TSET). *see* Total skin electron beam therapy (TSEBT)
- TP53 gene and TP53 protein  
   in astrocytoma, 453  
   in cervical cancer, 1176-1177  
   in DNA double-stranded break response, 43, 43f  
   in laryngeal cancer, 654  
   in multiple myeloma, 1548  
   mutation of, 1206-1207, 1423  
   in non-small cell lung cancer, 811
- Tracheoesophageal fistula, 860
- Tracking Cobalt Project, 294-296
- Trametinib (Mekinist), 81t-82t
- Transanal local excision, 167
- Transcription-coupled repair, 9
- Transcriptomics, chemotherapy-radiation interactions in, 78
- Transformation, neoplastic, 32
- Transforming growth factor- $\alpha$  (TGF- $\alpha$ ), 567
- Transforming growth factor- $\beta$  (TGF- $\beta$ ), 90, 90f
- Transhiatal procedure, for esophageal cancer, 848
- Transitional cell carcinoma (TCC)  
   of bladder, 202f, 1098  
   ovarian, 1268  
   of renal pelvis and ureter, 1141-1142
- Translocations  
   and salivary gland tumors, 699-700  
   and soft-tissue sarcoma, 1347, 1349t
- Transmission, 100-101, 100f
- Transoral laser microsurgery (TLM), 607-608
- Transoral robotic surgery (TORS), 608, 705f
- Transpupillary thermotherapy, 1436-1437
- Transrectal ultrasonography (TRUS), 1053  
   guidance, for prostate brachytherapy, 277f, 280, 281f
- Transurethral resection of bladder tumor (TURBT), 1100-1102, 1106
- Trastuzumab, 81t-82t, 83, 178, 184, 407  
   for breast cancer, 1300  
   for endometrial cancer, 1206.e1  
   for esophageal cancer, 854
- Trastuzumab-DM-1, 178
- Trauma, soft-tissue sarcoma and, 1346
- Treated volume (TV), 126, 126f
- Treatment management systems, 316
- Treatment planning  
   for brachytherapy, 142-145  
     dose specification in, 144-145  
     for gynecologic implants, 142, 142f-143f  
     with high-dose-rate remote afterloading, 143-144, 144f  
   for interstitial implants, 142-143, 143f  
   for external beam treatment, 124-129  
     beam nomenclature, 127, 127f  
     dose computation algorithms in, 127-128  
     dose specifications for, 125-127, 126f  
     dose recording and reporting, 126  
     dose reporting for different techniques, 126-127  
   evaluation and optimization of, 128  
   monitor unit calculations in, 128-129  
   purpose and procedures for, 125, 125f  
   three-dimensional, 127, 127f  
   two-dimensional, 127  
   system  
     commissioning with, 156-158, 157f  
     for stereotactic radiosurgery, 154-155
- Treatment portal imaging, 129, 129f
- Triazenes, 71
- Trigeminal neuralgia, 425, 425f
- Trimetrexate, 70
- Trimmer bars, 97
- Tri-modality therapies, 396
- Triple-negative breast cancer, 1299
- Triptorelin, for prostate cancer, 1085
- TROG. *see* Tasman Radiation Oncology Group (TROG)
- TSC1 gene, 1142
- Tuberous sclerosis, 1142
- Tumeur d'emblée, 1561
- Tumor angiogenesis, 47-48
- Tumor cell survival, dose and, 5
- Tumor control, stereotactic body radiation therapy *versus*, 429
- Tumor control dose assay, 14
- Tumor control probability (TCP), 5, 309
- Tumor cure, 5
- Tumor detection, 63
- Tumor environment, modification of, 404
- Tumor hypoxia, 51-52  
   acute, 51-52, 56, 57f  
   and chemoradiation, 66-67  
   chronic, 51, 52f  
   diffusion-limited, 23  
   evidence for, 52, 53f  
   fluctuant or intermittent, 23  
   importance of oxygen in, 51-52  
   measurement of, 23-24, 23f  
   microenvironment and radiation response in, 47  
   overcoming, 53-57  
     with bioreductive drugs, 56-57, 57f  
     by changing oxygen consumption, 56  
     by dealing with the problem of fluctuating (acute) hypoxia, 56, 57f  
     by dose modification based on hemoglobin, 55-56  
     by high-oxygen-content gas breathing, 53-57  
     with hypoxic cell radiosensitizers, 53-55, 54f, 55f  
   perfusion-limited, 23  
   and radiotherapy for cervical cancer, 1183
- Tumor metabolism, hyperthermia and, 384
- Tumor microenvironment  
   and chemoradiation, 66-67  
   responses to ionizing radiation in vivo, 47-48
- Tumor necrosis factor (TNF), in early and late effects, 33
- Tumor-node-metastasis stage grouping, of non-small cell lung cancer, 817-819, 818t
- Tumor oxygenation, 384
- Tumor pathogenesis  
   angiogenesis and, 85  
   EGFR family and, 83
- Tumor progression, essential steps in, 41
- Tumor regression grading, rectal cancer, 998
- Tumor suppressor genes (TSGs), 561, 936
- Tumor targeting, 399-400
- Tumor vasculature, modification of, 404  
   "tumoritis", 605
- Two-dimensional irradiation field design, 1012, 1012f-1013f
- Two-dimensional treatment planning, 127
- Two-stage design, 242, 242t
- Tyrosine kinase inhibitors (TKIs), 84  
   for soft-tissue sarcoma, 1370, 1371f  
   for thyroid cancer, 725, 725t
- U**
- Ulcer, rodent, 764
- Ultrasonography  
   biopsy guided by, 159  
   endoscopic  
     for pancreatic adenocarcinoma, 164  
     for staging of rectal cancer, 165-166  
     for prostate cancer, 1053
- Ultrasound heating, 387t, 389
- Ultraviolet A (UVA), 1566
- Ultraviolet B (UVB), 1566-1567
- Undifferentiated pleomorphic sarcoma (UPS), 1349
- Undifferentiated uterine sarcoma, 1220
- Unilateral radiation, for tonsillar region carcinomas, 609-610, 609t, 620, 621f
- Union Internationale Contre le Cancer (UICC), 995, 1024.e1
- Univariate analysis, impact of distance from anal verge by, 1001.e1t
- University of California-San Francisco (UCSF) researchers, 639
- Unknown head and neck primary site, 731-737  
   adjuvant therapy for, 731  
   biologic characteristics of, 731  
   evaluation of, 731-732, 732b, 732t-733t  
     CT or magnetic resonance imaging for, 731  
     FDG-PET for, 731-732, 732t  
     FDG-SPECT for, 731-732, 732t  
     laryngoscopy for, 732, 732t  
     tonsillectomy for, 732, 733t  
   incidence of, 731  
   locally advanced, 731  
   palliation for, 731  
   primary therapy for, 731, 733-736  
     algorithm for, 733-734, 735f  
     complications of, 735-736  
     neck dissection in, 734, 734t  
     results of, 734-735, 735f-736f  
     techniques for, 733-734, 733f  
   staging of, 731
- Upper gastrointestinal cancers, irradiation tolerance of, 903
- Ureter(s), after intraoperative radiotherapy, 329-330
- Ureteral cancer, 1036-1037, 1139-1159  
   adjuvant irradiation for, 1147-1148, 1148t  
   adjuvant therapy for, 1139  
   topical, 1149  
   biologic characteristics of, 1139, 1142  
   chemotherapy for, adjuvant, 1148-1149  
   clinical manifestations of, 1143  
   epidemiology of, 1140  
   etiology of, 1140-1141  
   grade and nodal status of, 1144t  
   IMRT for, 1155  
   incidence of, 1139  
   irradiation techniques and tolerance for, 1155-1156, 1157f  
   locally advanced disease, 1139, 1150  
   metastatic disease and, 1152  
   molecular biology of, 1142  
   palliation of, 1139, 1152  
   pathology of, 1141-1142  
   pathways of spread of, 1142  
   patient evaluation for, 1143  
   prevention and early detection of, 1141  
   primary irradiation for, 1147  
   primary therapy for, 1139, 1147-1149  
   staging of, 1139, 1143, 1144t  
   surgery for, 1147  
   treatment algorithm, conclusions, and future possibilities for, 1158
- Urethral cancer, brachytherapy for, 282, 282f
- Urethral stenosis, penile cancer and, 1168-1169
- Urinary reservoir, cutaneous, 1104.e1
- Urinary tract reconstruction  
   continent, 1104  
   incontinent, 1104
- Urothelial carcinoma, 200
- Uterine cancer  
   epithelial, classification of, 1205.e1b  
   mesenchymal and mixed, 1205, 1205.e1b



- Uterine sarcomas, treatment of, 1220  
 Uterine tumors, primary, 202-203  
 Uveal melanoma, etiology and epidemiology of, 541  
 Uveal metastasis, 548
- V**
- VA Lung Cancer Study Group's Staging System, 800  
 Vaccines, for human papillomavirus infection, 600  
 Vagina, clear cell adenocarcinoma of, 1255, 1262-1263  
 Vaginal brachytherapy  
   for endometrial cancer, 1225  
   stage II, 1214  
   for vaginal cancer, 1259-1260, 1260t  
 Vaginal cancer, 1230-1263  
   adjuvant therapy for, 1254  
   biologic characteristics of, 1254  
   brachytherapy for, 1259-1260, 1260t  
   chemoradiation for, 1259  
   chemotherapy for, neoadjuvant, 1258.e1  
   clinical manifestations of, 1255-1257  
   complications of treatment for, 1261-1262  
   diagnostic algorithm for, 1256, 1256f  
   etiology and epidemiology of, 1254-1255  
   external beam irradiation for, 1260-1261  
   incidence of, 1254  
   irradiation techniques and tolerance for, 1259-1262  
   locally advanced disease and, 1259  
   palliation of, 1254, 1259  
   pathology of, 1254-1255  
   pathways of spread of, 1255  
   patient evaluation of, 1255-1257  
   prevention and early detection of, 1255  
   primary therapy for, 1254, 1257-1259  
     invasive, 1257-1259  
     rationale and general principles, 1257-1258, 1258t  
     results, 1258-1259, 1258t  
     VAIN, 1257  
   salvage for, 1254  
   staging of, 1254-1257, 1257t  
   tolerance to treatment for, 1261-1262  
   treatment algorithm and future possibilities for, 1262  
   and vaginal intraepithelial neoplasia, 1254, 1257  
 Vaginal carcinoma, 1172  
 Vaginal cylinder brachytherapy, 279  
 Vaginal intraepithelial neoplasia (VAIN), 1254  
 Vaginal malignancies, nonsquamous, 1262-1263  
 Vaginal melanoma, 1262  
 Vaginal sarcomas, 1262  
 Vaginal vault brachytherapy, 279, 279f  
 Valence band, 112-113  
 Valvular heart disease, radiotherapy and, 267  
 VAMP chemotherapy, for Hodgkin's lymphoma, 1480  
 Vandetanib (Caprelsa), 81t-82t, 85-86  
 Variance, 239  
 Vascular brachytherapy, 292  
 Vascular disrupting agents, 58, 58t, 59f  
 Vascular endothelial growth factor (VEGF), 83f, 85  
   antibodies against, 86  
   for esophageal cancer, 845, 850  
 Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), 85-86  
 Vascular permeability, agents that increase, 404
- Vascular response, to hyperthermia, 382, 382f  
   and improvement in macromolecular and liposomal drug delivery, 382-384, 383f  
 Vascular supply, tumor cells and, 52, 52f  
 Vascular system, radiobiologic reactions in, 1373  
 Vascular targeting agents, tumor hypoxia and, 51, 58, 58t  
   angiogenesis inhibitors as, 58  
   vascular disrupting agents as, 58, 59f  
 Vasectomy, and prostate cancer, 1040.e1  
 Vegetative intermitotic (VM) cells, 27  
 Vemurafenib, 81t-82t, 177  
 Veno-occlusive disease (VOD), 347  
 Verification, for external beam treatment, 129-130, 129f  
 Verrucous carcinoma  
   HPV and, 562  
   of larynx and hypopharynx, 651, 661  
   of vulva, 1232, 1252  
 Vertebral hemangioma(s), 538, 1381  
 Very low dose rate (vLDR) brachytherapy, 280, 281t
- Vestibular schwannoma(s), 491  
   biologic characteristics of, 491  
   clinical manifestations of, 492  
   combined-modality therapy for, 497  
   etiology and epidemiology of, 491  
   incidence of, 491  
   with neurofibromatosis 2, 497-498  
   pathology and pathways of spread of, 492, 492f  
   patient evaluation in, 492, 494t  
     for facial nerve function, 492, 494t  
     imaging in, 492, 493f  
     for sensorineural hearing loss, 492, 493f  
   primary therapy for, 491, 494-498  
   proton beam radiotherapy for, 363  
   radiotherapy for, fractionated stereotactic, 495-499, 497t, 499f  
   staging of, 491-492, 492t  
   stereotactic radiosurgery for, 424, 424f, 495, 496t, 498, 498f  
   surgery for, 494-495, 495t  
   surveillance for, 497  
   targeted therapy for, 497  
   treatment algorithms for, 500, 500f
- VHL gene, 1142  
 Vinblastine, 71, 181t  
 Vinca alkaloids, 71, 171  
 Vincristine, 71  
 Vinorelbine, 71, 710  
 Virtual simulation, 124  
 Virtual wedge, 120  
 Visual toxicity, of total body irradiation, 347  
 Vitamin D, and prostate cancer, 1039.e1  
 Volasertib, 81t-82t  
 Volume doubling times, cell cycle and, 28, 28t, 29f  
 Volume effect(s), after radiotherapy, 33-34  
 Volumes of interest, 125-126, 126f  
 Volumetric modulated arc therapy (VMAT), 294, 312-314  
 von Hippel-Lindau (VHL) syndrome  
   renal cell carcinoma with, 1142  
   spinal hemangioblastoma in, 537  
 Vorinostat  
   as biologic modifier, 81t-82t  
   in chemotherapy, 180  
   for mycosis fungoides, 1567  
 Vulva, lymphatics of, 1233, 1233f  
 Vulvar cancer, 1172, 1230-1263  
   adjuvant therapy for, 1230  
   bilateral inguinal node dissection for, 1231  
   biologic characteristics of, 1230  
   biology of, 1234-1235
- Vulvar cancer (*Continued*)  
   challenges of, 1252  
   chemoradiation for  
     GOG Protocol, 1242, 1242t, 1243f  
     preoperative, 1240-1242, 1241f, 1242.e1f-1242.e2f  
     primary, 1242-1244  
     treatment of inguinal nodes, 1243-1244, 1244t  
     treatment of primary lesions, 1242-1243  
   clinical manifestations of, 1235, 1235.e1f-1235.e2f  
   controversies in, 1252  
   diagnostic algorithm for, 1235-1236, 1236f  
   etiology and epidemiology of, 1231, 1231.e1f  
   future possibilities for, 1252  
   IMRT for, 1249-1250, 1250f  
   incidence of, 1230  
   inguinal lymph nodes in, 1233  
     assessment of, 1233-1234, 1234t  
     contralateral, 1234  
     incidence of metastasis to, 1234, 1234t  
     locally advanced disease and, 1247, 1247.e1f  
     management of, 1237  
     noninvasive imaging with, 1237, 1237.e1f  
     pathologic ultrastaging of, 1237  
     and primary tumor size, 1234t  
     sentinel node dissection for, 1236-1239  
     sentinel node study for, 1238, 1238.e1f  
     surgical exploration of, 1236  
     treatment of, 1243-1244, 1244t  
   irradiation techniques and tolerance for, 1248-1252  
     adjuvant postoperative, 1250-1251  
     groin and nodal, 1248-1250, 1249f, 1250t-1251t, 1249.e1f  
     preoperative/definitive, 1251, 1251.e1f  
   locally advanced, 1246-1248  
   palliation of, 1230, 1246-1248  
   pathology of, 1232-1233, 1232f  
   pathways of spread of, 1233-1234, 1233.e1f  
   patient evaluation for, 1235  
   poorly differentiated, 1232  
   prevention and early detection of, 1231-1232  
   primary therapy for, 1230, 1237-1245  
   prognostic factors of, 1234-1235  
   radiation therapy for, 1239-1244  
     adjuvant postoperative, 1239-1240  
     preoperative, 1240  
     primary, 1242-1244  
     tolerance and treatment sequelae, 1251-1252, 1252.e1f, 1251.e1f  
   radical excision for, 1238  
   radical vulvectomy for, 1231, 1238  
   recurrence, surgical margins and, 1235, 1235t  
   squamous, 1232, 1232f  
   staging of, 1230, 1235-1237, 1235t  
   surgical margins for, 1235, 1235t  
   surgical trends for, 1237-1239  
   techniques for, 1248  
     modified segmental boost, 1248-1249  
     partial transmission block, 1248  
   treatment algorithms and approaches for, 1244-1245  
     for early, favorable, or low-risk disease, 1244-1245, 1245f-1246f, 1245.e1f  
     for locally recurrent or metastatic disease, 1248, 1248.e1f  
     for small primary tumors encroaching on midline structures, 1245, 1247f, 1245.e1f  
     treatment of primary lesions, 1242-1243  
   verrucous, 1232  
 Vulvar intraepithelial neoplasia (VIN), 1231  
 Vulvar malignancies, 1252-1253

Vulvar melanoma, 1232, 1252-1253, 1252.e1f, 1253.e1t-1253.e2t  
 staging of, 1253  
 treatment of, 1253  
 types of, 1253  
 Vulvar sarcomas, 1253, 1253.e2f  
 Vulvectomy, radical, 1231, 1238

## W

W particle, 93-94  
 W value, 109  
 WAGR syndrome, 1423  
 Waiting lists, 218-223  
   Canadian case study in, 223, 224f  
   causes of, 220  
   consequences of, 220-223, 221b  
   direct effects of, 221-222, 221b, 222f  
   as indicator of access, 224  
   indirect effects of, 221b, 222-223  
   kinetics of, 220  
   measurement of, 219-220, 219f  
   societal effects of, 221b, 223  
 Waiting times, 219-220, 219f  
 Waldeyer's ring lymphoma, 1544  
 Warts, plantar, 1380  
 Watch-and wait approach, 1002.e1t  
 Waveguide length, 97  
 Weak force, 93-94  
 Wedged-field plan, 131f  
 Wharton's duct, 575  
 Whipple procedure, 165, 941, 942f  
 Whole-abdomen irradiation (WAI), for ovarian cancer  
   advanced-stage, 1276, 1277t  
   early-stage, 1271-1272, 1271t  
   technique for, 1281, 1281f  
 Whole body radiation syndromes, 30-31  
 Whole brain radiotherapy (WBRT), 443-444, 444t  
 Whole-breast fractionation, 1322  
 Whole-breast irradiation, 1319-1320  
   accelerated partial-breast irradiation *versus*, 1323, 1323.e3t  
   deep-inspiration breath-holding and, 1319-1320, 1319.e3f  
 Whole-breast irradiation (*Continued*)  
   for ductal carcinoma in situ, 1308  
   field borders and blocks in, 1319, 1320b, 1320f-1321f, 1319.e1f  
   intensity-modulated, 1319, 1319.e2f  
   multiple-gantry angle in, 1319-1320, 1320.e1f  
 Whole liver irradiation, 446  
 Whole-pelvic radiation field, 1012  
 Whole-pelvis radiotherapy (WPRT), 1080  
 Whole ventricle volume, 1399f  
 Wide-field radiotherapy, for bone metastases, 438, 439t  
 Will Rogers phenomenon, 801  
 Wilms' tumor, 1422-1432  
   adjuvant therapy for, 1422  
   anaplastic, 1424, 1425f, 1429-1430  
   biologic characteristics of, 1422  
   chemotherapy for, 1429-1430  
   clinical manifestations of, 1426  
   etiology and epidemiology of, 1422-1423  
   evaluation of, 1426, 1426f  
   familial, 1423  
   histology of, 1422  
   incidence of, 1422  
   nephrogenic rests and, 1424  
   pathology of, 1424-1426  
   pathways of spread of, 1424-1426  
   prevention and early detection of, 1423  
   primary therapy for, 1422, 1426-1427  
   radiation therapy for, 1427-1429, 1428t-1429t  
     abdominal, 1427-1428, 1429t  
     flank, 1427-1428, 1429t  
     intensity-modulated, 1428-1429  
     late effects of, 1431-1432  
     long-term results of, 1428t  
     recommendations for, 1428t-1429t, 1430  
     techniques of, 1430, 1430f-1431f  
     whole-lung, 1428  
   retrieval therapy for, 1422, 1431  
   staging of, 1422, 1426, 1427t  
 Winston-Lutz test, 154, 156f  
 Wnt signaling pathway genes, 1423  
 Woringer-Kolopp disease, 1562  
 Wortmannin, 48  
 Wound healing, 163

WR 2721. *see* Amifostine  
 WT1 gene, 1423  
 WT2 gene, 1423  
 WTX gene, 1423

## X

Xanthoastrocytomas, pleomorphic, 453t, 460  
 Xenografts, patient-derived, 78  
 Xeroderma pigmentosum, 8  
 Xerostomia, 624-625, 645, 712  
 X ray(s), 96t  
   on actively dividing cells, 6  
   Bremsstrahlung, 99, 100f, 107-108  
   characteristic, 103  
   photon interaction with, 102-105  
 X-ray cross-complementation (XRCC) groups, in DNA strand break repair, 44  
 X-ray repair cross-complement group 1 (XRCC1), 1099-1100

## Y

Yolk sac tumor  
   ovarian, 1280  
   pediatric, 1489  
   testicular, 1124.e1  
 Yttrium-90 (<sup>90</sup>Y)-CC49, 406, 405.e2t-405.e4t  
 Yttrium-90 (<sup>90</sup>Y)-COL-1, 407  
 Yttrium-90 (<sup>90</sup>Y)-cT84.66 anti-CEA, 402, 405  
   with chemotherapy, 406, 405.e2t-405.e4t  
 Yttrium-90 (<sup>90</sup>Y)-HMFG1, 408  
 Yttrium-90 (<sup>90</sup>Y)-ibritumomab, 402  
 Yttrium-90 (<sup>90</sup>Y)-ibritumomab tiuxetan, 410  
 Yttrium-90 (<sup>90</sup>Y)-m170, with chemotherapy, 406, 405.e2t-405.e4t  
 Yttrium-90 (Y-90) microspheres, 446

## Z

Z particle, 93-94  
 Zalutumumab, for oropharyngeal cancer, 616  
 ZD6474, 86  
 Zero interaction, 68  
 Ziv-aflibercept, 179  
 Zoledronic acid, 434  
   for multiple myeloma, 1553